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Abstract 
An increasing number of pharmaceuticals have been found in the aquatic 
environment and the issue has become a human and environmental health concern. 
Many pharmaceuticals are not fully degraded in wastewater treatment plants (WWTPs) 
and are continuously released in the aquatic environment resulting in concentrations in 
the low µg/l range in the receiving waters. Diclofenac is a widely used non-steroidal 
anti-inflammatory drug (NSAID) and is persistent in the aquatic environment. This 
pharmaceutical has been frequently reported in wastewater effluents, surface waters, 
groundwaters and even drinking water. NSAIDs are known to inhibit the 
cyclooxygenase activity, an enzyme present in many species of the animal kingdom 
responsible for the synthesis of prostanoids, and chronic exposure to environmental 
diclofenac may have detrimental effects on metabolism of non-target organisms 
including microbes and fish. In this thesis, microbiology, genomics and metabolomics 
approaches were used to investigate the effects of diclofenac on aquatic microbes and 
fish. 
In the first study of the thesis (chapter 3), the biodegradation of selected 
NSAIDs was investigated, together with their potential toxicity to aquatic microbes. 
Aerobic biodegradation experiments were conducted using activated sludge and 
wastewater effluents as microbial inocula and diclofenac, ketoprofen or naproxen as 
sole carbon source (1-10 mg/l) in order to isolate and identify the bacterial degraders. 
Changes in the bacterial populations were monitored by optical density and PCR-
DGGE. The analytical techniques solid phase extraction (SPE) and ultraperformance 
liquid chromatography-mass spectrometry (UPLC-TOF-MS) were optimised to quantify 
the pharmaceuticals in environmental samples. High recovery rates were obtained with 
94% for diclofenac; 92% for ketoprofen and 85% for naproxen and with detection 
capabilities down to 3-7 ng/l. Results from the biodegradation experiments showed that 
ketoprofen and naproxen were eliminated at up to 99 and 55% respectively over a 40 
days period. Consistently with previous studies, diclofenac showed no significant 
degradation. In all the enrichments, a significant decrease in the bacterial abundance 
was observed as a consequence of NSAIDs exposure and attempts to isolate the 
bacterial degrading populations were unsuccessful. Given the apparent micro-toxicity of 
these NSAIDs, the standardised test Microtox@ was carried out with Vibrio fischeri. 
The EC50 (15 min) estimated ranged from 13.5 mg/l + 2.3 for diclofenac to 42.1 mg/l + 
3.9 for naproxen. Further toxicological tests were performed with diclofenac on 
bacterial strains isolated from activated sludge. Growth inhibitory effects were observed 
from 50-70 mg/l for Micrococcus luteus, Zoogloea ramigera and Comamonas 
denitrificans. Pseudomonas putida seemed more tolerant to diclofenac exposure and 
toxic effects were observed from 90 mg/l. These studies showed that diclofenac was the 
most toxic NSAID but toxicological effects in bacteria only occurred at concentrations 
at least 1,000 times higher than those found in the environment. However, chronic 
exposure to lower concentrations may cause similar interferences and affect the 
degradation potential of naturally occurring microbial populations. 
The second study (chapter 4) investigated the biological effects of sub-chronic 
exposure to waterborne diclofenac (0.5, 1, 5 and 25 µg/l) in female juvenile rainbow 
trout Oncorhynchus mykiss. After 21-day exposure, mRNA expression levels of 
cytochrome p450 1a1 (cyp1a1), cyclooxygenase (cox) 1 and 2, and p53 were 
investigated in the liver, kidney and gills using RT-PCR and QPCR. These genes were 
selected as they are likely targets for diclofenac in mammals. Histopathological 
investigations were carried out in the small intestine, liver and kidney because 
iii 
 
diclofenac has been reported to induce toxicity responses in these tissues. Fish bile was 
also analysed by SPE and UPLC-TOF-MS to evaluate the bioconcentration potential of 
diclofenac and look for evidences of diclofenac metabolism. Results showed a 
significant reduction of both cox1 and cox2 expression in the liver, gills and kidney 
from 1 μg diclofenac/l. In contrast diclofenac induced an increase in mRNA levels for 
cyp1a1 in the liver and gills but a significant reduction of cyp1a1 expression in the 
kidney from 1 µg/l. There were no clear effects of diclofenac on the mRNA levels of 
p53. Diclofenac exposure caused tissue damages at exposure concentrations as low as 1 
µg/l. Histopathological injuries included inflammation, hyperplasia and fusion of the 
villi in the small intestine and tubule necrosis in the kidney. There were no obvious 
changes in the liver of diclofenac-exposed fish. The analysis of bile revealed a 
bioconcentration potential between 509 + 27 and 657 + 25. A reactive metabolite of 
diclofenac was also detected at the highest exposure concentration which may be 
responsible for the severe injuries found in those fish. Sub-chronic exposure to 
environmental concentrations of diclofenac altered gene expression and it is possible 
that long term exposure to environmental diclofenac lead to significant impacts on fish 
health. 
In the final part of this thesis (chapters 5 and 6) effects on the metabolite 
composition of biofluids were analysed in diclofenac-exposed fish. This work entailed 
developing and validating appropriate methodologies to analyse fish bile and blood 
plasma. Methanol extraction and UPLC-TOF-MS were optimised to analyse the plasma 
metabolome but the methodologies were not suitable to detect low abundance molecules 
such as eicosanoids due to the interferences (ion suppression) in the samples matrix. 
Multivariate data analysis failed to detect the endogenous metabolites of the plasma 
affected by the chemical exposure. The only discriminating metabolite was found after 
analysis of the plasma samples from control vs. 25 µg/l treatment groups and identified 
as the exogenous compound diclofenac. To analyse the bile, the developed SPE 
methodology was carried out in order to separate the metabolites between a free steroids 
(fatty acids, eicosanoids, etc.) fraction and a conjugated steroids (bile salts) fraction. 
Due to high levels of taurocholic acid masking other metabolites in the conjugated 
fraction, some bile samples were hydrolysed to deconjugate these metabolites. The non-
hydrolysed and hydrolysed bile fractions were analysed by UPLC-TOF-MS in positive 
and negative ionization. Multivariate data analysis using principal component analysis 
(PCA) and partial least square discriminant analysis (PLS-DA) revealed significant 
perturbations in the bile metabolite profile of diclofenac-exposed rainbow from the 
lowest exposure concentration (0.5 µg/l). Over 50 metabolites were elevated or reduced 
as a result of the 21-day exposure, suggesting that diclofenac affected several metabolic 
pathways. One metabolite was identified as a lipooxygenase product. This suggests that 
the inhibition of prostanoids synthesis can cause a shift in the arachidonic cascade and 
increase the synthesis of other eicosanoids. Most of the other discriminative metabolites 
remain unidentified and FT-MS analysis will be performed to obtain a structural 
identity. The metabolomics study further highlights the concern of environmental 
diclofenac in non-target organisms and the need to investigate the metabolic pathways 
affected.  
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CHAPTER 1: General Introduction 
 
1.1. Pharmaceuticals in the environment 
The extensive use of pharmaceuticals in human and veterinary medicine has 
become a major environmental concern because pharmaceuticals are designed to be 
highly active or toxic to biological systems. Even though individual pharmaceuticals 
have been detected in low concentrations (ng-µg/l) the occurrence of numerous 
pharmaceuticals with similar mechanisms of action may have significant effects on 
aquatic and terrestrial wildlife through additive exposures (Daughton and Ternes, 1999). 
Much research has been done on antibiotics and endocrine disrupting chemicals (EDCs) 
especially pesticides, polycyclic aromatic hydrocarbons (PAHs), polychlorinated 
biphenyls (PCBs) and synthetic oestrogens (D'Ascenzo et al., 2003). As a result 
pesticides are now some of the most highly regulated chemicals. A series of studies 
have shown that synthetic estrogens (e.g. 17β-estradiol (E2) and 17α-ethinylestradiol 
(EE2)) are ubiquitous in the aquatic environment and exposure to environmental 
concentrations (ng/l range) can affect the physiology and reproductive health of wildlife 
(Jobling et al., 1998; Filby et al., 2007). The increasingly high use of antibiotics has also 
led to the genetic selection of more resilient and harmful bacteria, which is of great 
concern for human and environmental health (Díaz-Cruz et al., 2003). Over the last 
decade, research focus has turned to the occurrence and fate of other therapeutic classes 
including anti-epileptics, lipid regulators and non-steroidal anti-inflammatory drugs 
(NSAIDs). Ecotoxicological investigations have demonstrated that these compounds 
can strongly interfere with metabolic activities of non target organisms and cause 
serious tissue damage (Ferrari et al., 2003). 
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1.1.1. Origin 
Approximately 100,000 different pharmaceuticals are manufactured each year 
but there is no data on the worldwide use of these pharmaceuticals (Kümmerer, 2009). 
The annual consumption of individual pharmaceuticals can vary considerably from 
country to country. Some pharmaceuticals are only available with prescription whilst 
others can be purchased over the counter or on the internet, making it difficult to 
determine the actual amounts consumed. In Germany, 50,000 pharmaceuticals were 
registered in 2001 (Kümmerer, 2004). Data collected in Europe indicate that the most 
frequently used are often sold in the 100 tons per year (Fent et al., 2006). These include 
acetylsalicyclic acid (e.g. 836 tons in Germany in 2001), paracetamol (e.g. 390 tons in 
England in 2000), carbamazepine (87 tons in Germany in 2001) and diclofenac (85 tons 
in Germany in 2001). Pharmaceuticals can enter the environment via several routes 
(Figure 1.1). After human application, pharmaceuticals are excreted, intact or 
metabolised, via urine and faeces. Pharmaceuticals and their metabolites enter 
wastewater treatment plants (WWTPs) where the compounds not readily degraded are 
discharged within the wastewater effluents leading to a continuous input of 
pharmaceuticals in the receiving waters. The sludge produced in WWTPs can be used as 
fertiliser in agricultural fields and contaminate the soil. Waste discharged from hospitals 
and pharmaceutical industries are also treated in WWTPs and contribute significantly to 
the amounts released in the environment (Bound and Voulvoulis, 2005). 
Pharmaceuticals used for veterinary purposes are introduced in the environment via 
animal excretions. Manure can be applied to landfill and subsequently leach in 
groundwaters or reach surface waters via run-offs (Koutsouba et al., 2003). In addition, 
the use of food additives such as antibiotics and growth promoters used in aquaculture 
has led to a direct input of pharmaceuticals in waters and soil (Díaz-Cruz et al., 2003).  
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Figure 1.1 – Routes of entry for pharmaceuticals (adapted from Boxall, 2004). 
Pharmaceuticals used for human medicine are the main source of entry in the aquatic 
environment. 
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These various routes along with an inappropriate disposal of used medicines, contribute 
to an increased load of pharmaceuticals in surface and river waters and in exceptional 
cases pharmaceuticals have been found to reach drinking water (Jones et al., 2005). 
 
1.1.2. Occurrence in the aquatic environment 
The first compound of pharmaceutical origin, clofibric acid, was reported in the 
US in treated WWTP effluents at concentrations between 0.8 and 2 µg/l (Garrison et al., 
1976). Clofibric acid is a metabolite of the lipid regulators clofibrate and etofibrate and 
has become the most widely detected pharmaceuticals. Subsequently, an increasing 
number of pharmaceuticals have been found in WWTP effluents, rivers, estuaries, 
seawater, groundwater and even drinking water (Richardson and Bowron, 1985; Stumpf 
et al., 1999; Thomas and Hilton, 2004; Zorita et al., 2009). Surveys of WWTP influents 
and effluents have concluded that the main therapeutic classes detected are β-blockers, 
analgesics, anti-epileptics and lipid regulators. Highest environmental concentrations 
have been found near WWTPs which suggests that conventional WWTPs are not well 
adapted for the complete removal of pharmaceuticals. The occurrence of 32 
pharmaceuticals was reported in WWTP effluents in Germany with the anti-epileptic 
carbamazepine and the lipid regulator gemfibrozil detected at maximum concentrations 
of 6.3 and 4.6 µg/l respectively (Ternes, 1998). Metcalfe et al. (2003) found elevated 
levels of carbamazepine, naproxen and diclofenac (up to 2 µg/l) in Canadian treated 
wastewater. Castiglioni et al. (2005) detected up to 30 different pharmaceuticals in 
treated WWTP effluents across Italy. The concentrations measured ranged from 150-
1081 ng/l for the antibiotic ofloxacin, 27-1168 ng/l for the β-blocker atenolol and 33-
1318 ng/l for carbamazepine. A monitoring study carried out in the UK found 
propranolol (mean 75 ng/l) in all, diclofenac (mean 500 ng/l) in 86% and ibuprofen 
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(mean 3000 ng/l) in 84% of the WWTP effluents analysed (Ashton et al., 2004). In 
India, exceptionally high levels of antibiotics ciprofloxacin (up to 3100 µg/l) and 
losartan (up to 2500 µg/l) and β-blocker metoprolol (950 µg/l) were detected in the final 
effluents of WWTPs treating wastewaters from pharmaceuticals industries (Larsson et 
al., 2007).  
The receiving waters usually contain fewer compounds occurring at lower 
concentrations. A survey on the occurrence of pharmaceuticals in US streams showed 
that the pharmaceuticals ibuprofen, fluoxetine and triclosan found at low levels (ng/l 
range) in WWTP effluents were no longer detected in surface waters (Boyd et al., 
2003). A similar contamination pattern had been reported by Ternes (1998). However, 
other studies have shown that some pharmaceuticals are ubiquitous and can be detected 
in the receiving waters. In the UK, pharmaceuticals were detected in estuaries at 
concentrations up to 111 ng/l for clofibric acid, 125 ng/l for diclofenac and 928 ng/l for 
ibuprofen (Thomas and Hilton, 2004). More recently Kasprzyk-Hordern et al., (2008) 
found more than 50 pharmaceuticals, EDCs and illicit drugs in UK surface waters. The 
anti-inflammatory compounds codeine (up to 813 ng/l), naproxen (up to 146 ng/l), 
ketoprofen (up to 14 ng/l), ibuprofen (up to 93 ng/l) and diclofenac (up to 261 ng/l) 
were amongst the most frequently detected. Certain pharmaceuticals are very 
recalcitrant and can reach groundwater and drinking water supplies (Heberer, 2002; 
Loraine and Pettigrove, 2006). The NSAID phenazone has been found in drinking 
waters at concentrations up to 400 ng/l (Jones et al., 2005). Concentrations of some 
pharmaceuticals the most frequently detected in the aquatic environment are listed in 
Table 1.1. 
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Table 1.1 – Concentrations of selected pharmaceuticals in the aquatic environment. 
Compound  
therapeutic use 
Concentration 
(ng/l) 
Aquatic 
environment 
Country Reference  
Bezafibrate 
lipid regulator 
4600 
27 
wastewater effluent 
drinking water 
Germany 
Germany 
Ternes (1998) 
Jones et al. (2005) 
Carbamazepine 
antiepileptic 
2300 
100 
258 
wastewater effluent 
surface waters 
drinking water 
Canada 
Sweden 
US 
Metcalfe et al. (2003) 
Bendz et al. (2005) 
Jones et al. (2005) 
Clofibric acid 
lipid regulator 
metabolite 
1600 
4000 
270 
wastewater effluent 
groundwater 
drinking water 
Germany 
Germany 
Germany 
Ternes (1998) 
Heberer (2002) 
Heberer (2002) 
Diclofenac  
anti-inflammatory 
5450 
91 
89 
6 
wastewater effluent 
surface water 
groundwater 
drinking water 
Italy 
UK 
Germany 
Germany 
Andreozzi et al. (2003) 
Ashton et al. (2004) 
Heberer (2002) 
Heberer (2002) 
Gemfibrozil  
lipid regulator 
4760 
70 
wastewater effluent 
drinking water 
Italy 
Canada 
Andreozzi et al. (2003) 
Jones et al. (2005) 
Ibuprofen 
anti-inflammatory 
27300 
2500 
82 
3 
wastewater effluent 
surface water 
groundwater 
drinking water 
UK 
Spain 
Germany 
Germany 
Ashton et al. (2004) 
Farré et al. (2001) 
Heberer (2002) 
Jones et al. (2005) 
Metoprolol 
β-blocker 
2200 
60 
wastewater effluent 
surface water 
Germany 
Sweden 
Ternes (1998) 
Bendz et al. (2005) 
Naproxen 
anti-inflammatory 
33900 
110 
wastewater effluent 
surface water 
Canada 
Sweden 
Metcalfe et al. (2003) 
Bendz et al. (2005) 
Paracetamol  
analgesic 
6000 
10000 
wastewater effluent 
surface water 
Germany 
US 
Heberer (2002) 
Kolpin et al. (2002) 
 
1. General Introduction 
7 
 
1.2. Non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed to reduce 
inflammation and manage pain in primary care such as back pain, migraine, fever or 
arthritis. Many can be purchased over the counter including acetylsalicylic acid, 
ibuprofen, naproxen, diclofenac and indomethacin. In Germany, it has been estimated 
that more than 80 tons of diclofenac are used each year (Zwiener and Frimmel, 2003). 
In 2001, naproxen, diclofenac and ibuprofen were amongst the top 25 pharmaceuticals 
used in the UK (Jones et al., 2002). After application, it has been shown that up to 15% 
of diclofenac and 8% of ibuprofen ingested is excreted from the human body (Jjemba, 
2006). NSAIDs entering WWTPs are poorly removed and have been detected 
worldwide (Koutsouba et al., 2003; Löffler and Ternes, 2003; Carballa et al., 2004; 
Tauxe-Wuersch et al., 2005; Yamamoto et al., 2009). They are often found in the ng-
µg/l range in WWTP effluents, surface waters, rivers, estuaries and groundwaters (see 
Table 1.1). Stumpf et al. (1999) were the first to report the presence of diclofenac in the 
aquatic environment. Ibuprofen and diclofenac were even detected in drinking water in 
Germany at low ng/l concentrations (Heberer, 2002). Figure 1.2 illustrates some of the 
NSAIDs detected during environmental surveys. A monitoring study carried out in 
Canada showed that the NSAIDs naproxen, ibuprofen and diclofenac were amongst the 
most frequently detected in WWTP effluents at maximum concentrations of 1.2, 0.77 
and 0.75 µg/l respectively (Lishman et al., 2006). In the UK an increasing number of 
studies have reported the presence of NSAIDs in WWTP effluents and rivers (Thomas 
and Hilton, 2004; Jones et al., 2007; Kasprzyk-Hordern et al., 2008). Hilton et al. (2003) 
observed that diclofenac was the most frequently detected in WWTP effluents. 
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1.2.1. Mode of action 
The exact mode of action is not well understood but the primary action of 
NSAIDs is to inhibit the activity of the cyclooxygenase (cox) enzyme that oxygenates 
fatty acids such as arachidonic acid and eicosapentaenoic acid into prostanoids. In most 
vertebrates species studied, two isoforms have been found (Chandrasekharan and 
Simmons, 2004; Ishikawa and Herschman, 2007). The first cyclooxygenase, called 
cox1, is usually constitutively expressed in many tissues including kidney, intestine, 
brain; and is responsible for the maintenance of basal prostanoids synthesis (Cha et al., 
2006). The second cyclooxygenase, cox2, is mainly inducible by a wide range of 
extracellular and intracellular stimuli. Prostanoids synthesised by cox activity, 
comprised the eicosanoids prostaglandins and tromboxanes and have been shown to 
play key roles in physiological functions of cells (Dubois et al., 1998). Figure 1.3 shows 
the pathway for prostanoids synthesis and their distribution in tissues. In addition 
arachidonic acid can serve as substrate for lipooxygenase enzymes to form lipoxins, 
leukotrienes and hydroxyeicosatetraenoic acids (HETEs) and for cytochrome P450 
monooxygenase enzymes to produce epoxyarachidonic acid (Cha et al., 2006). 
Eicosanoids regulate a variety of physiological functions such as renal blood flow, 
platelets aggregation, synthesis of gastric mucus and blood clotting, embryonic 
implantation (Simmons et al., 2004). Toxicity caused by NSAIDs has been attributed to 
the non selective inhibition of both cox. The application of new NSAIDs (e.g. celecoxib, 
meloxicam, etoricoxib and rofecoxib) selectively inhibiting cox2 is thought to reduce 
the adverse effects (Dorne et al., 2007). 
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Figure 1.3 – Schematic diagram of the conversion of arachidonic acid to prostanoids. 
Boxed are the tissues where these molecules are expressed in mammals. Diagram adapted from 
Cha et al. (2006). 
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1.3. Removal of NSAIDs in the environment 
The fate of pharmaceuticals depends on the following key factors: adsorption 
potential, biodegradability and photosensitivity. Research on the removal of 
pharmaceuticals has not always established whether these compounds are completely 
degraded (mineralisation) or simply chemically altered (Kümmerer, 2009). As the rate 
of pharmaceutical discharge in the environment is often faster than the rate of removal, 
those poorly removed may accumulate in the aquatic environment and affect the aquatic 
wildlife. 
 
1.3.1. Wastewater treatment plants 
WWTPs are the major route of entry for NSAIDs via municipal and hospital 
wastewaters, and are designed to reduce the amount of suspended particles and 
chemicals in wastewaters before the release in receiving waters (Figure 1.4). 
Conventional plants treating municipal wastes often have a preliminary treatment used 
to remove inorganic matters from the wastewaters. Raw wastewater flows through 
screens to remove any large solids (e.g. plastics, toilet paper, etc.) that may block the 
machinery and then passed into grit removers. Once the flow contains only organic 
matter, it is transferred into primary settlement tanks to allow the suspended solid 
matters to settle out. The raw sludge formed at the bottom of the tanks will be further 
treated and used on landfill. The secondary treatment also called biological treatment is 
a critical stage for the removal of pharmaceuticals. Wastewater is kept for a prolonged 
duration in oxygenised tanks with sludge containing microorganisms; known as 
activated sludge. Compounds with a low polarity tend to be retained in the sludge and 
degraded by the microorganisms, whilst more polar compounds remain in the aqueous  
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Figure 1.4 – Schematic diagram of a wastewater treatment plant. In some cases a fourth 
treatment can be applied such as ozonation or UV treatment to purify the final effluent before its 
release into the aquatic environment. 
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phase and will be discharged in the environment (Bendz et al., 2005). Activated sludge 
is then settled in order to clarify the wastewater flow and the final effluent is discharged 
into rivers, estuaries or seawater. To improve the removal efficiencies of pollutants 
WWTPs may use a tertiary treatment and UV disinfection. 
 
1.3.2. Removal efficiency in wastewater treatment plants 
The efficiency of WWTPs can be evaluated by measuring the concentration of 
pharmaceuticals in the influents and effluents. Removal efficiencies of NSAIDs have 
shown a great variability for the same compound depending on treatment technologies 
in the WWTPs. For example, the removal of ketoprofen has been reported between 8-
53% in WWTPs in Sweden (Tauxe-Wuersch et al., 2005). Occasionally, negative 
removal efficiencies have been reported due to the degradation of conjugated 
metabolites leading to the release of the parent compound. Diclofenac has been found to 
increase in concentration from influent to effluent and removal as low as -105% have 
been measured (Zorita et al., 2009). In general ibuprofen has been removed by 90-100% 
during wastewater treatment whilst variable removal efficiencies have been reported for 
naproxen (15-78%) and ketoprofen (48-69%) (Stumpf et al., 1999). Diclofenac is one of 
the pharmaceuticals with the lowest average removal efficiency (17-23%) in WWTP 
(Heberer, 2002; Quintana et al., 2005). 
 
1.3.3. Biodegradation 
Microbial degradation is possibly the most important removal mechanism for 
NSAIDs because they remain in the aqueous phase. In WWTPs, bacteria and fungi can 
degrade partially or completely these compounds in the aerobic and anaerobic phases of 
the activated sludge. Fungal species have been reported to degrade pharmaceuticals. 
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Zhong et al. (2003) discovered three fungal species of Cunninghamella that were able to 
degrade naproxen. Microbial degradation of diclofenac has also been observed by the 
fungal species Epiccocum nigrum (Webster et al., 1998). Research has shown that 
biodegradation rates are difficult to predict and can be affected by the hydraulic 
retention time, age of the activated sludge and weather conditions (Daughton and 
Ternes, 1999). Diclofenac was found to be significantly biodegraded when the hydraulic 
retention time was at least 8 days (Fent et al., 2006). The rates of elimination of 
ibuprofen and naproxen appeared to be elevated in WWTPs with hydraulic retention 
times greater than 12 hr (Metcalfe et al., 2003). Aged activated sludge contains 
microbial populations that have been exposed to pharmaceuticals for a few years and 
are more effective to remove these compounds. González et al. (2006) found that the 
biodegradation rate of diclofenac was enhanced if microbes were acclimated to the 
compounds. However, the introduction of entirely new pharmaceuticals each year 
means that microbes may not be adapted enough and degradation can be challenging. 
The removal of acidic pharmaceuticals by microbes in the activated sludge is a 
topic of research interest. Laboratory based experiments showed that ibuprofen and 
naproxen were fully mineralised by microbes present in activated sludge but only after 
addition of lactose as another carbon source, a mechanism known as co-metabolism 
(Quintana et al., 2005). The study also revealed that ketoprofen was used as sole carbon 
source by the microbes and transformed in 28 days producing stable metabolites, only 
diclofenac showed no degradation. Similarly, Yu et al. (2006) reported that diclofenac 
was poorly degraded with only 30% of the initial concentration removed, and ibuprofen, 
ketoprofen and naproxen were biodegraded in the activated sludge by more than 80% in 
50 days. It has been established that microbial degradation can also occur in the 
receiving waters. Microcosm experiments using river water have shown that ibuprofen 
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can be rapidly degraded in 21 days (Winkler et al., 2001). Yamamoto et al. (2009) 
found that biodegradation can be slow and variable in river water with half-lives of 2-58 
days for acetaminophen, 450-480 days for ibuprofen, 12-104 days for mefenamic acid 
and 410-430 days for indomethacin. A study on microbial degradation of 
pharmaceuticals in estuarine and seawater reported the fast biodegradation of 
acetaminophen (half-life 11 days) and a much slower degradation for ketoprofen with a 
half-life over 100 days (Benotti and Brownawell, 2009). However, most biodegradation 
studies have used NSAIDs at concentrations one or two orders of magnitude higher than 
the concentrations detected in the aquatic environment. It may be that environmental 
concentrations entering WWTPs are too low to trigger the appropriate enzymatic 
reactions for degradation of these compounds (Daughton and Ternes, 1999). 
Little is known about the microbial communities actively degrading 
pharmaceuticals. Gröning et al. (2007) investigated the microbes degrading diclofenac 
and were able to identify bacteria at a group level. They observed that diclofenac 
degradation was restricted to Gram negative bacteria from the γ-Proteobacteria and the 
Cytophaga-Flavobacterium group. Kraigher et al. (2008) demonstrated that the 
exposure of activated sludge microbes to 5-500 µg/l of diclofenac, ibuprofen, naproxen 
and ketoprofen can lead to a shift in the community structure and inhibit the growth of 
bacteria (genus Nitrospira) that play a key role in nitrification during wastewater 
treatment. This, may in turn, reduce the removal efficiency of NSAIDs in wastewaters. 
 
1.3.4. Sorption 
Sorption is the physical sequestration of dissolved organic compounds onto 
filterable materials. In WWTPs this process facilitates the removal of poorly soluble 
pharmaceuticals from wastewaters into the sludge. NSAIDs are present in their ionised 
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form at pH of natural waters and remain dissolved, thus sorption may not be a relevant 
removal process (Benotti and Brownawell, 2009). A degradation study by Urase and 
Kikuta (2005) reported that acidic pharmaceuticals have a low sorption potential that 
may increase with lower pH conditions. Basic pharmaceuticals however, can absorb to 
suspended solids to a considerable extent. Antibiotics and synthetic estrogens have a 
strong tendency for adsorption and are retained in the sludge (D'Ascenzo et al., 2003; 
Díaz-Cruz et al., 2003). Thus they are often found in soils and can leach to surface 
waters and groundwaters. 
 
1.3.5. Abiotic processes 
Abiotic degradation of pharmaceuticals is possible by photodegradation and 
hydrolysis. Pharmaceuticals are known to resist hydrolysis and this process is usually 
regarded as negligible for most pharmaceuticals found in the aquatic environment. 
Photodegradation of pharmaceuticals has been reported in the receiving waters and the 
aerated tanks of WWTPs. Using field measurements and laboratory experiments, Buser 
et al. (1998) identified photodegradation as the main removal mechanism of diclofenac 
in surface waters with a half-life of 1 hr. These results were supported by a study on the 
abiotic degradation of diclofenac exposed to sunlight (Andreozzi et al., 2003) and a 
rapid degradation rate was measured (half-life 5 days). Lin and Reinhard (2004) 
investigated the photodegradation rate of various pharmaceuticals by solar irradiation. 
They reported half-lives of 1.4 hr for naproxen and 15 hr for ibuprofen indicating that 
these compounds are photosensitive. Degradation of pharmaceuticals is important to 
reduce the bioavailability and minimise the adverse effects. Research has shown that in 
some cases the photoproducts may be toxic. DellaGreca et al. (2003) demonstrated that 
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some photoproducts of naproxen formed by irradiation were as toxic as or more than the 
parent compound. 
 
1.4. Environmental impact of NSAIDs 
Pharmaceuticals entering the aquatic environment can remain biologically active 
and as such can interact with the aquatic wildlife. Ecotoxicological testing has provided 
valuable information on the toxic effects of pharmaceuticals which can be used for 
ecological risks assessment (Henschel et al., 1997). Mathematical models such as 
ECOSAR have also been developed to predict the behaviour and potential toxicity of 
pharmaceuticals, but in vivo and in vitro studies have been more useful to understand 
the mechanism of toxicity and tissues affected (Fent et al., 2006). Because 
pharmaceuticals are continuously released in the environment aquatic populations are 
exposed to low concentrations of pharmaceuticals throughout their life which may 
affect their development, reproduction or survival rate. For example, cyclooxygenase 
enzymes are conserved in many vertebrates and invertebrates, thus NSAIDs may affect 
prostanoids biosynthesis and cause adverse effects in non target organisms. 
 
1.4.1. Acute toxicity 
Environmental risk assessments have been largely based on acute toxicity tests. 
Many standardised tests exist using invertebrates, bacteria, fish and algae with a range 
of endpoints including luminescence, growth, mobility and mortality (Crane et al., 
2006). Farré et al. (2001) analysed the acute toxicity of NSAIDs on the luminescence of 
bacteria (Vibrio fischeri) and reported a 50% reduction in bioluminescence (EC50= 30 
min) of 13.5 mg/l for diclofenac, 19.2 mg/l for ibuprofen and ketoprofen and 35 mg/l 
for naproxen. Naproxen has been observed to cause acute toxic effects in invertebrate 
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species Ceriodaphnia dubia with EC50 (24 hr) of 66.4 mg/l (Isidori et al., 2005). Jones 
et al. (2002) and Carlsson et al. (2006) have compiled the acute toxic effects of 
pharmaceuticals including diclofenac, naproxen, ibuprofen and ketoprofen. They 
concluded that diclofenac and ibuprofen are potentially dangerous to the environment. 
However, insufficient data are available for naproxen and ketoprofen to determine the 
risks of these compounds in the environment. Of all the NSAIDs diclofenac has shown 
the highest acute toxicity to aquatic species with lowest observed effect concentration 
often below 100 mg/l (LOEC) (Fent et al., 2006). The crustacean C. dubia [LOEC (7 
days)= 1 mg/l] seems to be the most sensitive to acute diclofenac concentrations (Ferrari 
et al., 2003). Acute toxicity of diclofenac has also been reported for aquatic plant Lemna 
minor [EC50 (7 days)= 7.5 mg/l (Cleuvers, 2003)] and rotifer Brachionus calyciflorus 
[LOEC (48 hr)= 25 mg/l (Ferrari et al., 2003)]. Little is known on the effects of acute 
exposure in fish. Laville et al. (2004) published one of the first in vitro study of acute 
toxicity of diclofenac in rainbow trout primary hepatocytes and observed effects on cell 
toxicity [EC50 (24 h)= 420 µM] and cytochrome P450 enzymatic activity [EC50 (24 hr)= 
63 µM]. Recently, acute exposure of medaka fish (Oryzias latipes) to 1 µg/l and 8 mg/l 
diclofenac resulted in a significant increase of cyp1a, vitellogenin and p53 gene 
expression in the liver, gills and intestine (Hong et al., 2007). 
 
1.4.2. Chronic toxicity 
An earlier study reported the toxicity of diclofenac in three Gyps vulture species 
with catastrophic declines in the populations in Pakistan and India (Oaks et al., 2004). 
Vultures that prey on dead carcasses had been eating diclofenac-treated cattle but they 
were not able to metabolise and excrete diclofenac efficiently. Low concentrations of 
diclofenac [LOEC= 0.007 mg/kg] found in the vultures resulted in renal failure. Since 
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then extensive research has been carried out on chronic toxicity of environmentally 
relevant concentrations of diclofenac especially in fish. In zebrafish (Danio rerio) 
diclofenac had no effects on the embryonic development except for a small delay in 
hatching time after 1 and 2 mg/l exposure (Hallare et al., 2004). Many chronic 
exposures to diclofenac have been done using salmonid species as they are easily 
maintained under laboratory conditions and can occur in freshwater and seawater 
environments. Rainbow trout (Oncorhynchus mykiss) exposed to diclofenac for 28 days 
presented renal lesions and alterations in the morphology of the gills from 5 µg/l as well 
as bioconcentration of diclofenac in the liver, kidney, gills and muscles (Schwaiger et 
al., 2004). The highest bioconcentration factor (2732) was found in the liver of fish at 1 
µg/l. Subtle subcellular damages were even detected in the liver, gills and kidney of the 
fish from 1 µg/l (Triebskorn et al., 2004). A 21 day study with brown trout (Salmo 
trutta) reported the inflammation of the gills and kidney from 5 µg diclofenac/l due to 
the accumulation of granulocytes in these organs (Hoeger et al., 2005). A field study 
also reported that rainbow trout exposed to WWTP effluents bioconcentrated diclofenac 
in the plasma (Brown et al., 2007). It is a general consensus that chronic exposure to 
diclofenac can impair renal functions in fish. The kidney has also been found to be the 
target organ of diclofenac toxicity in many organisms such as birds (Oaks et al., 2004; 
Meteyer et al., 2005), mice (Hickey et al., 2001) and human (Ng et al., 2006). Other 
studies have observed side effects in the small intestine of diclofenac-exposed 
organisms (Seitz and Boelsterli, 1998; Hoeger et al., 2008). 
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1.5. Xenobiotic metabolism in fish 
Many xenobiotics are lipophilic and must be biotransformed in order to produce 
more polar compounds and facilitate renal excretion. Fish have been shown to 
metabolise xenobiotics through two phase reactions (Goksøyr and Förlin, 1992). In 
phase I reaction, a functional group is added to the molecule. This involves the 
cytochrome P450 monooxygenase system. During phase II reaction, xenobiotics (or its 
phase I metabolite) bind to polar endogenous molecules such as glucuronic acid, 
sulphate, glutathione or amino acids and form conjugates with a higher water solubility 
and more easily excreted by the kidney (Daughton and Ternes, 1999). The metabolism 
can lead to detoxification or bioactivation into reactive intermediates more toxic than 
the parent compound (Sarasquete and Segner, 2000). 
 
1.5.1. Cytochrome P450 monooxygenase system 
Cytochromes P450 (P450s) are a super family of heme proteins involved in the 
oxidative metabolism of a broad range of substrates in mammals, aquatic vertebrates 
and bacteria (Hasler et al., 1999). P450s monooxygenases are located predominately in 
the endoplasmic reticulum membrane (microsomes) and mitochondria of the liver where 
they catalyse reactions including bile acid formation, aromatic hydroxylation and 
xenobiotics metabolism (Gonzalez, 1990). In fish, P450s have been found in the liver, 
intestine, kidney, gills and brain, and established as dominant enzymes during phase I 
reactions metabolism (Sarasquete and Segner, 2000). The main function of P450s is to 
bind and activate molecular oxygen to a substrate molecule. They can also utilise 
oxygen from peroxides for monooxygenations (Anzenbacher and Anzenbacherová, 
2001). The main catalytic functions of cytochrome P450s are shown in Figure 1.5. 
P450s can catalyse other types of reactions including hydroxylation of an aliphatic or 
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aromatic carbon; epoxidation of a double bond; heteroatom oxygenation, oxidative 
group transfer, cleavage of esters and dehydrogenation (Testa et al., 2007). 
 
 
 
                           R-H R-OH 
 XOOH + O2 +2e- + 2H+ XOH + H2O 
 
Figure 1.5 – Hydroxylation reactions catalysed by cytochrome P450s. R–H substrate; R–OH 
hydroxylated product; XOOH peroxide; XOH hydroxylated by-product. 
 
 
 
1.5.2. Cytochromes P450 in fish and use as biomarker of aquatic pollution 
There are multiple P450 isoforms classified into families and subfamilies 
according to their function or presence in a particular species. The activity of individual 
isoforms can vary from species to species and is influenced by water temperature, 
seasons, sex, developmental and reproductive stage (Andersson and Förlin, 1992). 
Members of cyp1, cyp2, cyp3 and cyp4 families play a key role in human xenobiotics 
metabolism and many of them have been characterised in fish (Stegeman, 1992; Thibaut 
et al., 2006). Isoforms of cytochrome P450 1a (cyp1a) subfamily have been found 
critical during phase I reaction metabolism of pharmaceuticals and as such have been 
extensively studied (Bucheli and Fent, 1995; van der Oost et al., 2003; Rudzok et al., 
2009). Fish act as a lipophilic sink for many pharmaceuticals and they can build up to 
levels sufficient to induce cyp1a (Williams et al., 1998). The induction of cyp1a 
cytochrome P450
cytochrome P450
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expression and the related activities (ethoxyresorufin-O-deethylase (EROD) or aryl 
hydrocarbon hydroxylase (AHH)) are now well established as in vivo biomarkers of 
pharmaceutical exposure and uptake in fish (Tyler et al., 2008). Some pharmaceuticals 
have also been shown to inhibit cyp1a activity (Laville et al., 2004). However as 
mentioned previously, cyp1a activity can be affected by a number of endogenous and 
exogenous factors. This needs to be taken into account when using cyp1a as a 
biomarker of environmental exposure. 
 
1.5.3. Bile as major excretory route of pharmaceuticals 
The rate and route of pharmaceutical excretion depends on molecular size and 
lipid solubility of the compound. In fish, bile is the major route of excretion for 
pharmaceuticals and their metabolites (Gibson et al., 2005). Excretion can also occur by 
branchial and urinary route. Many endogenous and exogenous compounds as well as 
their phase I and phase II metabolites have been identified in the bile (Seitz and 
Boelsterli, 1998; Pettersson et al., 2006). Pharmaceuticals metabolised by the 
hepatocytes in the liver are concentrated in the bile and can transverse the intestine in 
order to be eliminated via the faeces. A study on diclofenac metabolism has shown that 
liver cells can bioactivate a major phase II metabolite into a highly reactive glucuronide 
conjugate. Lipophilic compounds and conjugates found in the bile have the potential to 
be reabsorbed by the intestinal cells in a process called enterohepatic recirculation, 
leading to morphological and functional damages in the intestine (Hoeger et al., 2008). 
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1.6. Analysis of pharmaceuticals in environmental samples 
1.6.1. Sample preparation 
The detection of pharmaceuticals in environmental samples at concentrations 
down to 1 ng/l is an analytical challenge. Therefore the success of the analysis relies on 
the quality of the extraction. Several techniques exist for sample preparation such as 
soxhlet extraction, pressurised liquid extraction, ultrasonic solvent extraction, stir bar 
sorptive extraction and more recently on-line solid phase extraction, liquid phase 
microextraction and solid phase microextraction have been developed for minimal 
solvent use (Zhang et al., 2009). Liquid-liquid extraction (LLE) and solid phase 
extraction (SPE) are the most common techniques used to separate and concentrate 
pharmaceuticals from environmental aqueous matrices (Ridgway et al., 2007). LLE 
separates organic compounds by direct partitioning with an immiscible solvent. This 
technique can separate a wide range of molecules based on their relative solubility to the 
solvents (Silvestre et al., 2009). The main disadvantage is the large volumes of solvent 
required and samples may need to be further concentrated in order to detect trace 
molecules. SPE has become a technique of choice in environmental studies because it 
overcomes many of the disadvantages of LLE (Pavlovic et al., 2007). A range of SPE 
cartridges containing solid sorbents with different physico-chemical properties are 
available to extract specific compounds from complex matrices (e.g. wastewater 
effluent, urine, blood, tissue homogenates). The pH of the samples can be adjusted to 
favour the extraction of acidic or basic pharmaceuticals. SPE provides an improved 
selectivity, reproducibility and high recoveries of trace pharmaceuticals. SPE can also 
be automated and that can increase the sample throughput. However the properties of 
the matrices can affect the ability of the sorbent to retain molecules (Ridgway et al., 
2007). 
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1.6.2. Detection techniques 
A number of instrumental techniques have been employed for residue analysis 
of pharmaceuticals in environmental samples, with mass spectrometry (MS) being the 
most frequent. Various mass analysers are available including single or triple 
quadrupole, ion-trap, time-of-flight (TOF) and Fourrier transform (FT). MS techniques 
are usually coupled with the separation technique gas chromatography (GC) or liquid 
chromatography (LC). Many pharmaceuticals lack volatility and must be derivatized in 
order to be compatible with GC analysis (Buchberger, 2007). Derivatization is a lengthy 
procedure that can introduce errors in the detection but GC is less affected by the 
interferences in the matrix and is a method well established for environmental studies 
(Koutsouba et al., 2003; Metcalfe et al., 2003). LC offers an improvement over GC 
since derivatization is avoided but limit of detection down to a single ng/l can still be 
achieved (Kot-Wasik et al., 2007). Many studies have employed LC-MS to analyse 
WWTP effluents and detect NSAIDs occurring in low concentrations (Farré et al., 
2001; Löffler and Ternes, 2003; Lindqvist et al., 2005; Zorita et al., 2009). LC coupled 
with tandem MS (LC-MS-MS) has proven successful for the simultaneous 
determination of several pharmaceuticals from different therapeutic classes including 
NSAIDs (Castiglioni et al., 2005; Gómez et al., 2006). The recent development of 
ultraperformance liquid chromatography (UPLC) technology has provided an improved 
sensitivity to analyse environmental water samples. Using UPLC-TOF-MS, Kosjek et 
al. (2009) were able to detect diclofenac and its metabolites in WWTPs. 
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1.7. Ecotoxicogenomics to assess biological effects of pharmaceuticals in aquatic 
organisms. 
Ecotoxicogenomics refer to the integration of the “omics” technologies 
genomics, proteomics and metabolomics into ecotoxicology. The purpose is to provide 
an insight into the physiological status of organisms and understand their interactions 
and responses to xenobiotics (Steinberg et al., 2008). Molecular changes occur at 
concentrations lower than changes at tissue or organism level. Therefore the analysis of 
gene expression, protein levels and metabolites fluxes in organisms exposed to a 
pollutant can help for the discovery of biomarkers more informative, sensitive and 
species/pollutant specific than the traditional biomarkers used (e.g. histopathology, 
mortality, reproductive success) (Poynton et al., 2008). “Omics” technologies have been 
applied in controlled laboratory experiments to identify time, concentration or tissue 
specific responses and determine the mode of action of pollutants. The results generated 
can be used to predict environmental effects of a pollutant in the aquatic environment. 
However, very few studies have applied ecotoxicogenomics in the field to assess the 
effects of pharmaceuticals on wild animals. 
 
1.7.1. Genomics 
Genomics is the study of the genome of an organism. In the context of 
ecotoxicogenomics, it is known as transcriptomics and has been defined as the analysis 
of mRNA levels in a pollutant-exposed tissue or organism compared with a steady state 
(Poynton and Vulpe, 2009). The aim is to identify and associate gene expression 
profiles with a toxicological outcome and to facilitate a better understanding of the 
mechanisms of toxicity (Farr and Dunn, 1999). Microarrays, either as cDNA or 
oligonucleotides, and more recently digital transcriptomics are the main techniques 
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employed. The application of transcriptomics to study pharmaceuticals exposure has 
provided greater insights into the biological effects of synthetic estrogens and their 
mimics in fish. For example, Santos et al. (2007) used a 17,000 oligonucleotide based 
microarray to analyse the expression of over 100 genes in zebrafish (Danio rerio) 
exposed to EE2.The genes affected were mainly associated with protein metabolism in 
males and mitochondria organisation and biogenesis in females. Wintz et al. (2006) 
studied the gene expression profile of fathead minnow (Pimephales promelas) exposed 
to 2,4-dinitrotoluene and were able to link the genes affected with lipid metabolism and 
respiration (oxygen transport). Garcia-Reyero et al. (2008) used a 22,000 
oligonucleotide microarray to compare gene expression profile of laboratory fish with 
the expression profile of fish caged upstream and downstream a WWTP effluent. They 
found that 48 hr exposure to the WWTP effluent was sufficient to affect metabolic 
pathways involved in cell communication, innate immune response and embryonic 
development. The use of genomics in environmental studies remains limited by the lack 
of sequenced and identified genes in ecologically relevant species (Finne et al., 2007). 
 
1.7.2. Proteomics 
Proteomics is the large-scale study of proteins in cells or tissues. Changes in 
gene expression affect protein levels but some proteins are modulated independently of 
any effects on the transcriptome (Poynton et al., 2008). The comparison of protein 
profiles from stressed conditions versus controls should provide information regarding 
the molecular mechanisms of response to xenobiotics. The separation techniques 2-
dimensional polyacrylamide gel electrophoresis (2D-PAGE) and the identification 
techniques LC-MS and Fourrier Transform (FT)-MS have been used to assess 
differential protein expression profiles (Miracle and Ankley, 2005). Although 
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proteomics is a relatively new technology, it has been applied in environmental 
monitoring studies in vertebrate and invertebrate species (Iguchi et al., 2006). 
Albertsson et al. (2007) investigated proteins expression in the liver of rainbow trout (O. 
mykiss) following exposure to WWTP effluents. They observed significant alterations in 
the protein profiles of WWTP effluent exposed fish compared to control fish and 
reported that the exposure interfered with ATP synthesis in mitochondria. Although the 
biological implications are not always clear, this technique was able to identify the 
metabolic functions affected. 
 
1.7.3. Metabolomics 
Metabolomics refers to the analysis of metabolites fluxes in a cell or tissue. It is 
also known as metabonomics. Transcript levels of a gene are not always correlated to 
protein expression and translated proteins are not always enzymatically active. 
Metabolomics, however, aims to profile the end products (e.g. signalling molecules, 
hormones, lipids) of the cellular processes and hence is more closely related to the 
physiological state of an organism (Ankley et al., 2006). This approach is ideal for 
studying multiple species because it is not dependent on knowledge of an organism's 
genome (Viant, 2008). Analytical techniques used in metabolomics include nuclear 
magnetic resonance (NMR), LC-MS and GC-MS (Weckwerth and Morgenthal, 2005). 
Metabolomics technologies have been applied to the study of pharmaceuticals in aquatic 
organisms (Bundy et al., 2009). Many laboratory studies have investigated the effects of 
chemical exposure on the metabolic profile of fish to determine the metabolic pathways 
and physiological functions affected (Samuelsson et al., 2006; Ekman et al., 2007; 
Katsiadaki et al., 2009). Viant et al. (2006) used a metabolomics approach to determine 
the mode of action of the herbicide dinoseb on medaka fish embryo (O. latipes). They 
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reported changes in the levels of ATP and selected amino acids which resulted in 
reduced growth and abnormal development. Metabolomics is a promising approach but 
a large number of metabolites found remain unidentified and interpretation of the effects 
observed can be extremely challenging (Viant, 2003). 
 
1.8. Bioinformatics 
Ecotoxicogenomics studies involve the analysis of many components in 
biological samples and generate a large amount of data. Big changes in the gene 
expression, protein levels or metabolites composition are easy to identify, but subtle 
changes require statistical processing to determine the significance of the changes 
observed (Idborg et al., 2004). Multivariate analysis is generally applied to “omics” data 
using unsupervised and supervised projection methods to reduce the dimension of the 
data and allow the class separating metabolites to be distinguished (Ramadan et al., 
2006).  
The unsupervised method principal component analysis (PCA) is used to 
simplify complex datasets into interpretable models and display the interrelationship 
between the samples (observations) analysed. This method does not require any 
information on the samples (Eriksson, 2006). Data are represented as points in a 
multivariate K-dimensional space. PCA finds the line with maximum variance (called 
the first principal component, PC1) in the K-dimensional space of the whole data and 
each observation is projected onto this line. If the first PC is not enough for modelling 
the systematic variation of the data set then, another PC, orthogonal to the first one, is 
calculated which best explains the second greatest systematic variation of the data 
(Eriksson, 2006). PCA aims to explain as much variation as possible in as few 
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components as possible (van den Berg et al., 2006). PCA can also be applied to 
subgroups in order to discriminate amongst the samples and find potential biomarkers. 
The supervised methods projection to latent structures (PLS), or partial least-
squares discriminant analysis (PLS-DA) and orthogonal PLS (OPLS) require initial 
information about the classes, such as gender, concentrations, time, etc., to build a 
model and identify the class separating metabolites (Griffin et al., 2007). These 
techniques are applied to the data when PCA do not establish clearly the markers 
discriminating between sample groups (UMETRICS, 2007). In PLS the information 
about the different classes of observations is recorded in matrix X data (observations x 
predictors matrix) and the responses from PCA are kept in a matrix now called Y data 
(Eriksson, 2006). PLS then fits two PCA-like models at the same time, one for X and 
one for Y, and simultaneously aligns these models, creating a model to predict Y from 
X. Thus, PLS has been shown to enhance the separation between groups of observations 
by rotating PCA components facilitating the identification of the most important 
biomarkers (Wagner et al., 2007). 
 
1.9. Aims of the thesis  
As more pharmaceuticals are produced and released in the market, it is 
important to gather knowledge on existing pharmaceuticals and find suitable methods to 
predict the fate and behaviour of the new ones.  
The hypotheses of this thesis were: 
1) Diclofenac can be readily biodegraded by environmental microbes without 
altering their dynamics within the populations. 
2) The toxicity of diclofenac reported in small mammals and humans is the same in 
fish. 
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In this thesis microbiology, animal physiology, genomics and metabolomics 
approaches were applied to investigate the effects of the NSAID diclofenac in the 
aquatic environment. This thesis is presented as a series of chapters. The experiments 
and aims of each study are described below: 
 
Chapter 2 provides a detailed description of the protocols optimised, chemicals 
purchased and equipments used during this project. 
 
 
In Chapter 3 microcosm experiments were conducted with river water and 
activated sludge. The environmental microbes were cultured under laboratory 
conditions with diclofenac and other NSAIDs (ketoprofen and naproxen) as sole carbon 
source in order to promote the growth of degrading bacteria. Cultures were routinely 
monitored to measure the degradation rate of NSAIDs and the bacterial growth rate. The 
toxicity of diclofenac was investigated and compared to other NSAIDs using a 
standardised microtoxicity test on Vibrio fischeri. Further toxicity analyses were carried 
out using bacteria isolated from activated sludge to determine the effects of diclofenac 
on microbial growth. The aims of this study were: 
 
• To investigate the biodegradability of low concentrations of diclofenac. 
• To isolate and identify the bacteria involved in the degradation process. 
• To evaluate the toxic potential of diclofenac on microbial organisms using 
growth and luminescence as endpoints. 
 
 
In Chapter 4, a laboratory based exposure was carried out using rainbow trout 
(Oncorhynchus mykiss). Fish were exposed to environmentally relevant concentrations 
of diclofenac via the water (0.5, 1, 5 and 25 µg/l) for 21 days. The effects of diclofenac 
exposure on rainbow trout were investigated in the gills, kidney, intestine and liver 
using histopathology and mRNA expression levels of cox1, cox2, cyp1a1 and p53 as 
endpoints. Bile analysis was carried out to study the bioconcentration potential of 
diclofenac. The aims were: 
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• To assess the ability of exposure to environmentally relevant concentrations of 
diclofenac to induce or inhibit the expression of selected genes in the kidney, 
gills and liver of rainbow trout. 
• To determine the morphological alterations caused by diclofenac exposure in 
key organs (kidney, liver and small intestine). 
• To gain a better understanding of the metabolism and fate (degradation and 
bioaccumulation) of diclofenac in rainbow trout. 
 
 
Chapter 5 reports the various methods and parameters tested to analyse fish 
biofluids. The extraction methods solid phase extraction and methanol extraction were 
used for bile and blood plasma samples respectively. The parameters of the detection 
technique UPLC-TOF-MS were optimised to detect simultaneously various classes of 
signalling molecules. The methods were validated using samples spiked with known 
chemicals in order to assess the specificity, accuracy and reproducibility of the 
techniques to detect and identify a large number of metabolites at once. The aims were: 
 
• To develop a methodology to extract and identify key molecules (eicosanoids, 
bile acids, fatty acids) in bile samples. 
• To optimise methanol extraction and UPLC-TOF-MS methodologies in order to 
purify plasma samples and detect low abundance molecules such as eicosanoids 
in those samples. 
• To analyse the plasma metabolome and find plasma markers affected by 
diclofenac exposure. 
 
 
In Chapter 6 the methods developed in Chapter 5 were employed to analyse the 
bile metabolome of fish from the diclofenac exposure. Bile samples were treated by 
hydrolysis when required, fractionated and analysed by UPLC-TOF-MS. Multivariate 
data analysis was applied to the resulting metabolic profiles to probe for concentration 
related effects and identify key metabolites and biochemical pathways affected by 
exposure to diclofenac. The aims were: 
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• To determine the lowest concentration of diclofenac able to induce changes in 
the metabolic profile of rainbow trout after 21 day exposure. 
• To identify the exogenous (diclofenac and its metabolites) and endogenous 
metabolites induced or inhibited. 
• To discover new metabolic pathways affected by diclofenac exposure in fish and 
possibly link them to mammalian systems. 
 
 
The final chapter (Chapter 7) provides a critical synthesis on the major findings 
from the thesis work and their implications for the discharge of diclofenac (and other 
NSAIDs) in the aquatic environment. Our research revealed that diclofenac is not 
readily biodegraded and that sub-chronic exposure to environmental concentrations of 
diclofenac can have significant effects on fish metabolism. These findings provide 
additional but valuable information for the environmental risk assessment of diclofenac 
in order to understand and predict the fate of this compound in the environment. This 
chapter further considers future research required to improve the removal of diclofenac 
in WWTPs and to fully understand the toxicity in aquatic organisms. 
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CHAPTER 2: General Materials and Methods 
 
2.1. Biodegradation studies 
The objectives of this study were to enriched environmental samples with the 
non-steroidal anti-inflammatory drugs naproxen, diclofenac and ketoprofen and isolate 
and identify microbial communities able to degrade these compounds. 
 
2.1.1. Sampling sites  
Environmental sampling was carried out in the Exe catchment (Devon, United 
Kingdom) from December 2005 to February 2007. River Exe receives sewage effluents 
from eight different wastewater treatment plants treating domestic and industrial wastes. 
Water samples used in the biodegradation studies were taken from the two main 
wastewater treatment plants (WWTPs) in the area (see Figure 2.1). River water was 
collected 100 m downstream the Tiverton WWTP (SS 954 103 GB grid). Activated 
sludge, sewage effluent and river water were collected at Countess Wear (SX 948 891 
GB grid). The samples were collected in 1 l amber bottles filled to the top and sealed. 
The bottles were previously acid washed and autoclaved at 121°C for 15 min. All 
samples were stored at 4°C. The sampling sites are described Figure 2.1. The samples 
were collected into sterile 1 l amber bottles filled to the top and sealed and stored at 
4°C, until required.  
 
2.1.2. Bacterial growth media 
All glassware and culture media were autoclaved at 121°C for 15 minutes. The 
cultures were grown in minimal salts media (MSM) with pharmaceutical as sole carbon  
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Images reproduced with permission of Ordnance Survey and Ordnance Survey of Northern Ireland 
 
Figure 2.1 – Maps of the sampling sites. Tiverton WWTP is located in a rural area and 
Countess Wear WWTP is located in an urban area. 
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source. The MSM was prepared as described by Tett et al., (1994) in deionised water 
using the following chemicals (g/l): MgSO4 0.2, (NH4)2SO4 0.5, KH2PO4 0.5, 
Na2EDTA 0.12, NaOH 0.02 and 0.5 ml of concentrated H2SO4. A stock solution of 
trace elements was made up using the following chemicals (g/100 ml deionised water): 
ZnSO4 0.4, CuSO4 0.1, Na2SO4 0.01, Na2MoO4 0.1, CoCl2 0.01, MnSO4 0.04, and 1 ml 
of this solution was added per 1 l of MSM. The pH was adjusted to 7.0 using 0.5 M 
NaOH solution. 
 
2.1.3. Microcosm enrichment cultures 
Triplicate cultures were established in 250 ml Erlenmeyer flasks containing 100 
ml MSM and spiked with ketoprofen, naproxen or diclofenac. The pharmaceuticals 
were previously dissolved in deionised water to a final concentration of 10 mg/ml. A 
volume of 1-5 ml of environmental sample (listed in Table 2.1) was added to the 
enriched media. The flasks were closed with porous foam and incubated statically for 48 
hours then transferred to an orbital shaker at 200 rpm at 25°C. At each sampling time 
point all the cultures were analysed for optical density measurements and sampled for 
DNA extraction. The absorbance was read at 600nm against an abiotic control. The 
concentrations of pharmaceuticals present in the enrichments were monitored using 
Solid Phase Extraction (SPE) to extract the pharmaceuticals and liquid 
chromatography/mass spectrometry for chemical quantification. 
Control cultures were established in triplicate. Positive controls (biotic) were 
initiated using 100 ml MSM and 1 mg of environmental sample. Negative control 
cultures (abiotic) were set up using 100 ml MSM spiked with the pharmaceuticals in 
order to determine the rate of abiotic loss. All flasks were closed with porous foam and 
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incubated with enrichment cultures. Biotic controls were sampled at each time point as 
for the experimental samples. 
 
2.1.4. Sub-culturing method 
At day 5, 10, 15 and 40, the enrichments were sub-cultured in order to isolate 
the bacterial degraders. 1 ml of each culture was inoculated into fresh MSM with the 
relevant pharmaceutical. The flasks were closed and incubated at 25°C.  
 
2.2. Nucleic acid extraction 
2.2.1. 5% CTAB/phosphate buffer 
The following stock solutions were required for the nucleic acid extractions and 
were made us as follows: 10% CTAB in 0.7 M NaCl (10 g CTAB and 4.09 g of NaCl in 
1L deionised water), K2HPO4 (8.71 g of K2HPO4 in 50 ml deionised water) and 
KH2PO4 (1.36 g KH2PO4 in 10 ml deionised water). The potassium phosphate buffer 
240 mM (pH 8) was prepared by mixing 22.56 ml of K2HPO4 with 1.44 ml of KH2PO4 
stock solutions and making up to 100 ml with deionised water. The 5% 
CTAB/Phosphate buffer (120 mM pH 8) was prepared by mixing 50 ml of the 10% 
CTAB in 0.7 M NaCl with 50 ml of the potassium phosphate buffer. 
 
2.2.2. Extraction procedure 
Environmental samples were filtered through 0.22 µm pore size membranes 
using a Watson-Marlow vacuum pump. The cells were recovered by introducing the 
filters in the barrel of a 5 ml syringe and washing them with 0.6 ml of CTAB buffer. 
The CTAB resuspension was transferred into a 2 ml screw-capped tube containing 0.5-
1.0 g of zirconia/silica beads (0.1 mm diameter, Biospec Products). 0.5 ml of phenol 
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chloroform: isoamyl alcohol (25:24:1) was added and cells were lysed in a mini bead 
beater (Biospec Products) for 40 seconds at maximum rate. The tubes were then 
centrifuged at 13,000 rpm for 5 min. The supernatant was transferred into a sterile 
Eppendorf tube and an equal volume of phenol chloroform:isoamyl alcohol was added 
(about 0.5 ml). The samples were vortexed and centrifuged at 13,000 rpm for 5 min. 
The top aqueous layer was transferred to a new sterile Eppendorf tube. DNA was 
precipitated by adding 1 ml of 30% Polyethylene Glycol (PEG)/1.6 M NaCl solution 
and incubated overnight at room temperature (or a minimum of 4 hr). After incubation, 
the tubes were centrifuged at 13,000 rpm for 10 min to pellet the nucleic acids and the 
supernatant was discarded. The pellets were washed with 100% ice cold ethanol. The 
ethanol and any remaining liquid were removed.  The pellets were then allowed to air 
dry. The DNA was resuspended in 40 μl ultrapure PCR quality water (Sigma) and 
stored at -20°C. Successful DNA extraction was confirmed by agarose gel 
electrophoresis  
 
2.3. Agarose gel electrophoresis 
50x TAE buffer was prepared by dissolving 242 g TRIS in 600 ml deionised 
water. 57.1 ml of glacial acetic acid and 100 ml of 0.5 M EDTA were added. The 
solution was sterilized by autoclaving at 121 °C for 15 min. 
Electrophoresis was performed using a 1% agarose gel. 1 g of agarose was 
dissolved in 98 ml of deionised water and 2 ml of 50x TAE buffer. The solution was 
heated in a microwave until the agarose was fully dissolved. After cooling, 4 µl 
ethidium bromide (10 mg/ml) was added and the gel solution was gently mixed before 
pouring into a gel tank. Gels were left to set for 30 min, and then inserted into an 
electrophoresis tank containing 1x TAE buffer. Gels were loaded with 5 μl sample 
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mixed with 2 µl of loading dye (Promega). A DNA ladder (Hyperladder 1, Bioline) was 
loaded for each gel to indicate product size. Gels were run at 100 V for 30 minutes and 
visualised on a UV transilluminator (AutoChemiSystem) using LabWorks 46 Gel Pro 
Application Software. 
 
2.4. Polymerase chain reaction amplification of 16S rRNA gene 
Polymerase Chain Reaction (PCR) was used for subsequent identification of the 
bacterial species in the enrichments. This enzymatic process which amplifies genomic 
sequences was developed by Kary Mullis and co-workers in 1983. DNA amplification 
was carried out using the method described by Muyzer et al. (1993). The 16S rRNA 
gene of different bacterial species was amplified using primers corresponding to 
positions F341 (5'-CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGG 
GCCTACGGG-AGGCAGCAG-3') and R534 (5'-ATTACCGCG GCTGCTGG-3') in 
Escherishia coli. These primers contain a 40 nucleotide GC rich sequence (GC-clamp). 
Each PCR reaction was performed in 50 μl volume and contained: 2 μl of each primer 
(10 pM/μl), 25 μl master mix (containing 50 units/ml Taq polymerase, 400 μM of each 
dNTPs, 3 mM Mg Cl2, Promega), 19 μl of ultrapure water and 2 μl template DNA (50 
ng). A negative control was also performed whereby no template DNA was added. All 
PCR reactions were performed with a ThermoHybaid® PCR thermocycler. The 
temperatures and cycling conditions were as follows: 1 cycle at 95°C for 1 min; 
denaturation step 30 cycles at 95°C for 1 min, annealing step at 55°C for 1 min, 
elongation step at 72°C for 2 min and a final elongation step at 72°C for 7 min. Products 
were visualized by agarose gel electrophoresis. 
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2.5. Microtox acute toxicity test 
The toxicity of selected pharmaceuticals was evaluated using Microtox® 
toxicity test. The marine bacteria Vibrio fischeri naturally emit light as a result of their 
metabolic activity. Toxic substances changing their metabolic status would lead to a 
reduction of the bioluminescence. The bacteria freeze-dried (NRRL B-11177), 
reconstitution solution, diluent (2% NaCl) and an osmotic adjusting solution were 
purchased from SDI (Newark, USA). The pharmaceuticals were dissolved in deionised 
water for a final concentration of 50 mg/l. The bioassay was conducted on a Microtox 
Model 500 Analyzer and the ’49.5% Basic Test’ protocol was followed. The percent of 
inhibition (%I) was estimated against a saline control solution after 5 and 15 min of 
pharmaceutical exposure. Data obtained were analysed with the MicrotoxOmni® data 
reduction software (Azur Environmental). The inhibition curves produced were used to 
estimate the 50% effective concentration (EC50) of each pharmaceutical. 
 
2.6. Disc diffusion assay 
The bioassay was optimised to assess the toxicity of diclofenac on specific 
bacteria naturally occurring in WWTPs. The minimum inhibitory concentration of 
diclofenac was calculated for each bacterial strain. 
 
2.6.1. Bacterial strains 
The following strains were purchased from DSMZ (Germany): Pseudomonas 
putida (5232), Comamonas denitrificans (17787), Micrococcus luteus (14235) and the 
filamentous bacteria Zoogloea ramigera (287). All bacteria were revived in nutrient 
broth and incubated at 28°C for 24 hr. 
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2.6.2. Toxicity test protocol 
Diffusion discs were made with filter paper (Whatman grade 1) using a hole 
puncher and sterilised by autoclaving at 121°C for 15 min. 15 ml of nutrient agar was 
dispensed in plastic petri dishes. The plates were allowed to cool and 500 µl of bacterial 
inocula were spread over the agar. The discs were then placed onto the plates using 
tweezers. A serial dilution of diclofenac was prepared and 50 µl of the relevant solution 
was added to the discs for final concentrations of 10, 20, 30, 40, 50, 60, 70, 80, 90 and 
100 mg/l of diclofenac. The plates were incubated for 16 hr at 28°C. After incubation, 
the inhibition zone around each disc was measured in 3 different directions to obtain the 
mean diameter. 
 
2.7. Detection of pharmaceuticals in water samples 
Analytical methods were optimised to isolate and detect diclofenac in water 
matrices. The technique was then applied to quantify diclofenac in water samples taken 
from the biodegradation study and the fish exposure tanks.  
 
2.7.1. Solid phase extraction (SPE) 
The cartridges Oasis HLB 6cc (Waters, Milford, USA) and Strata X 
(Phenomenex, Macclesfield, UK) were tested at acidic pH, and the cartridges Strata X-
AW (Phenomenex, Macclesfield, UK) were tested at neutral pH. The extraction was 
performed using a SPE manifold (Alltech). The protocols are summarised Table 2.1. 
The internal standard (IS) tolfenamic acid was added to the elution solvents to quantify 
the extraction efficiencies of the target pharmaceuticals. The highest extraction 
efficiencies were obtained at acidic pH with Oasis HLB 6cc and these cartridges were 
subsequently used to analyse the aqueous samples of the biodegradation study and the 
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tank water of the fish exposure. All samples were filtered using GF/C paper (Whatman) 
and diluted to 5% methanol. The internal standard was added at 5% of the concentration 
of the tested pharmaceuticals prior to the extraction. The samples were loaded into the 
cartridges that were previously conditioned, then washed with ultrapure water and 
eluted in the same way as described in Table 2.2. The solvents collected sequentially 
were evaporated to dryness in a SpeedVac concentrator (Savant Instrument, NY, USA). 
The samples were reconstituted in 200 μl of methanol:water (1:1, v/v) and filter-
centrifuged for 1 min at maximum speed using VectaSpin MicroAnapore (0.2 μm, 
Whatman). All samples were then transferred to HPLC vials and sealed using PFTE 
liner solid caps. All glassware used for the extraction were baked at 500°C for 2 hr to 
eliminate any organic contaminants. 
 
2.7.2. Ultraperformance liquid chromatography time-of-flight mass spectrometry 
The extracted samples were separated using an Acquity UPLC BEH C18 column 
(100 mm x 2.1 mm, 1.7 µm particle size; Waters, Elstree, UK). An injection volume of 
20 μl was used. The mobile phase consisted of 5% methanol and 0.2% formic acid in 
water (A) and 0.2% formic acid in methanol (B) at a flow rate of 0.1 ml/min. The 
mobile phase gradient was kept at 50% solvent A for the first 3 min followed by a linear 
gradient over 12 min to 100% solvent B. This was held for 4 min and re-equilibrated to 
50% A for 7 min. The pharmaceuticals were detected on a Micromass QTOF-MS 
system (Manchester, UK) with electrospray ionization operated in either positive (+ESI) 
or negative (-ESI)  ionization mode. The internal calibration (lockmass) of the mass 
spectrometer was performed with sodium formate and sulfadimethoxine infused at 40 
µl/min via lockspray interface to ensure accurate mass measurements. The internal 
lockmass m/z were 311.0814 (+ESI mode) and 309.0658 (-ESI mode).  
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Table 2.1 – Solid phase extraction protocol. 
 Acidic pH Neutral pH 
Sample 
preparation 
20 ml water with 200 µl acetic 
acid 
500 ng of the relevant 
pharmaceutical 
20 ml water with 30 mM sodium 
acetate buffer (pH 7) 
500 ng of the relevant 
pharmaceutical 
Cartridges 
Oasis HLB 6cc (200 mg/6 ml) 
Strata X 33µM Polymeric 
Sorbent Patent (200 mg/6 ml) 
Strata X-AW 33µM Polymeric 
Weak Anion (200 mg/6 ml) 
 
Conditioning 
4 ml ethyl acetate 
4ml methanol 
4 ml 1% acetic acid in HPLC 
water 
4 ml ethyl acetate 
4ml methanol 
4 ml 30 mM sodium acetate buffer 
 
Load the samples 
Wash with 3 ml of HPLC water 
Dry cartridges by vacuum aspiration 
Elution 
4 ml ethyl acetate 
4 ml methanol 
4 ml 2% formic acid in methanol 
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Nitrogen was used as nebulizing and desolvation gas and argon was used as collision 
gas. The MS parameters were collision energy 7 eV, capillary voltage 2.65 kV, cone 
voltage 35 kV, source temperature 100ºC with a cone gas flow of 0 l/hr, desolvation gas 
308 l/hr and desolvation temperature 250ºC. Data were acquired with MassLynx 4.1 and 
a mass window of 50 ppm was used to extract signals from the total ion current (TIC). 
Full scan spectra of the compounds were recorded in positive and negative mode in 
order to select the most abundant m/z ion. The theoretical parent ion for each analyte 
was calculated by using the Molecular Weight Calculator software (MassLynx V 4.1) 
from the atomic mass of the most abundant isotope of each element.  
 
2.7.3. Quantification of pharmaceuticals 
Five samples with known concentration for each pharmaceutical were injected in 
the UPLC-TOF-MS using the conditions described in section 2.8.2. To determine the 
extraction efficiency, a method known as internal calibration was used. Calibration 
curves were constructed by plotting a linear trend line of the ratio of the pharmaceutical 
peak area to IS peak area against concentration. For the experimental samples, a 
calibration curve was constructed by plotting a linear trend line of the pharmaceutical 
peak area against concentration, a method known as external calibration. In order to 
estimate how closely the estimated values for the trend line corresponded to the actual 
data, the regression coefficient (R2) was calculated. The sensitivity of the method was 
evaluated by the instrumental limit of detection (LOD) for the different compounds and 
this was estimated as 3 times the signal-to-noise ratio. Each sample was analysed in four 
replicates and the precision (reproducibility) was calculated by the relative standard 
deviation of the measurements. 
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2.8. Fish studies 
Fish were exposed to low concentrations of the pharmaceutical diclofenac for 3 
weeks. The tissues collected after the exposure were analysed to assess the effects of 
diclofenac on selected gene expression and tissues’ health. 
 
2.8.1. Supply and maintenance of the fish 
Juvenile female rainbow trout (Oncorhynchus mykiss) (~200 g) were acquired 
from Houghton Springs Fish Farm in Dorset (UK) and acclimated for 6 weeks in the 
laboratory prior to exposure to diclofenac. Fish were maintained in tanks with 
dechlorinated aerated tap water at a temperature of 10ºC under a 12:12 hr light:dark 
photoperiod. They were fed three times a week with standard trout pellets (2 mm 
pellets, Biomar Ecoline, Denmark). All fish were PIT (Passive Integrated Transponder) 
tagged to allow subsequent identification of individual fish. Fish were also weighed and 
measured. 
 
2.8.2. Experimental set up 
Exposure to diclofenac was carried out in 150 l aerated tanks equipped with a 
flow through water system (18 l/hr). The experimental set up for the exposure is 
illustrated Figure 2.2. Fish were placed in groups of 15 per replicate tank and exposed to 
diclofenac (98% purity, Sigma) for 21 days at nominal concentrations of 0, 0.5, 1, 5 and 
25 µg/l. In order to monitor the concentration of diclofenac in the tanks, 1 l water 
samples were taken at day 0, 7, 14 and 21. The samples were fixed with 5% methanol 
and stored at 4ºC for up to 24 hr before analysis by SPE and UPLC-TOF-MS (section 
2.7). Feeding was withheld 5 days before the final sampling day. 
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a)  
 
 
Figure 2.2 – Diclofenac (DCF) in vivo experimental set-up showing (a) header tank and 
peristaltic pump and (b) tank lay-out. 
Header Tank Fresh Water 
Peristaltic 
Pump 
b) 
0.5 µg /l DCF 
1 µg /l DCF 
5 µg /l DFC 
25 µg /l DCF 
Water control 
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2.8.3. Dissection and tissue collection 
Anaesthesia of the fish was carried out in accordance with Animals Act 1986 
(Scientific Procedures). A solution of the anaesthetic benzocaine (ethyl 4-
aminobenzoate) was prepared in ethanol (500 mg/l) and diluted in tap water (1:10, v/v). 
On day 21, fish were placed in a lethal dose of anaesthetic solution until movement of 
the operculum had ceased. The fish were then removed and the brain was destroyed.  
The length, weight and tag number of each fish were recorded. Liver, gills, intestine, 
kidney, blood and bile samples were excised from each fish. 
Liver, gills and kidney samples collected for molecular studies were stored in 
1.5 ml Eppendorf tubes and immediately frozen in liquid nitrogen. The samples were 
then stored at -70ºC. Samples of liver, kidney and small intestine kept for histological 
analysis were placed in glass bottles and fixed with Bouin’s solution. This solution 
contained a combination of fixative reagents (piric acid, formaldehyde and acetic acid) 
which prevent structural decomposition and excessive tissue hardening. After 4 hr, the 
tissues were transferred into 70% industrial methylated spirits (IMS). After 24 hr the 
tissues were placed into a fresh solution of 70% IMS and stored at room temperature 
until further analysis. Blood samples of 200 µl were taken from the caudal vein using 
heparinised syringes (23G 0.6 x 30 mm MicrolanceTM needle, Becton Dickinson, UK) 
and transferred to 1.5 ml Eppendorf tubes containing 5 µl of aprotinin. The tubes were 
centrifuged at 10,000 g for 15 min at 4°C (Biofuge fresco, Heraeus, Germany) and the 
plasma was transferred to methanol rinsed glass vials containing 400 µl of methanol for 
metabolomics studies. The bile and blood sampled for metabolomics analysis were 
stored in methanol rinsed glass vials containing two volumes of ice cold methanol. 
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2.9. Total RNA extraction and quantification 
Total RNA was used to quantify the expression of specific genes using Q-PCR. 
Total RNA was extracted using Tri Reagent (Sigma) according to the manufacturer’s 
protocol. This method is based on the RNA isolation technique developed by 
Chomczynski and Sacchi in 1986. Frozen samples (liver, kidney, gills) were 
immediately placed onto ice. In order to lyse the cells, the samples were homogenised 
with 1 ml of Tri Reagent using pellet pestles (Sigma-Aldrich) previously soaked in 0.1 
M NaOH and rinsed with HPLC water. The homogenates were incubated for 5 min at 
room temperature to permit the dissociation of nucleoproteins. A volume of 200 µl 
chloroform was added to each tube and the samples were shaken vigorously by hand for 
15 sec. The tubes were incubated at room temperature for 15 min and centrifuged at 
13,000 rpm for 15 min at 4°C. After centrifugation, the RNA remained in the colourless 
aqueous phase at the top. The DNA and proteins were present in the interphase and the 
lower organic phenol-chloroform phase respectively. The aqueous phase was transferred 
to a fresh tube and 1 ml of ice cold isopropanol was added. The samples were incubated 
overnight in the freezer at -20°C to precipitate the RNA. The following day the tubes 
were centrifuged at 13,000 rpm for 20 min at 4°C to pellet the RNA at the bottom. The 
supernatant was discarded and the pellets were washed with 1 ml of ice cold 75% 
ethanol, briefly vortexed and centrifuged at 7,500 rpm for 5 min at 4°C. Finally the 
RNA pellets were air dried and dissolved in 50 µl HPLC water. The samples were 
stored at -80°C until used for Q-PCR. The isolated RNA was quantified with an ND-
1000 Nanodrop spectrophotometer at 260 nm. The ratio of absorbance at 260/280 nm 
was used to assess the quality of the RNA. Samples with a ratio of ~2 were considered 
as pure. The ratio of absorbance at 260/230 nm was also used as a secondary measure of 
purity Values between 1.8 and 2 were considered acceptable. Lower ratios indicated the 
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presence of contaminants such as proteins. All samples were diluted to a final 
concentration of 1 µg/µl using HPLC water. 
 
2.10. Reverse transcription (RT)-PCR 
RT-PCR was carried out to purify the RNA extracted and synthesise the first 
strand of cDNA. The procedure was conducted in a thermal cycler (MyCyclerTM Bio-
Rad) using DNase/RNase free PCR tubes (0.2 ml Thermo-tubes, Thermo Scientific). 
All reagents and RNA samples were kept on ice. First, the RNA samples were subjected 
to DNase treatment using RQ1 RNase-Free DNase (M6101, Promega, Southampton, 
UK). This initial stage uses an endonuclease to degrade any contaminating DNA. Each 
reaction contained 5 µl HPLC water, 1 µl RNase-free DNase 10x reaction buffer, 2 µg 
relevant RNA (~2 µl) and 2 µl DNase enzyme for a total volume of 10 µl. Samples were 
pulse spun briefly and incubated at 37°C for 30 min in the thermal cycler. Following the 
DNase digestion reaction, 1 µl of RQ1 stop solution was added. The samples were 
mixed well and incubated at 65°C for 10 min to deactivate completely the DNase. The 
samples were then returned on ice. 
Reverse transcription was then performed to synthesize the first strand of cDNA 
forming a mRNA:cDNA hybrid. Random hexamers (10 pM/µl; 5’-NNNNNN-3’) were 
ordered from MWG (Biotech, Germany) and 1 µl was added to each PCR tube. The 
samples were mixed well, incubated in the thermal cycler at 70°C for 5 min to melt the 
secondary structures within the RNA template and immediately chilled on ice to prevent 
the reformation of the secondary structures. RT-PCR reaction was performed using 
Moloney murine leukemia virus (M-MLV) reverse transcriptase (M1701, Promega, 
Southampton, UK). 6µl of HPLC water, 1µl dNTP mix (10 mM each of dATP, dCTP, 
dGTP, dTTP; Invitrogen, UK), 1 µl M-MLV reverse transcriptase enzyme, and 5 µl 5x 
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M-MLV buffer were added. The samples were pulse spun briefly and incubated in the 
thermal cycler at 25°C for 15 min to allow the annealing of the random hexamers, then 
at 42°C for 50 min for cDNA synthesis and finally at 70°C for 10 min to inactivate the 
reaction. The tubes were then chilled at 4°C and stored in the freezer at -20°C. 
 
2.11. Quantitative real-time PCR (Q-PCR) 
Quantitative real-time PCR was used to quantify the expression of target 
mRNAs. The amplification reaction is monitored in real time using fluorescent reporters 
that bind to the PCR products (amplicons) formed. Data is acquired during the 
exponential phase of the reaction, where the doubling of amplicons occurs at every 
cycle. SYBR® Green was used as the fluorescent dye. The increase in fluorescence is 
proportional to the number of amplicons. Quantification is assessed by measuring the 
number of cycles required to reach above a fluorescent background, a parameter known 
as threshold cycle value (CT value). 
 
2.11.1. Primer design for Q-PCR 
Beacon Designer software (Premier Biosoft International, Palo Alto, CA) was 
used to design SYBR Green PCR primer pairs. Sequences of the target genes were 
found in the genomic database available at NCBI and were aligned using program 
Clustal W (http//www.ebi.ac.uk/clustalw) to detect sequence similarities. The sequences 
were then inserted in the software to design primer specific to the target mRNAs. The 
design parameters were set as follow: melting temperature (TM) of both primers 50-
55°C, primer length 18-24 bp, amplicon length 80-140 bp and GC content 40-60%. 
Primer pair with a TM close to 55°C and a low chance of hairpin loop, self or cross 
dimers were selected. These primers would be unlikely to form secondary structures 
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caused by inter- or intra-molecular interactions. Beacon Designer also automatically use 
Basic Local Alignment Search Tool (BLAST; NCBI) to confirm primer specificity to 
only one homologous sequence. The primers selected were purchased from MWG-
Biotech. 
 
2.11.2. Optimisation of primer-pair annealing temperature 
The optimisation of the annealing temperature of a primer pair is important to 
maintain a high PCR product yield and specificity. A temperature gradient with 8 
different annealing temperatures was run in triplicate for each primer pair. The range of 
temperatures tested was set at 1°C below the annealing temperature predicted by the 
primer design software up to 5°C above this temperature (range of 6°C). In this study 
the temperature gradient ranged from 56 to 62°C. The Q-PCR reactions were prepared 
as described section 2.12.4. A pool sample of cDNA from rainbow trout tissues was 
diluted 10-fold in HPLC water and 0.75 µl was added to each reaction. The cycling 
conditions were set as follow: 1 cycle at 95°C for 15 min followed by a denaturation 
step of 40 cycles at 95°C for 10 seconds and an annealing step at each of the 8 
temperatures for 20 seconds. The temperature closest to 60°C with the lowest CT value 
was selected. 
 
2.11.3. Determination of Q-PCR amplification efficiency and melt curve 
The amplification efficiency, linearity and specificity of the primers were 
evaluated by running a standard curve followed by a melt curve. Triplicate Q-PCR 
reactions (section 2.12.4) were run with 0.75 µl of 5 dilutions of cDNA (neat, 10-1, 10-2, 
10-3, 10-4). The cycling conditions were: 1 cycle at 95°C for 15 min followed by 50 
cycles of denaturation at 95°C for 10 seconds and annealing at the optimised 
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temperature of the primer pair (section 2.12.2) for 45 seconds. During this stage the data 
are collected to determine the CT value of each sample. The standard curve was 
generated using the iCycler software (iQTM Multicolour Real-Time PCR Detection 
System Optical Software Version 3.1, Bio-Rad) by plotting the logarithm of cDNA 
dilution against its corresponding CT value (Figure 2.3). Primer efficiency should be 
close to 100% (E = 2.0) suggesting that the products are doubled at every cycle.  
Because SYBR Green binds to double stranded DNA with no discrimination 
between the amplicons and other non specific amplification products, a melt curve was 
performed to determine the specificity of the primer pair (1 cycle at 95°C for 1 min, 1 
cycle at 55°C for 1 min and 80 cycles for 10 seconds starting at 55°C with a temperature 
increase of 0.5°C for each subsequent 10 seconds cycle). In each sample the total 
fluorescence generated by SYBR green was recorded as the temperature changes and 
plotted in a graph (Figure 2.4). The amplicons for the targeted product have 
approximately the same melting point and produce a distinct single peak on the plot. 
Primer dimers melt at lower temperatures and additional PCR products have a higher 
melting point. 
 
2.11.4. QPCR protocol for tissues 
Real time PCR was performed on an iCycler iQTM Real-time Detection System 
(Bio-Rad Laboratories, Hercules, CA) and data were acquired using iCycler software 
(as detailed above). For each reaction the PCR mastermix contained 7.5 μl 2x 
AbsoluteTM QPCR SYBR® Green Fluorescein Mix (ABgene, Epsom, UK), 6 μl HPLC 
water and 0.375 μl of the appropriate forward and reverse primer (10 μM). SYBR® 
Green I Fluorescein Mix contained a Thermo-Start® DNA polymerase, a hot-start Taq 
polymerase and the dye fluorescein used to normalise amplification data. 
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Figure 2.3 – Real-time PCR amplification graph. Each response curve corresponds to serial 
dilution of cDNA  – a) neat, b) 10-1, c) 10-2, d) 10-3, e) 10-4.  The points where the curves cross 
the threshold line are known as the threshold cycle (CT) values. CT values plotted against the 
relative fluorescence are directly proportional to the initial amount of template in the standards. 
 
 
Figure 2.4 – Melt curve analysis. Fluorescence drops rapidly when the amplicons melt and 
produce a distinct peak. 
Threshold line                a       b      c     d    e
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Samples were run in triplicate in 96 well optical plates (ABgene, Epsom, UK). 14.25 μl 
of mastermix and 0.75 μl of the relevant cDNA were dispensed in each well. Each plate 
also had a negative control (0.75 μl of HPLC water instead of cDNA) to check for 
cDNA contamination and a pooled cDNA sample to assess inter-assay variability. The 
plates were sealed using optical quality plate seals (Bio-Rad). The Q-PCR cycling 
conditions were as follows: initial denaturation step at 95°C for 15 minutes, which 
activates the hot-start Taq polymerase, followed by 40 cycles of denaturation at 95°C 
for 10 seconds, and annealing at the appropriate optimised annealing temperature for the 
primer pair for 20 seconds. Following the amplification, a melt curve was performed (1 
min at 95°C, 1 min at 55°C, then 80 cycles each of 10 seconds, beginning at 50°C, 
temperature increasing by 0.5°C at each cycle).  
 
2.11.5. Data analysis 
Relative gene expression levels were calculated based on the arithmetic 
comparative method of Livak and Schmittgen, (2001). Efficiency correction was added 
to the equation as it was not assumed that the efficiency of both the house keeping gene 
and the target gene were 100% (E = 2). Instead the efficiency values calculated with the 
standard curves were entered. Relative expression levels were calculated as follows: 
RE =      (E ref )CT  ref     
              (E target) CT  target  
RE = relative gene expression 
CT = threshold cycle value 
ref = housekeeping gene 
target = gene of interest  
E = real time PCR amplification efficiency for each gene 
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2.12. Histopathology on fish tissues 
The liver, small intestine and kidney of the rainbow trout were processed and 
stained to examine the histopathological alterations caused by diclofenac exposure. 
 
2.12.1. Dehydration and embedding 
Tissues were placed in labelled plastic cassettes and kept in 70% IMS until 
processing. Because fixed tissues are not firm enough to cut thin sections, they were 
embedded in paraffin wax. Fixative solutions and paraffin wax are not miscible. Thus 
the samples were placed in a tissue processor (Shandon Citadel 2000) in order to 
remove all fixative and ensure that the wax infiltrates completely the samples (Table 
2.2). First the tissues were dehydrated through a series of alcohol solutions (step 1-7) to 
remove the fixatives and tissue water content. Then the tissues were transferred to 
Histo-clear® (Fisher Scientific), a clearing fluid miscible with alcohol and paraffin wax 
(step 8-10). Finally the tissues were impregnated with molten wax before the final 
embedding stage (step 11 and 12). Embedding was carried out in stainless steel moulds 
using a wax dispenser (Electrothermal Engineering Ltd., UK). The cassettes were 
incorporated to the blocks which were allowed to cool onto a cold plate (RA Lamb, 
London, UK).  
 
2.12.2. Sectioning of the embedded tissues 
Prior to sectioning, the blocks were put on ice to solidify the paraffin wax and 
produce better sections. The blocks were trimmed with a straight blade scalpel and 
sections of 5 µm were made with a rotary microtome (Shandon AS325 retraction). The 
sections were transferred in a bath of 30% IMS to reduce static charges and floated onto 
a warm water bath at 40°C to smooth the wax. The sections were then collected onto 
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Superfrost glass slides (BDH Laboratory Supplies), labelled and allowed to dry for 24 
hours on a metal hot plate at 40°C. 
 
2.12.3. Haematoxylin and Eosin (H&E) staining  
To examine the tissue elements under light microscopy, the slides were routinely 
stained with haematoxylin and eosin, one of the most widely used histological stain 
(Bancroft and Stevens, 1982). Harris’ haematoxylin is a basophilic dye which stains 
nucleic acids such as cell nucleus and ribosomes in blue/purple. Eosin is a counterstain 
that colours the cytoplasm and proteins in bright pink. Staining was completed using the 
protocol described Table 2.3. The slides were immersed in Histo-clear to be dewaxed 
and transferred though a series of graded IMS solutions to hydrate the tissue. After the 
haematoxylin staining, the slides were washed with tap water and 0.5 % acid alcohol. 
The sections were counterstained with eosin and progressively dehydrated in increasing 
concentrations of IMS. Finally the tissues were cleared in Histo-clear. Stained slides 
were mounted under glass coverslips (Fisherbrand) using the mounting medium 
histomount (National Diagnostics). The slides were allowed to dry for a few days at 
room temperature.  
 
2.12.4. Analysis of fixed tissue sections  
Stained slides were examined by light microscopy (Zeiss Axioskop 40 
microscope; Carl Zeiss Ltd., Germany) coupled with an Olympus DP70 CCD camera 
(Olympus Optical, UK). The digital images were analysed using the software analysis 
3.2 software (Soft Imaging System GmbH, Munster, Germany) for histopathological 
lesions. 
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Table 2.2 – Processing program for histological analyses. 
Step Solution Immersion time 
        1 70% IMS 1 hr 
        2 70% IMS 1 hr 
        3 80% IMS 1 hr 
        4 90% IMS 1.5 hr 
        5 98% IMS 1.5 hr 
        6 100% ethanol 1.5 hr 
        7 100% ethanol 1.5 hr 
        8 Histo-clear 1.5 hr 
        9 Histo-clear 1.5 hr 
       10 Histo-clear 1 hr 
       11 Molten wax (~65°C) 1 hr 
       12 Molten wax (~65°C) 2 hr 
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Table 2.3 – H&E staining protocol for fixed sections. 
Step Solution Immersion time 
1 Histo-clear 5 min 
2 Histo-clear 5 min 
3 100% IMS 2 min 
4 90% IMS 2 min  
5 80% IMS 2 min 
6 Tap water 2 min 
7 Harris’ haematoxylin non acidified 
(Thermoshandon, Pittsburg, US) 
15 min 
8 Tap water 2 min 
9 0.5% of concentrated HCl in 70% IMS 2 min 
10 Tap water 30 sec 
11 70% IMS 30 sec 
12 Tap water 30 sec 
13 Eosin Y aqueous (Thermoshandon, US) 10 sec 
14 Tap water 30 sec 
15 80% IMS 30 sec 
16 90% IMS 1 min 
17 95% IMS 1 min 
18 100% IMS 2 min 
19 100% ethanol 2 min 
20 Histo-clear  2 min 
21 Histo-clear  3 min 
 
2. General Materials and Methods 
58 
 
2.13. Metabolomics studies 
Blood and bile samples were analysed to determine their metabolite 
compositions and identify the metabolites affected by the chemical exposure. This study 
aimed to find biomarkers indicative of exposure to diclofenac. 
 
2.13.1. Hydrolysis of bile samples 
The following stock solutions were prepared: (A) sodium dihydrogen 
orthophosphate (0.2 M) and (B) disodium hydrogen orthophosphate (0.2 M). Phosphate 
buffer (0.1 M pH 6.05) was made by adding 16 ml stock A and 4 ml stock B to 20 ml 
HPLC grade water. Aliquots of 300 µl bile samples were transferred into glass tubes 
and evaporated in a SpeedVac. The samples were reconstituted in 500 µl of 0.1 M 
phosphate buffer. Deconjugation was carried out by adding 200 µl of the following 
enzymes β-glucuronidase (type VII from Eschericia coli, 1000 units/ml) and sulphatase 
(type VI from Aerobacter aerogenes, 2 units/ml). A blank sample was prepared using 
10 µl of HPLC instead of bile. The top of each tube was covered with foil and closed. 
The samples were vortexed and incubated at 37°C for 2 hr and left overnight at room 
temperature. After incubation, the reaction was not stopped with acetic acid to maintain 
the pH neutral. Controls were set up to monitor the activity and specificity of both 
enzymes. Glucuronidase and sulphatase (20 µl) were incubated separately with 50 µl 
phosphate buffer, 20 µl HPLC water and 10 µl nitrophenol glucuronide (10 mg/ml) or 
potassium nitrophenyl sulphate (10 mg/ml). Working enzymes should turn the solution 
yellow. All glassware used were washed with detergent, rinsed with water and washed 
with acetone. They were then wrapped in foil and baked at 500°C for 2 hr. 
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2.13.2. Solid phase extraction of bile samples 
Extraction of the bile samples was carried out using the cartridges Strata X-AW 
(60 mg, 6 ml, weak anion exchange) (Phenomenex, Macclesfield, UK). Samples were 
diluted in 7 ml sodium acetate buffer (300 mM, pH 7.0) and loaded into the cartridges 
previously conditioned with 3 ml ethyl acetate, 3 ml 2% formic acid in methanol, 2 ml 
HPLC water and 3 ml sodium acetate buffer. After sample loading, the cartridges were 
washed with 1 ml of HPLC water and dried under vacuum aspiration for 10 min. Bile 
extracts were eluted with 2 ml ethyl acetate and 2 ml 2% formic acid in methanol as one 
fraction. The cartridges were then rinsed with 1 ml HPLC water, dried for 10 min and 
further eluted with 2 ml 2% ammonium hydroxide in methanol. The fractions were 
evaporated to dryness in a SpeedVac and brought up in 100 μl of methanol:water (1:1, 
v/v). The bile extracts were vortexed, centrifuged in 0.22 µm ultrafiltration tubes 
(Millipore) for 1 min at maximum speed and transferred to HPLC vials using a Pasteur 
pipette. The extracts were stored at -20°C until UPLC-TOF-MS analysis. 
 
2.13.3. Methanol extraction of blood plasma samples 
Blood metabolites were separated using a methanol extraction procedure. 
Aliquots of 200 μl plasma samples were mixed to 200 μl of ice cold methanol in glass 
test tubes and 80 μl of internal standard (IS) E2-d4-S and P-d9 (working solution 10 
pg/μl). A control sample was prepared with 200 μl methanol instead of blood plasma. 
Samples were vortexed and kept on ice for 5 min then centrifuged for 10 min at 3,000 
rpm. The supernatant was transferred to a new glass tube with a glass pipette and 
evaporated to dryness in a SpeedVac. Blood extracts were reconstituted in ice cold 
methanol:water (1:1, v/v), vortexed and kept one ice for 15 min. The extracts were then 
purified using an Extraction Plate Manifold and 96-well Sirocco TM Protein 
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Precipitation Plates (Waters, UK). The extraction plates were washed with methanol: 
water (1:1, v/v) and dried for 10 min by vacuum aspiration. The extracts were 
transferred to the 96-well plates, filtered by vacuum aspiration and placed in HPLC 
vials and stored at -20°C. The samples were then analysed using the UPLC-TOF-MS 
system detailed section 2.7.2. 
 
2.13.4. Pre-processing of data 
Chromatographic raw data were processed using MarkerLynx V 4.1 software 
package (Waters Corporation, Milford, USA). The chromatograms were aligned with 
the IS where applicable and normalized to spectral area. The parameters used for the 
detection of the spectral peaks were optimised to reduce the noise level.  
Data collected were then exported to SIMCA-P software (Umetrics UK Ltd., 
Windsor Berkshire, UK) where it was centered by subtracting their averages and scaled. 
Principal Component Analysis (PCA) was performed and provided an overview of the 
data and to detect outliers. This projection method reduces the dimensionality of the 
dataset, usually 2-5 dimensions (components) to provide a general overview of the data. 
The components are uncorrelated variables transformed from the original variables of 
the data and they account for as much of the variability of the data as possible. Strong 
and moderate outliers were identified in the score plot and in the distance to the model 
X-space (DModX) respectively. Outliers were removed for subsequent analysis. 
 
2.13.5. Multivariate analysis 
A supervised analysis PLS (partial least-squares to latent structures) was 
performed to find class-separating differences amongst the treatments. A 7-fold cross 
validation was used to determine the significant components of the model. In order to 
2. General Materials and Methods 
61 
 
improve the PLS model findings, OPLS (orthogonal PLS) models were performed so 
that class separation is found only in the first predictive component. The potential 
markers were selected from the S-plot of the OPLS models, a plot of contribution of 
variables vs. confidence, where high confidence variables with large changes between 
groups are found at the extreme ends of the “S”. Variables represent the ion of a 
metabolite (e.g [M+H] or [M-H]) depending on the ESI mode. The accuracy of the 
models was evaluated using the explained variation (R2X for PCA, and R2Y for PLS 
and OPLS), and the predicted variation (Q2). R2 informs on how well the model fits to 
the data and Q2 is the cross-validation parameter estimating the predictive ability of the 
model. 
 
2.13.6. Model and data validation 
To assess the risk of overfitting, a cross validation was performed on the PLS-
DA models with a predicted variation (Q2) higher than 0.4. Training sets were built 
leaving five observations of each treatment out in turn and remodelling the data until 
60% of the observations were used to predict class membership (external validation).  
The raw data (not normally distributed) of each potential metabolite marker was 
analysed using the non-parametric test Kruskall-Wallis followed by a Mann-Whitney 
test post hoc for pair-wise comparisons of the control vs. one the exposure. Post hoc 
tests can increase the number of false positives (Type I errors), thus a Bonferroni 
corrected critical value was calculated dividing 0.05 by the number of variables in each 
model. No observations were removed for this analysis. 
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Abstract 
The occurrence of pharmaceuticals in the aquatic environment has become an 
issue of growing concern. Non-steroidal drugs are some of the most frequently detected 
pharmaceuticals in the aquatic environment due to a combination of their recalcitrance 
and continuous input. Although the concentrations reported are generally too low to 
cause acute toxicity to vertebrates, effects of chronic exposure on naturally occurring 
microbial communities are unknown, with potentially major environmental 
consequences. This study investigated both the ability of aquatic microbes to degrade 
the non-steroidal anti-inflammatory drugs (NSAIDs) diclofenac, naproxen and 
ketoprofen, and subsequently the biological effects of these drugs on selected bacteria. 
Activated sludge and wastewater effluents collected from local wastewater treatment 
plants (WWTPs) were used in microcosm experiments in order to assess the 
biodegradation potential of NSAIDs. Solid phase extraction and liquid chromatography-
mass spectrometry were used to detect the pharmaceuticals in the enrichments. Up to 
60% of naproxen and 99% of ketoprofen was removed after 40 days of incubation, 
whereas diclofenac was not eliminated and reached up to 90% of its initial 
concentration. The test pharmaceuticals reduced the growth rate of these microbial 
communities, suggesting toxic impacts from a few µg/l. Assessment of the toxicity of 
the NSAIDs on Vibrio fischeri (Microtox® test) and bacteria isolated from activated 
sludge showed toxicological effects at concentrations 10,000 times higher than those 
detected in the environment. Further evaluations on the abilities of microbial 
communities to degrade pharmaceuticals and their direct effects on microbes are much 
needed to more fully assess the persistence and impacts of pharmaceuticals in 
freshwater ecosystems. 
 
Keywords: Diclofenac, Ketoprofen, Naproxen, Microbial degradation 
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3.1. Introduction 
The occurrence of pharmaceuticals in the aquatic environment has been known 
for some time (Richardson and Bowron, 1985) and has become an issue of international 
environmental concern. Many pharmaceuticals have been detected in wastewater 
effluents, surface waters and groundwaters, often at concentrations in the range of 0.1-
10 µg/l (Halling-Sorensen et al., 1998). Traces of clofibric acid (5-270 ng/l), diclofenac 
(up to 6 ng/l), carbamazepine (24-258 ng/l), and a variety of other active ingredients 
have also been detected in drinking water (Jones et al., 2005). Several surveys have 
shown that globally, wastewater treatment plants (WWTPs) are the major route of entry 
for pharmaceuticals into the aquatic environment (e.g. UK, Ashton et al., 2004; 
continental Europe, Andreozzi et al., 2003; Canada, Lishman et al., 2006; US, Kolpin et 
al., 2002; Brazil, Stumpf et al., 1999), but other sources include via livestock, point 
sources (e.g. via agricultural effluents) or diffuse run-off (Boxall, 2004). Thus low 
levels of pharmaceuticals are continuously discharged in the aquatic environment and 
prolonged exposures could lead to effects for non target organisms, especially given that 
these drugs are specifically designed to modify biological processes, many of which are 
highly conserved across taxa. In India, exceptional levels of pharmaceuticals (e.g. 
antibiotic ciprofloxacin) enter the aquatic environment at concentrations exceeding 
levels toxic to bacteria (Larsson et al., 2007). This is potentially a major health hazard 
since the presence of antibiotics in the environment may predispose bacteria to develop 
drug resistance. 
Most pharmaceuticals entering the aquatic environment via WWTPs are derived 
from human excretions and inappropriate disposals of prescription drugs and are thus 
found unmodified from the ingested drug, as metabolites and/or as conjugates. The 
primary elimination mechanisms for pharmaceuticals in the environment are via 
microbial degradation and sorption to filterable particulates (Daughton and Ternes, 
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1999). Other abiotic transformations such as hydrolysis and photodegradation also 
contribute to the elimination process.  
Non-steroidal anti-inflammatory drugs (NSAIDs) are some of the most 
frequently detected pharmaceuticals worldwide in aquatic environments (Bendz et al., 
2005). In 2000, ibuprofen, naproxen, diclofenac and mefenamic acid were reported to 
be amongst the 25 pharmaceuticals most used drugs in the UK (Jones et al., 2002). 
NSAIDs are organic acids with a low sorption coefficient (pKa ~4) which implies that 
microbial degradation plays an important role for their removal during wastewater 
treatment. Environmental studies on NSAIDs have reported limited rates of microbial 
degradation and have attempted to identify the metabolites produced (Zwiener and 
Frimmel, 2003; Quintana et al., 2005; Gonzalez et al., 2006; Gröning et al., 2007). 
These studies have concluded that ibuprofen is easily degraded in the environment, 
whereas diclofenac was usually described as recalcitrant. Photodegradation is currently 
considered the main pathway of environmental naproxen and diclofenac transformation 
(Tixier et al., 2003). 
The recalcitrance of pharmaceuticals has been shown to induce toxic effects in 
wildlife populations. In Pakistan, the virtual extinction of three vulture populations has 
been ascribed to diclofenac-induced renal toxicity (Oaks et al., 2004). The occurrence of 
NSAIDs and other biologically active compounds in the aquatic environment has raised 
concerns about their adverse effects on the microbial communities, but there has been 
little study in this regard (Boxall, 2004). Ecotoxicological risk assessments have 
focussed mainly on aquatic organisms using data on pharmaceutical distribution, 
measured environmental concentration (MEC), predicted environmental concentration 
(PEC) and predicted no effect concentration (PNEC) (Yamamoto et al., 2009). Acute 
and chronic toxicities of pharmaceuticals were evaluated using standardised tests with 
bacteria, algae and crustaceans (Farré et al., 2001; Ferrari et al., 2003; Cleuvers, 2004). 
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These tests provided valuable information on the toxicity of single compound and 
initiated further investigations on the additive effects of pharmaceutical mixtures in the 
aquatic environment (Richards et al., 2004). More recently, research has considered the 
toxic effects of pharmaceutical metabolites in the environment. For example clofibric 
acid, is a product converted from a pharmacologically inactive parent compound 
(Daughton and Ternes, 1999). Naproxen photoproducts have also exhibited higher 
toxicity than the parent compound (Isidori et al., 2005). These observations emphasise 
the need to consider the degradation pathway and products of pharmaceuticals in order 
to predict their potential effects in the environment. Degradation pathways can help in 
studies on the biodegradability and toxicity of chemicals. Several databases such as the 
BIOWIN software are now available to predict the biodegradation behaviour of 
pharmaceuticals in wastewater treatment and the receiving waters. However, the results 
do not always reflect the behaviour predicted. Yu et al. (2007) found that different 
databases give very different results. 
Here we conducted a series of laboratory experiments to assess the 
biodegradability and toxicity of selected NSAIDs (diclofenac, naproxen and ketoprofen) 
in the aquatic environment. The objectives were to enrich and isolate bacterial 
communities able to degrade diclofenac, ketoprofen and naproxen and to gain a better 
understanding of the effects of these compounds on aquatic microbes. Furthermore, the 
identification of degrading microbes in mixed communities may provide beneficial 
information for the improvement of bioremediation for these NSAIDs.  
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3.2. Materials and methods 
3.2.1. Chemicals and reagents 
The pharmaceuticals used in this study are described in Table 3.1. They were 
purchased from Sigma-Aldrich (Poole, UK) at the highest purity available. All other 
chemicals were obtained from Fisher (UK). HPLC-grade solvents were supplied by 
Rathburn Chemicals Ltd (Walkerburn, Scotland). 
 
3.2.2. Environmental sampling  
Microbial inocula used in the experiments were collected from the River Exe 
catchment (South Devon, UK). Countess Wear is the largest WWTP in the Exe 
catchment and receives wastewater from a domestic population of 130,658 people as 
well as discharges from a major hospital and local industries (SX 948 891 GB grid). 
Activated sludge and river water at the sewage outfall were collected from this site. The 
WWTP at Tiverton treats mainly domestic wastewater from about 19,233 people and is 
located in a more rural area compared with Countess Wear WWTP (SS 954 103 GB 
grid). River water was collected approximately 100 m downstream Tiverton WWTP. 
Samples were kept in autoclaved 1 l amber glass bottles filled completely and sealed. 
 
3.2.3. Biodegradation study 
To identify potential communities of degrading microbes, a first batch of 
enrichment cultures was set up with 1 ml of activated sludge as a microbial inoculum 
and spiked with 10 mg/l of diclofenac, ketoprofen or naproxen. A second batch of 
enrichments was conducted with 1 ml sludge or 5 ml collected water and 1 mg 
diclofenac/l as the sole carbon source. All the enrichments were initiated in triplicate in  
Table 3.1 – Properties of NSAIDs used in this study 
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Compound 
(CAS no) 
MW 
Structure 
Excreted 
unchanged 
Reference 
Diclofenac 
(15307-86-5) 
295.016 
 
 
5-15% a, b 
Naproxen 
(22204-53-1) 
230.094 
 
 
<1%  b 
Ketoprofen 
(22071-15-4) 
254.094  
 
<1%  b 
Ibuprofen 
(15687-27-1) 
206.130 
 
  
1-8%  
 
a, b 
a- Bendz et al., (2005); b- Kasprzyk-Hordern et al., (2009) 
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250 ml Erlenmeyer flasks containing 100 ml of minimal salts growth medium.  
Minimal salts medium was prepared as described in Tett et al. (1994) and 
contained: 0.2 g MgSO4, 0.5 g (NH4)2 SO4, 0.5 g KH2PO4, 1.5 g K2HPO4, 0.12 g 
Na2EDTA, 0.02 g NaOH and 0.5 ml of concentrated H2SO4 per litre of deionised water. 
A 1 ml of trace elements solution was added (0.4 g Zn SO4, 0.1 g CuSO4, 0.01 g 
Na2SO4, 0.1 g Na2O4, 0.04 g MnSO4, and 0.01 g CoCl2 in 100 ml of deionised water). 
Biotic controls were set up without the addition of pharmaceuticals and abiotic controls 
contained an autoclaved bacterial inoculum. Activated sludge contains many carbon 
sources readily available for microbes. Thus the microbial growth of the enrichments 
was compared to biotic controls in order to determine whether the microbes were 
metabolising the pharmaceuticals or other carbon sources present in the environmental 
samples. The flasks were closed with porous foam to allow the oxygen transfer. The 
enrichments were incubated statically for 48 hr then transferred to an orbital shaker at 
25ºC. The turbidity of the medium was used as an indicator of microbial growth 
measured at 600 nm. To ensure that sufficient carbon source was available during the 
experiments and enhance the growth of the bacterial degraders, the enrichments were 
sub-cultured at day 5, 10, 15 and 40. 5 ml of each culture was inoculated into fresh 
MSM with the relevant pharmaceutical. 
 
3.2.4. Solid Phase Extraction (SPE) 
Preliminary experiments investigated the extraction efficiency of the NSAIDs 
using the cartridges Oasis HLB 6cc (200 mg, Waters, UK) and Strata X (200 mg, 
Phenomenex, UK). The recoveries were determined with 20 ml of tap-water spiked with 
500 ng of each pharmaceutical (n=4). For this study, cartridges Oasis HLB 6cc were 
preferred as similar recovery rates were obtained for all chemicals. Prior to the 
extraction, the environmental samples were filtered using GF/C paper (Whatman, UK) 
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and diluted to 5% methanol. A volume of 50 µg/l of tolfenamic acid was added as an 
internal standard for subsequent quantification. The extraction protocol is described in 
Figure 3.1. During the procedure, the cartridges were not allowed to dry unless stated. 
Elution solvents collected sequentially in glass test tubes were evaporated to dryness in 
a SpeedVac concentrator (Savant Instruments Inc.- SpeedVac Plus) and made up to 500 
µl with methanol: water (1:1, v/v). A thorough vortex was applied to the fractions and 
they were centrifuged in filter tubes (VectaSpin MicroAnapore, 0.22 µm pore size, 
Whatman). The filtered extracts were transferred to vials for chemical analysis. 
 
3.2.5. Ultraperformance Liquid Chromatography/Electrospray ionisation time-of-
flight- Mass Spectrometry 
Chromatography was performed on a Waters Acquity UPLC autosampler 
equipped with an Acquity UPLC BEH C18 column (1.0 x 100 µm, 1.5 µm particle size; 
Waters, Elstree, UK). The extracted samples were injected at a volume of 20 µl. The 
mobile phase was made of 5% methanol and 0.2% formic acid in water (A) and 0.2% of 
formic acid in methanol (B) at a flow rate of 0.1 ml/min. The elution gradient started 
with 50% eluent B for 3 min followed by a 12 min linear gradient to 100% eluent B. 
This was held for 4 min and re-equilibrated to 50% B in 4 min.  
The LC system was coupled with a Micromass QTOF-MS system (Manchester, 
UK), with an electrospray source operating in positive ion mode. The parameters of the 
MS system were optimised and set as follow: collision energy 7 eV, capillary voltage 
2.65 kV, cone voltage 35 kV, source temperature 100ºC with a cone gas flow of 0 l/hr, 
desolvation gas 308 l/hr and desolvation temperature 250ºC. 
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Figure 3.1 – Solid Phase Extraction protocol at acidic pH using Oasis HLB 6cc cartridges 
employed to analyse the water samples. 
 
Environmental sample containing 5% 
methanol and 50 µg/l tolfenamic acid 
Addition of 1% glacial acetic acid 
Cartridges conditioned with: 
4 ml ethyl acetate 
4 ml methanol 
4 ml 1% acetic acid in water 
Sample loaded at flow rate 1 ml/min 
Vacuum aspiration for 15 min 
Elution solvents: 
4 ml ethyl acetate 
4 ml methanol 
4 ml 2% formic acid in methanol 
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3.2.6. Quantification of NSAIDs 
A 5-point calibration curve was constructed for each test pharmaceutical prior to 
sample analysis. Standards were prepared in methanol:water (1:1, v/v). Data were 
acquired and analysed using the software Masslynx V4.1 (Waters Inc 2005). The limit 
of detection of each pharmaceutical was estimated as three times the signal-to-noise 
ratio.  
 
3.2.7. Bioluminescence assay 
Based on evidence from the enrichment studies for toxicity of the selected 
NSAIDs, a standardised acute toxicity assay was performed with the bioluminescent 
bacteria Vibrio fischeri (NRRL B-11177). Light emission is directly linked to metabolic 
activity and toxic compounds affecting the metabolism would lead to a reduction of the 
light emitted. The toxicity of ketoprofen, naproxen and diclofenac was compared to a 
widely used drug of the same class, ibuprofen. A Microtox® kit containing the freeze-
dried bacteria, reconstitution solution, diluent (2% NaCl) and an osmotic adjusting 
solution was purchased from SDI (Newark, USA). The test substances were dissolved 
in deionised water for a final concentration of 50 mg/l. The bioassay was conducted 
using the photometer Microtox Model 500 Analyzer. The ’49.5% Basic Test’ was 
followed. The natural bioluminescence of Vibrio fischeri was measured after 5 and 15 
min incubation to determine the effective concentration (EC50) of the compound that 
would reduce the bioluminescence by 50%. EC50 from concentration response curves 
were estimated using the software Microtox Omni V1.18 (Azur Environmental, 1999). 
 
3.2.8. Disc diffusion assay 
The toxicity of diclofenac was evaluated further using bacterial species 
commonly found in activated sludge (Dias and Bhat, 1964). Pseudomonas putida 
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(DSMZ 5232), Comamonas denitrificans (DSMZ 17787), Micrococcus luteus (DSMZ 
14235) and the filamentous bacteria Zoogloea ramigera (DSMZ 287) were selected to 
investigate the effects of diclofenac on colony growth The bacteria were grown in 
nutrient broth overnight and 0.5 ml of inoculum was subsequently applied to nutrient 
agar plates in duplicate. Filter paper discs (Whatman grade 1) containing diclofenac in 
concentrations of 0 to 100 mg/l were placed on the agar of each plate. The plates were 
then incubated for 16 hr at 28ºC and the diameter of the inhibition zone recorded. 
 
3.2.9. Predicted pathway for the biodegradation of diclofenac  
The biodegradation pathway of diclofenac was predicted using the University of 
Minnesota Biocatalysis/Biodegradation database (UM-BBD). This program, available 
online, predicts the chemical structures that can be formed under aerobic or anaerobic 
conditions. For this study only the aerobic pathways were considered. The database 
indicates the metabolic pathways that may occur in the environment and the metabolites 
produced as a result. For each metabolite selected, subsequent breakdown products are 
suggested, forming a putative biodegradation pathway. 
 
3.3. Results  
3.3.1. Recovery efficiencies for NSAIDs 
Diclofenac, ketoprofen and naproxen were recovered from clean water samples 
with extraction efficiencies of 94% + 6.4, 92% + 4.3 and 85% + 8.2 respectively. The 
pharmaceuticals recovered were predominantly eluted in the ethyl acetate and the 
remaining amounts in the methanol fraction. The limit of detection (LOD) obtained 
from the ethyl acetate eluting fraction were 4.7, 5.9 and 7.3 ng/l for diclofenac, 
ketoprofen and naproxen respectively. These rates of recoveries and detection 
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capabilities suggest that the protocol applied here is suitable for the screening of 
pharmaceuticals in environmental water samples.  
 
3.3.2. Biodegradation study 
Ketoprofen enrichments grew beyond the growth of the biotic controls, 
suggesting that the microbial communities in those enrichments were able to metabolise 
the pharmaceutical (Figure 3.2a). A rapid biodegradation was observed with a half-life 
of 17-20 days. However, the growth was not sustained beyond 15 days and sub-cultures 
did not produce pure bacterial cultures. The chemical analysis of the enrichments 
showed that ketoprofen was transformed in 40 days; although the degradation 
metabolites were not detected. The majority of the compound was eliminated after 15 
days, despite the fact that the microbial growth declined. Similar observations were 
made for the enrichments with naproxen. Between 45-58% of naproxen was recovered 
by day 40, indicating a relatively slow degradation rate (half-life of 39-45 days) (Figure 
3.2b). But the loss of the parent compound did not coincide with the increase in the 
microbial growth rate. The biodegradation of diclofenac was very slow with an 
estimated half-life of over 100 days. Unlike the other enrichments and the controls, 
there was no bacterial growth observed.  
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Figure 3.2 – Degradation of NSAIDs (conc. 10 mg/l) with sludge samples incubated in an 
orbital shaker at 25 ºC. Data represented as mean +SE; n=3. Samples were collected between 
January and July 2006. a) microbial growth monitored by optical density at 600 nm, b) 
percentage of NSAIDs recovered in the enrichments using LC-MS. 
a) 
b) 
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3.3.3. Diclofenac degradation study 
Further experiments were carried out to investigate the biodegradability of 
diclofenac using river water, sewage effluent and activated sludge samples as microbial 
inocula. In order to minimize the potential toxic effects of diclofenac, the concentration 
was reduced to 1 mg/l of growth medium. The analysis of the control cultures indicated 
that a small percentage of diclofenac can be lost by abiotic processes. The highest 
removal rate (half-life of 75 days) was measured in the enrichments with activated 
sludge (Figure 3.3b). A significant increase in microbial growth was recorded only in 
the enrichments with activated sludge, which contains other carbon sources readily 
available. Sub-culturing did not enhance the microbial growth and no pure cultures were 
isolated. The enrichments with river water exhibited a slow growth rate which declined 
after a few days of incubation. Biodegradation rates were slow in those enrichments and 
half-lives ranged between 100 and 150 days. 
 
3.3.4. Bioluminescence assay 
The environmental impact of diclofenac, naproxen and ketoprofen was assessed 
according to criteria of the European Community legislation on classification described 
by Carlsson et al. (2006). The pharmaceuticals had an acute toxicity ranging between 10 
and 50 mg/l, they can be considered harmful to aquatic organisms. Diclofenac was the 
most toxic of the four NSAIDs with an EC50 ranging between 11.1 and 13.9 mg/l. 
Naproxen, ketoprofen and ibuprofen showed more moderate levels of toxicity on Vibrio 
fischeri (Table 3.2). The EC50 measured for all four NSAIDs did not vary significantly 
after 5 and 15 min exposure. The toxic concentrations estimated in this study are much 
higher than those detected in the environment. Thus these pharmaceuticals are unlikely 
to cause acute toxic effects.  
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Figure 3.3 – Degradation of diclofenac (1 mg/l) using environmental samples. Samples were 
collected in February 2007 and the enrichments were incubated in an orbital shaker at 25 ºC. 
Data represented as mean +SE, n=3. a) microbial growth monitored by optical density at 600 
nm, b) percentage removal of diclofenac. S1- Tiverton WWTP effluent, S2- Countess Wear 
WWTP effluent, S3- activated sludge.  
a) 
b) 
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Table 3.2 – Acute toxicity testing (EC50, 15 min) of NSAIDs using Vibrio fischeri.  
  Diclofenac Ketoprofen Naproxen Ibuprofen 
EC50 (mg/l) 13.5 24.3 42.1 24.7 
95% CI 11.11 – 14.01 23.08 – 25.44 33.64 – 48.7 20.08 – 29.38 
R2 0.989 0.983 0.955 0.975 
CI: confidence interval. 
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3.3.5. Disc diffusion assay 
Further investigations into the toxicity of diclofenac showed that both Gram 
positive and negative bacteria can withstand high concentrations of diclofenac. The 
minimum inhibitory concentration (MIC) for P. putida was estimated at 90 mg/l. 
Diclofenac exposure did not significantly affect the bacterial growth (Table 3.3). MICs 
for Z. Ramigera, M. luteus and C. denitrificans were between 50-70 mg/l. Even though 
the mode of action of diclofenac was not fully investigated, the results suggest that 
diclofenac is bacteriostatic. Colonies sampled from the agar plates containing 50-100 
mg/l of diclofenac were sub-cultured onto fresh nutrient agar plates. After 24 hr 
incubation, the effects of diclofenac were reversed and the bacterial growth significantly 
higher. Diclofenac was able to impair the growth of both Gram-positive and Gram-
negative bacteria but significantly higher concentrations were necessary to kill the 
bacteria. 
 
3.6. Prediction of the biodegradation pathway for diclofenac 
Although diclofenac biodegradation has been previously reported, this study 
found no evidence of microbial degradation. The investigations on the putative 
degradation pathway of diclofenac provided similar conclusions. The environmental 
samples used were oxygen-rich, thus only the aerobic degradation pathway was 
considered. Diclofenac structure was entered into the UM-BBD but a clear degradation 
pathway could not be defined. Four breakdown products were proposed but none of 
them were likely to occur naturally under aerobic conditions. One compound could be 
identified as hydroxydiclofenac, a common metabolite during diclofenac 
transformation. Hydroxydiclofenac was selected as the first possible step in diclofenac 
degradation. The transformation of this metabolite was also described as unlikely to  
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Table 3.3 – Mean diameter of the inhibition zone.* 
Concentration of 
diclofenac (mg/l) 
Comamonas 
denitrificans 
Micrococcus 
luteus 
Pseudomonas 
putida 
Zoogloea 
ramigera 
0 - - - - 
10 - - - - 
20 - - - - 
30 - - - - 
40 - - - - 
50 11.6 - - 9.2 
60 12.7 10.3 - 12.8 
70 14.0 11.9 - 14.6 
80 17.8 13.8 - 18.6 
90 19.9 16.1 6.2 23.0 
100 22.3 18.7 9.4 24.2 
*This corresponds to the area surrounding the discs where bacterial growth was inhibited. 
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occur in the environment. This suggests that there are no known enzymes capable of 
successfully degrading the compound. A diagram of the proposed degradation of 
diclofenac is shown in Figure 3.4. 
 
3.4. Discussion 
There are approximately a hundred new biologically active compounds released 
each year into the environment (Kümmerer, 2004). Despite the hazard risk assessments 
that are carried out routinely for pharmaceuticals, some releases have had considerable 
adverse effects in the environment. In India and Pakistan the unusually high mortality 
rate of three Gyps vulture populations was caused by diclofenac (Fent et al., 2006). The 
presence of ethinylestradiol in rivers can impair the sexual development and function in 
fish (van Aerle et al., 2001). Surveys carried out worldwide have shown that some 
pharmaceuticals persist and accumulate to detectable levels in the receiving waters 
(Boxall, 2004).  
Many analytical techniques are now available to monitor these pharmaceuticals 
in environmental samples. The most frequently used techniques are gas 
chromatography-mass spectrometry (GC-MS) which often require a derivatization step, 
and liquid-chromatography-mass spectrometry (LC-MS). LC-MS has an improved 
selectivity and sensitivity compared with GC-MS to detect polar pharmaceuticals and 
their metabolites in complex matrices (Kosjek et al., 2008). In our study we applied SPE 
to extract the pharmaceuticals followed by UPLC-TOF-MS in positive electrospray 
ionization for chemical detection and quantification. The recovery rates of the NSAIDs 
compared favourably with the most efficient extraction rates reported for environmental 
samples (Farré et al., 2001; Gómez et al., 2006). The optimised technique proved to be 
suitable for the screening and identification of the acidic pharmaceuticals studied 
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Figure 3.4 – Proposed degradation pathways of diclofenac. Data from UM-BBD was 
used to critically assess the biodegradation potential of diclofenac in the environment. 
Arrows indicate whether the metabolites are likely (green) or unlikely (orange) to occur 
under aerobic conditions. 
diclofenac hydroxydiclofenac 
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at low concentrations (low ng/l range), and well within the range that they occur in 
the aquatic environment (Tixier et al., 2003). 
Biodegradation of NSAIDs is known to occur in the activated sludge during 
wastewater treatment (Ternes, 1998). Here, the enrichments were designed to 
promote bacterial growth, give a selective advantage to the NSAIDs degraders and 
identify them. After 40 days, ketoprofen was found below the limit of detection and 
naproxen appeared to be partially degraded. Biodegradation was relatively rapid for 
both compounds with half-lives of less than 50 days. There was no evidence, 
however, for any microbial degradation of diclofenac. Previous biodegradation 
experiments comply with these findings (Quintana et al., 2005). The effects of 
NSAIDs on the enriched microbial communities observed had never been reported. 
The bacterial population declined after 10-15 days though the highest removal rates 
of naproxen and ketoprofen were reported between 15 and 30 days. The enrichments 
contained less than 0.5 g of carbon/l which may not be sufficient to sustain the 
bacterial growth. To overcome this issue the enrichments were frequently sub-
cultured to ensure that the bacteria actively growing had enough carbon. Sub-
culturing did not improve the growth rate and bacterial degraders could not be 
isolated and identified. The observations suggest that the transformation of naproxen 
and ketoprofen was limited to small bacterial populations that may not be culturable 
under laboratory conditions.  
Abiotic transformation may have also played a role in the enrichments and 
contributed to the removal of these pharmaceuticals. Indeed, photodegradation has 
been shown to be an important process in the removal of diclofenac and other 
NSAIDs from surface waters (Buser et al., 1998; Tixier et al., 2003). Studies on 
naproxen degradation have also indicated that the compound is photosensitive and 
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that several metabolites formed can be more toxic than the parent compound (Isidori 
et al., 2005). Our enrichments were incubated in the dark but exposed to sunlight on 
a daily basis (~1 hr per day) whilst sampling and taking measurements. Therefore 
photodegradation may account for a small percentage of NSAIDs removal. Previous 
studies have shown that NSAIDs do not tend to adsorbed onto solid particulates, 
which suggests that sorption is not a relevant removal mechanism. However, 
investigations on the mobility of NSAIDs have demonstrated that diclofenac and 
ibuprofen had a much higher sorption potential in aquifer sediments than predicted 
(Scheytt et al., 2005). The comparative analysis of the enrichments and the abiotic 
controls indicates that sorption onto solid particulates was very minimal in our 
study. 
The second batch of enrichments with diclofenac did not provide better 
insights in the biodegradation process of this compound. Diclofenac removal rate 
was comparable to the abiotic loss (Figure 3.3b), which implied that biodegradation 
did not occur. The results were supported by the putative biodegradation pathway in 
Figure 3.6. According to the UM-BBD, it is unlikely that diclofenac would be 
readily degraded under aerobic conditions. Other predictive studies have also 
reported diclofenac as not readily biodegraded (Carlsson et al., 2006; Yu et al., 
2006). But whilst the recalcitrance of diclofenac has been established, the removal 
rates remain highly variable. Laboratory based experiments investigating the aerobic 
degradation of diclofenac reported very slow degradation rates with half-lives over 
100 days (Zwiener & Frimmel, 2003, Quintana et al., 2005). Other studies have 
reported up to 60% of diclofenac biodegraded in 30 days with no indications of the 
microorganisms involved (Yu et al., 2006). Recently, Gröning et al. (2006) 
investigated the microbial degradation of diclofenac in biofilms of river sediments. 
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They reported that diclofenac metabolism might be restricted to Gram negative 
bacteria from the γ-Proteobacteria and the Cytophaga-Flavobacterium group. A 
more precise identification of the degrading microbial communities (at species or 
genus level) can be challenging.  
Bacteria make up to 95% of the activated sludge microbial communities but 
less than 1% of the bacterial biodiversity can be cultured under laboratory conditions 
(Dias and Bhat, 1964). Beside, other microbes such as fungi, protozoa and sludge 
worms are present in activated sludge and may contribute to the removal process. 
The conditions of our enrichments were optimised to enhance the growth of bacteria 
alone and did not take into account the other microbes. Indeed fungal species have 
been reported to degrade certain NSAIDs. Zhong et al. (2003) discovered three 
fungal species of Cunninghamella that were able to degrade naproxen. Microbial 
degradation of diclofenac has also been observed by the fungal species Epiccocum 
nigrum (Webster et al., 1998). Because of the complexity of the microbial 
communities, in situ experiments might be more appropriate.  
One plausible hypothesis for the reduced bacterial growth is the toxicity of 
pharmaceuticals such as diclofenac on the bacterial populations. Recent studies 
demonstrated that NSAIDs at concentrations from 50 μg/l reduced the bacterial 
diversity in activated sludge (Kraigher et al., 2008). This may interfere with the 
biodegradation potential of the bacterial populations. The toxic concentrations 
measured in this study were consistent with the data found in the literature (Farré et 
al., 2001). The results of the acute toxicity were also in accordance with the findings 
of our biodegradation experiments. The bacteria were more sensitive to diclofenac, 
which suggests that diclofenac may cause long-term adverse effects in the aquatic 
environment through disruption of microbial communities. Diclofenac also exhibited 
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anti-bacterial properties and inhibited the growth rate of various bacterial strains. 
Other research further supports our findings. Dutta et al. (2004) have shown that 
DNA synthesis was inhibited after exposure to 10-20 mg diclofenac/l. The 
concentrations affecting the microbes were more than a 1,000 times higher than 
those detected in the environment.  
Even though a single pharmaceutical did not have a high toxicity, the adverse 
effects might be increased in the environment by synergic action. Indeed, 
pharmaceuticals are present as a mixture in the aquatic environment and some 
substances may target the same pathways in biological systems. Thus the cumulative 
effects of these compounds could increase the toxicity response of non-target 
organisms (Richards et al., 2004). Cleuvers (2004) demonstrated that the acute 
exposure of a mixture of diclofenac, ibuprofen, naproxen, and acetylsalicylic acid 
had a higher toxic effect on the planktonic crustacean Daphnia magna than a single 
compound exposure. To fully evaluate the fate of pharmaceuticals and other 
pollutants in the aquatic environment, it is important to consider the effects of the 
metabolites produced but also the possible interactions that a mixture of chemicals 
may have on non-target organisms. 
 
 
3.5. Conclusions 
Our study showed that biodegradation of diclofenac, ketoprofen and 
naproxen is a complex process in the aquatic environment. The slow degradation 
rates suggest that these pharmaceuticals may accumulate in the receiving water. 
Enrichment cultures and other classical isolation methods may not be suitable to 
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identify degrading communities. These techniques fail to culture and detect a great 
proportion of microbes present. The toxicity of these compounds also proved to be a 
limiting factor. Successful enrichments require concentrations of NSAIDs that 
exceed the toxic levels and impair the microbial metabolic activities. Further in situ 
research is necessary to understand the dynamics of microbial populations exposed 
to pharmaceuticals and other emerging pollutants. 
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Abstract 
Diclofenac, a non-steroidal anti-inflammatory drug, is widely detected in surface 
waters and can potentially cause deleterious effects in fish. Here, we investigated the 
biological effects of 21-day exposure to waterborne diclofenac at environmentally 
relevant concentrations (0, 0.5, 1, 5 and 25 μg /l) in rainbow trout. Bioconcentration in 
the bile and effects in selected tissues were assessed via responses in the expression of 
genes (cytochrome P450 (cyp) 1a1, cyclooxygenase (cox) 1 and 2, and p53) involved in 
metabolism of xenobiotics, prostaglandin synthesis and cell cycle control respectively, 
together with histopathological alterations in these tissues. Bioconcentration of 
diclofenac in the bile ranged between 509 + 27 and 657 + 25 and various metabolites of 
diclofenac were putatively identified as hydroxydiclofenac, diclofenac methyl ester and 
the potentially reactive metabolite hydroxydiclofenac glucuronide. Expression levels of 
both cox1 and cox2 in liver, gills and kidney were significantly reduced by diclofenac 
exposure from only 1 μg /l. Expression of cyp1a1 was induced in the liver and the gills, 
but inhibited in the kidney of exposed fish. Diclofenac exposure induced tubular 
necrosis in the kidney and hyperplasia and fusion of the villi in the gastrointestinal tract 
from 1 μg/l. This study demonstrates that sub-chronic exposure to environmental 
concentrations of diclofenac can interfere with the biochemical functions of fish and 
lead to tissue damage, highlighting further the concern about this pharmaceutical in the 
aquatic environment. 
 
Keywords: diclofenac, fish, bioconcentration, QPCR, cox, cyp1a1, p53, histopathology.  
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4.1. Introduction 
Pharmaceuticals are environmental pollutants of concern for human and 
environmental health and many enter the aquatic environment, continually via 
wastewater treatment plants (WWTPs) discharges. Pharmaceuticals are generally 
detected in wastewater effluents and surface waters in the ng-µg/l concentration range 
(Halling-Sorensen et al., 1998; Farré et al., 2008; Kümmerer, 2009), but in some 
exceptional circumstances significantly higher concentrations can occur (e.g. β-blockers 
and antibiotics found in treated wastewaters from plants serving drug factories in India 
(Carlsson et al., 2009)). Antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), 
β-blockers and oral contraceptives are the most frequently detected in aquatic 
environments (Daughton and Ternes, 1999; Fent et al., 2006). Typically effect 
concentrations for individual pharmaceutical in aquatic wildlife are at least one order of 
magnitude higher than concentrations measured in surface waters. For example, Gagné 
et al. (2006) demonstrated that analgesics caused cellular oxidative damages at 
concentrations 10 to 100 times higher than those detected in wastewater effluents. 
However, certain pharmaceuticals can induce biological effects in the low ng/l range, as 
is the case for feminised responses in fish exposed to the synthetic estrogen, 
ethinylestradiol (Jobling et al., 1998; Filby et al., 2007). 
The NSAID diclofenac is a widely used human and veterinary pharmaceutical 
prescribed to reduce inflammation and manage pain. In mammals it acts by inhibiting 
the cyclooxygenase (cox) enzymes which catalyse the synthesis of prostanoids. Cox 
genes are conserved in many vertebrate species and appear to serve similar functions to 
those in humans. Prostanoids are involved in many biochemical functions such as 
inflammation, blood flow regulation, platelets aggregation and secretion of gastric 
mucus (Phillis et al., 2006). In 2004, diclofenac was linked to the rapid decline of three 
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Gyps vulture populations in sub-continental India and these populations are now at risk 
of extinction (Oaks et al., 2004). Environmental surveys have shown that diclofenac and 
its metabolites are poorly removed in conventional WWTP and often detected in 
wastewater effluents in concentrations up to a few µg/l (Stülten et al., 2008; Letzel et 
al., 2009). A few studies have investigated the ecotoxicological effects of diclofenac on 
aquatic organisms, including fish and some of the side effects (e.g. an inhibition of 
prostaglandin synthesis) are consistent with side effects observed in humans treated 
with this pharmaceutical (Hoeger et al., 2005). 
Research on diclofenac metabolism in rats and humans has shown that several 
cyp isoforms are involved in its biotransformation (Tang et al., 1999). In fish, cyp1a is 
dominant in the liver but can also be found in the kidney and intestine (Sarasquete and 
Segner, 2000). The expression of cyp1a and its related enzyme activity, 
ethoxyresorufin-O-deethylase (EROD) are regularly used as indicators of 
pharmaceutical exposure and uptake in fish (van der Oost et al., 2003) and various 
classes of human pharmaceuticals can interfere with EROD activity (Laville et al., 
2004; Thibaut et al., 2006). Diclofenac has been shown both to enhance cyp1a 
expression and to  induce the expression of the p53 gene, suggesting effects on cell 
cycle control, in Japanese medaka (Oryzias. latipes) (Hong et al., 2007).  
In this study we investigated the uptake and exposure effects of waterborne 
diclofenac in the rainbow trout, with a focus on environmentally relevant 
concentrations. Fish bile was analysed to evaluate the bioconcentration factor (BCF) 
and metabolism of diclofenac in rainbow trout. Expression of cox1, cox2, cyp1a1 and 
p53 mRNA were used as biomarkers for responses in key biological process thought to 
be affected by diclofenac in fish. We further investigated for histopathological effects in 
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some of the most likely target tissues, specifically, the liver, intestine and kidney using 
light microscopy.  
 
4.2. Materials and methods 
4.2.1. Diclofenac exposure 
Juvenile female rainbow trout were obtained from Houghton Springs Farm 
(Dorset, UK). After acclimatisation for 6 weeks in the laboratory, the fish were placed 
in groups of 15 in duplicate (n=30 in total; for each treatment) 150 l aquaria under flow-
through conditions (water flow rate 18 l/hr). Fish were exposed to nominal 
concentrations of 0.5, 1, 5, 25 µg diclofenac/l and water control for 21 days. Fish were 
fed three times a week with commercial trout pellets. Photoperiod was maintained under 
a 12:12 hr light:dark regime and the water temperature was 12°C. 
 
4.2.2. Fish sampling 
After 21 days, fish were anaesthetised using benzocaine (500 mg /l in ethanol) 
and killed by destroying the brain according to UK Home Office Animal Licence 
procedures. The head kidney, first gill arch and the anterior liver were excised from 
each fish, snap-frozen and stored at -80°C until required for the gene expression 
analysis. The posterior kidney, posterior liver and a sample of the small intestine were 
fixed in Bouin’s solution for 24h and stored in 70% IMS for histological work .Bile 
samples were diluted with 2 volumes of ice cold methanol and kept at -80°C until 
required for chemical analysis to measure the concentration of diclofenac in the bile. 
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4.2.3. Condition factor 
On days 0 and 21 of the exposure, total length and body weight of each fish were 
recorded. From this the Fulton’s condition factor K was estimated using the formula:  
 
 K =       body weight (g) x 100__ 
        total length (cm)3 
 
4.2.4. Analysis of diclofenac in water and bile samples 
On days 0, 7, 14 and 21, 1 l water samples were collected from each tank, fixed 
with 5% methanol and stored at 4ºC for up to 24 hr before chemical extraction. Briefly, 
water samples were acidified with 1% acetic acid and the internal standard (IS) 
tolfenamic acid was added at 10% of diclofenac nominal concentration. Diclofenac was 
extracted on Oasis HLB 6cc solid phase extraction cartridges (200 mg, Waters, Milford, 
USA) and eluted in 4 ml of ethyl acetate. Bile samples (150 µl) from fish exposed to 
0.5, 5 and 25 µg/l were diluted in sodium acetate buffer (300 mM, pH 7.0). SPE 
extraction was performed using Strata X-AW cartridges (60 mg, Phenomenex, 
Macclesfield, UK) and diclofenac and its metabolites were eluted with 2 ml of 2% 
formic acid in methanol and 2 ml 2% ammonium hydroxide in methanol. 
The analysis of diclofenac was performed using ultraperformance liquid 
chromatography time-of-flight mass spectrometry (UPLC-TOF-MS) in +ESI and -ESI. 
The precision, recovery and detection limit of the methodology were optimised by 
spiking control water and fish bile samples (n=4) with diclofenac. Samples were 
quantified using a 6-point calibration curve. Diclofenac was recovered at 94% + 6.4 in 
water and 79% + 7.8 in bile. Data acquired were processed and analysed using the 
MassLynx software V4.1. Chromatographic data were searched to identify metabolites 
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of diclofenac. Structural identification was determined using the elemental composition 
tool in MassLynx. 
 
4.2.5. RNA extraction and reverse transcription (RT) PCR 
Total RNA was extracted from the liver, head kidney and gills using Tri Reagent 
(Sigma, UK) according to the manufacturer’s instructions. The RNA concentration was 
calculated by measuring the absorbance at 260 nm with a Nanodrop spectrophotometer. 
Ratios of absorbance at 260/280 and 260/230 were used to assess the quality of the 
RNA isolated. Prior to cDNA synthesis, the RNA (~2 µg per sample) was treated with 
RQ1 DNase (Promega, UK) to remove any contaminants. RT-PCR was performed on 
the DNase treated RNA to synthesise the first strand of cDNA using random hexamers 
primers (5’-NNNNNN-3’, MWG, Biotech) and Moloney murine leukemia virus (M-
MLV) reverse transcriptase (Promega, UK), according to the manufacturer’s 
instructions. 
 
4.2.6. Primer design and real-time PCR optimisation 
Sequences for cox1, cox2, cyp1a1, p53 genes were searched in NCBI GenBank 
database (www.ncbi.nlm.nih.gov) an specific primers for these target genes in the 
rainbow trout were designed using Beacon designer software 3.0 and synthesised by 
MWG-Biotech (see supplementary material S4.1). The annealing temperature of each 
primer pair was optimised on a temperature gradient. The amplification efficiency (E) 
and detection range of each primer pair were determined by running real-time PCR 
reactions in triplicate on a 10-fold serial dilution of rainbow trout cDNA. Standard 
curves were calculated as the threshold cycle (CT value; numbers of PCR cycles 
required for fluorescence to increase above background level) against the logarithm of 
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the cDNA dilution. The specificity of the primer pairs was confirmed by melt curve 
analysis.  
 
4.2.7. Real-time PCR 
Real time PCR was performed on an iCycler iQ Real-time Detection System 
(Bio-Rad, Hercules, CA). Each PCR amplification was run in triplicate in 15 μl reaction 
volume using 7.5 μl 2x Absolute QPCR SYBR Green Fluorescein Mix (ABgene, 
Epsom, UK), 6 μl HPLC water, 0.375 μl of the appropriate forward and reverse primer 
(10 μM) and 0.75 μl cDNA. A negative control with water replacing the template cDNA 
was run for each plate. To assess intra- and inter-assay variability, a common pooled 
sample of cDNA was quantified on each plate. The temperatures and cycling conditions 
were as follows: initial denaturation step at 95ºC for 15 min, which activates the hot-
start Taq polymerase, then 40 cycles of denaturation at 95ºC for 10 seconds and 
annealing at 59.9°C (cox1, cyp1a1 and p53) or 57.3°C (cox2) for 20 seconds followed 
by a melt curve analysis. Normalisation of the target cDNA, expression was conducted 
using the housekeeping gene rpl8 (sense 5’-ACAACCCAGAC ACCAAGAAG-3’, anti-
sense 5’-CAG CAACCACACCAACAAC-3’; annealing at 60°C) as reported previously 
by Filby and Tyler (2007). Relative expression (RE) levels were determined based on 
the arithmetic comparative method of Livak and Schmittgen (2001) with a correction in 
the differences of E between the target and housekeeping gene.  
 
RE = (E ref )CT  ref/(E target) CT  target  
 
where ref is the housekeeping gene, target is the gene of interest, E is PCR 
amplification efficiency for each gene and CT is threshold cycle value. 
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4.2.8. Histology 
Fixed tissues (10 samples per tissue per treatment) were embedded in paraffin 
wax and sections of 5 µm were cut, mounted onto slides and stained with haemotoxylin 
and eosin (H&E) using standard procedures. Each section was examined for histological 
alterations on a Zeiss Axioskop microscope (Carl Zeiss Ltd., Germany). The lesions 
were semi-quantified using a rating system: 
1 (normal) – All 8 sections examined for each sample are healthy with no apparent 
damage;  
2 (mild) – Minor changes observed in less than 3 of 8 sections analysed. Lesions 
included partial fusion and mild hyperplasia in the villi and high number of developing 
nephrons compared to the control fish in the kidney; 
3 (moderate) – Fusion, hyperplasia and proliferation of Goblet cells in the villi, 
numerous developing nephrons and reduction of Bowman’s space surrounding the 
glomeruli in the kidney. Lesions found in 5 of 8 sections of each sample;  
4 (severe) – Lesions (total fusion of villi, hyperplasia, enlarged Goblet cells, tubular 
necrosis, loss of Bowman’s space) in at least 6 of 8 sections analysed.  
 
4.2.9. Data analysis 
Statistical analysis was performed using SigmaStat 2.03 (Jandel Scientific 
Software). Differences between experimental groups were determined by one-way 
analysis of variance (ANOVA) with Dunnett’s post test against the water control 
groups. Non-normally distributed data were log-transformed prior to statistical analysis. 
Non-parametric data were analysed with Kruskal-Wallis ANOVA followed by Dunn’s 
multiple comparisons pot hoc test. Statistical differences were considered at p<0.05. All 
experimental data are represented as the mean ± standard error (SE). 
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4.3. Results 
4.3.1. Analysis of diclofenac concentrations in the tank water 
UPLC-TOF-MS analysis of water samples taken each week revealed that the 
actual exposure concentrations were 90-105% of the nominal concentrations for both 
replicate tanks (Table 4.1). 
 
4.3.2. Condition factor  
Exposure of rainbow trout to diclofenac did not affect the body size (length or 
weight, data not shown). There were also no significant effects of diclofenac on K 
between day 0 and day 21 within a treatment group (see supplementary material S4.2). 
 
4.3.3. Concentration of diclofenac and identification of its metabolites in fish bile 
Diclofenac was detectable in the bile of fish from the lowest exposure 
concentration 0.5 µg/l. Mean measured concentrations and factor of concentration are 
shown in Table 4.2. Diclofenac accumulated in the bile by a factor of 622 to 780 at 0.5 
µg/l, 499 to 601 at 5 µg/l and 406 to 600 at 25 µg/l exposure concentration. The highest 
level of diclofenac was found in the bile of fish exposed to 25 µg/l with a mean 
concentration of 12724 ng/ml.  
The analysis of the chromatograms resulted in the putative identification of 
different metabolites of diclofenac in fish bile from 0.5 µg/l (Table 4.3). A reactive 
metabolite of diclofenac, hydroxydiclofenac glucuronide (m/z 486.032) was detected at 
the highest exposure concentration (25 µg/l). 
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Table 4.1 – Mean measured diclofenac concentrations (µg/l + SE) in replicate tanks water. 
 Diclofenac concentration (µg/l) + SE 
Nominal concentration 0.5 1 5 25 
0.54 + 0.2 1.59 + 0.45 6.28 + 0.97 24.04 + 2.6 Measured concentration 
0.46 + 0.81 1.55 + 0.7 5.78 + 1.9 22.51 + 1.4 
 
 
 
 
Table 4.2 – Measured diclofenac concentrations (ng/ml, mean + SE) and estimated 
concentration factor in rainbow trout bile after 21-day exposure. 
Nominal concentration Mean measured concentrations 
in bile 
Factor of accumulationa  
0.5 328 + 13 657 
5 2672 + 73 534 
25 12724 + 640 509 
a  calculated as measured diclofenac concentration/nominal exposure concentration. 
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Table 4.3 – Putative metabolites of diclofenac identified in the bile of fish exposed to 
waterborne diclofenac for 21 days. 
m/z value RT ESI 
mode 
Putative elemental 
composition 
Putative compound 
310.003 4.39 - C14H10NO3Cl2 Hydroxydiclofenac 
310.0402 9.29 + C15H14NO2Cl2 Diclofenac methyl ester metabolite 
486.032 1.89 - C20H18NO9Cl2 Hydroxydiclofenac glucuronide  
m/z: mass to charge ratio; RT: retention time; ESI: electrospray ionisation. 
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4.3.4. Target gene expression 
Real-time PCR analysis of rpl8 mRNA levels measured in the liver, gills and 
kidney showed no significant variations between any of the treatment groups for any of 
the target tissues studied (ANOVA, p>0.05; Figure 4.1), consistent with previous 
studies confirming rpl8 as a reliable “housekeeping” gene for quantifying diclofenac 
exposure effects (Filby and Tyler, 2007). 
In control tissues, cyp1a1 levels were the highest in liver and cox1 and cox2 
mRNA highest in the gills and liver. Kidney tissues showed the highest mean 
expression levels of p53. Diclofenac exposure resulted in a decrease in the relative 
expression of cox1 mRNA in the kidney and liver at exposure s of 0.5 µg/l (Figure 4.2a) 
and 1 µg/l in the gills (ANOVA, p<0.05). Expression of cox1 in the kidney of fish 
exposed to 25 µg /l, was highly suppressed (p<0.01). Similarly cox2 mRNA showed 
reductions in expression (p<0.05) following diclofenac exposure in all three tissues 
(Figure 4.2b) with effective concentrations of 0.5 µg/l for the liver, 1 µg/l for the kidney 
and 5 µg/l for the gill tissues. Levels of cox2 mRNA expression seemed less affected 
than cox1 mRNA. Relative expression of cyp1a1 was up regulated in the gills and liver 
of diclofenac-exposed fish (Figure 4.2c) at exposure concentrations of 0.5 µg/l and 1 
µg/l, respectively (p<0.05). The maximum up regulation however was less than a 2-fold 
increase. Contrary to the results obtained in the liver and gills, cyp1a1 expression was 
down regulated in the kidney at a threshold concentration of 1 µg/l (p<0.05).  
Response patterns for the expression of p53 mRNA were more varied across the 
tissues studied (Figure 4.2d). There was no treatment effect on p53 mRNA in the liver 
but a significantly increased expression in the gills at the lowest two exposure 
concentrations (0.5 and 1 μg/l) and a down regulation in the kidney from an effective 
concentration of 1 μg/l (p<0.05).  
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Figure 4.1 – Average threshold cycle (CT) for rpl8 amplification in liver, gills and kidney 
after 21-day exposure to diclofenac. Data represented as mean + SE, n=15 fish. 
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Figure 4.2 – Relative expression of cox1 (a), cox2 (b), cyp1a1 (c) and p53 (d) in rainbow 
trout after 21-day diclofenac exposure. Data are represented as mean ± SE with n=15 fish. 
Statistical differences between treatment groups were determined by one-way ANOVA. 
*p<0.05 and **p<0.01.  
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4.3.5. Histopathological findings 
Histopathological examination of the liver indicated no visible lesions in any of 
the treatment groups (see supplementary material S4.3). In contrast, diclofenac induced 
morphological changes in both the small intestine and the kidney. In the small intestine, 
there was an increase of hyperplasia and fusion of the villi at a threshold concentration 
of 1 µg diclofenac/l and in concentration dependent manners (Figure 4.3). One fish from 
the 5 µg/l exposure tank and three fish from the 25 µg/l exposure tanks showed 
complete fusion of several villi (Figure 4.3b). Enlargement of goblet cells in the 
intestine occurred from a threshold concentration of 5 µg/l. In the posterior kidney, 
regressive changes were induced in the tubules and glomeruli (Figure 4.4). Diclofenac-
exposed fish also presented greater numbers of developing nephrons compared with the 
control fish. A mild tubular necrosis and a significant loss of interstitial space 
surrounding the glomeruli were observed at the two highest exposure concentrations.  
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Figure 4.3a – Histopathological lesions in small intestine of rainbow trout induced by 21-day 
diclofenac exposure. 1) healthy villi of control fish with single cell layer; 2) hyperplasia (H) and 
fusion (F) observed at 0.5 µg/l; 3) small fusion and hyperplasia and proliferation of Goblet cells at 
1 µg/l; 4) hyperplasia and proliferation of Goblet cells at 5 µg/l; 5) enlarged Goblet cells at 25 µg/l; 
and 6) hyperplasia, inflammation and fusion of the villi at 25 µg/l; H&E stain. 
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Figure 4.3b – Semi-quantitative assessment of histopathological lesions in the small intestine 
of rainbow trout exposed to diclofenac for 21 days. Data are represented as mean + SE, n=10 
fish. Fusion, hyperplasia and enlarged Goblet cells (GC) were observed. Rating system: 1= normal, 
2= mild/ moderate, 3= moderate/severe, 4= severe. Data analysed by Kruskal-Wallis ANOVA with 
Dunn’s test post hoc. 
* p<0.05. 
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Figure 4.4a – Histopathological lesions in the kidney of diclofenac-exposed rainbow trout 
after 21 days. N: nephrons, DN: developing nephrons, G: glomeruli, NC: necrosis, black arrow: 
Bowman space. 1) kidney from water control tissue; 2) fish exposed to 0.5 µg/l; 3) increasing 
number of developing nephrons in fish exposed to 5 µg/l; 4) tubular necrosis and loss of 
Bowman space at 25 µg/l. H&E stain, magnification 40x. 
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Figure 4.4b – Semi-quantitative assessment of histopathological lesions in the kidney of 
rainbow trout exposed to diclofenac for 21 days. Data are represented as mean + SE, n=10 
fish. Tissue damages included an increased number of developing nephrons (DN), tubular 
necrosis and loss of Bowman space surrounding the glomeruli. Rating system: 1= normal, 2= 
mild/ moderate, 3= moderate/severe, 4= severe. Data analysed by Kruskal-Wallis ANOVA with 
Dunn’s test post hoc. 
* p<0.05. 
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4.4. Discussion 
Since the discovery of a compelling link between diclofenac exposure and the 
extinction of some Asian Gyps vulture populations, an increasing body of research has 
investigated the ecotoxicological effects of diclofenac on non target organisms. Many 
studies conducted however have focused on acute effects at high exposure 
concentrations (Hallare et al., 2004; Laville et al., 2004; Hong et al., 2007). Here we 
show that chronic exposure to environmental concentrations of waterborne diclofenac 
can both induce disturbances in normal molecular processes controlling metabolism of 
xenobiotics and prostaglandin synthesis, induce adverse tissue pathologies in intestine 
and kidney. Diclofenac is presently measured in effluents and surface waters in low µg/l 
concentrations. However its release from a prescription only usage, and thus ability to 
purchase it over the counter, is likely to result in an increased usage and disposal in the 
future, adding to the potential exposure problems for aquatic organisms. Our 
investigations showed that diclofenac was concentrated in the bile of rainbow trout with 
a factor ranging between 509 and 657 for the different exposure concentrations. Bile is a 
major excretory route of many xenobiotics, including diclofenac (Treinen-Moslen and 
Kanz, 2006). Our findings compare favourably with a previous study on diclofenac-
exposed rainbow trout where BCFs of up to 2732, 971, 763 and 69 were reported in the 
liver, kidney, gills and muscles respectively for a 28 day exposure (Schwaiger et al., 
2004). However our estimated accumulation factors in fish bile are lower compared to 
other pharmaceuticals. Nonylphenol bioconcentrated to much higher levels in roach 
after 14-day exposure to 5 µg/l (Smith and Hill, 2004). More recently research by 
Brown et al. (2007) demonstrated that ibuprofen (BCF 18667) and gemfibrozil (BCF 
199) bioconcentrated in the plasma of rainbow trout exposed to wastewater effluents at 
higher levels than diclofenac (BCF 11). 
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Exposure to diclofenac appears to target similar pathways in fish as in mammals 
and both isoforms of the cox gene were down regulated in the kidney, gills and liver of 
the exposed fish. Prolonged inhibition of the cox activity has been shown to alter the 
prostaglandin-regulated mechanisms such as blood flow in the kidney (Fent et al., 
2006). Impairment and the subsequent failure of renal functions was established as a 
major cause of the widespread mortality of Asian Gyps vultures exposed to diclofenac 
(Taggart et al., 2007), although the specific mechanisms for this effect are not yet 
known (Ng et al., 2006; Hoeger et al., 2008). Interestingly, in this study diclofenac had 
an inhibitory (rather than stimulatory) effect on cyp1a1 expression in the kidney of 
rainbow trout. This might indicate a reduced capability for the metabolism of diclofenac 
in this tissue which could lead to an enhanced bioconcentration and greater likelihood 
for tissue damage. The histopathological analysis of the kidney reinforced this 
hypothesis. Concentration dependent effects were seen on the developing nephrons, 
tubules and glomeruli, structures vital for normal kidney functions. Signs of 
nephrotoxicity even occurred at the lowest diclofenac exposure concentration. The 
decreased levels of p53 mRNA in the kidney (from 1 μg/l) could potentially result in 
reduced regeneration rates for damaged kidney tissues. Renal lesions caused by 
diclofenac have been reported in salmonids previously but only at higher concentrations 
(5 µg/l) exceeding those measured in the natural environment (Schwaiger et al., 2004; 
Hoeger et al., 2005). Using electron microscopy as a technique, thus with higher visual 
resolution than light microscopy, previous studies have shown induction of 
glomeruloneophritis, necrosis of endothelial cells, and hyaline droplet degeneration in 
the kidney of diclofenac-exposed rainbow trout from 1 µg/l (Triebskorn et al., 2004). 
In fish, gills are the primary route of entry of many xenobiotics making them 
vulnerable to contaminant exposure (Teh et al., 1997). In the gills of the diclofenac-
4. Uptake and biological effects of diclofenac in rainbow trout 
112 
 
exposed rainbow there was an up regulation of cyp1a1 mRNA at the lowest exposure 
concentration (0.5 μg/l), in accordance with that shown in medaka (Hong et al., 2007) 
indicating possible metabolism of diclofenac in this tissue. The significant reduction in 
cox1 and cox2 in the gills implies that eicosanoids production was decreased in this 
tissue. Although the functional role of these molecules is not well understood, it is 
believed that the reduction in eicosanoids can affect blood coagulation, homeostasis and 
immune responses in the gills (Holland et al., 1999). Histopathological examinations 
were not carried out on the gills, but the existing studies have all concluded that 
exposure to diclofenac in the lower μg/l range can lead to severe structural damages in 
the fish gills, including pillar cell necrosis, epithelial lifting, hyperplasia and 
hypertrophy of epithelial chloride cells (Schwaiger et al., 2004) and in turn affect 
respiration and other gill physiological functions (Triebskorn et al., 2004; Hoeger et al., 
2005). In our work, the gills of diclofenac-exposed trout also had an enhanced level of 
p53 mRNA, a gene that plays a key role in cell cycle control, at exposure concentrations 
of 0.5 and 1 µg/l. 
Diclofenac has been shown to induce cyp activity in the hepatocytes affecting 
metabolism (Bort et al., 1999; Rudzok et al., 2009). Here we found  a threshold 
concentration for effects on cyp1a1 mRNA at 1 µg/l, however, although changes in 
cyp1a1,and cox1 and cox2 mRNA were observed, no obvious tissue damage was 
evident in the liver of the diclofenac-exposed fish. Triesbskorn et al. (2004) found 
evidence of cellular toxicity such as glycogen depletion and macrophage infiltration in 
the liver of diclofenac exposed fish rainbow trout from 1 µg/l. A previous study 
reported elevated p53 mRNA levels in the liver, gills and intestine of medaka exposed 
to 1 µg diclofenac/l for 4 days (Hong et al., 2007) but we found no significant effects in 
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the liver and a reduction in the kidney. P53 mRNA levels were increased only in the 
gills of trout exposed to 0.5 µg diclofenac/l.  
Diclofenac and the metabolites formed in the liver are excreted into the bile 
(Rudzok et al., 2009) and recently, it has been demonstrated in fish that these 
compounds can re-enter the liver via the intestine leading to damages of the intestinal 
tract (Hoeger et al., 2008). This enteric recirculation also occurs in mammals and has 
been demonstrated to result in injuries to the gastric epithelium in rats (Seitz and 
Boelsterli, 1998). This is thought to be caused by reactive metabolites of diclofenac 
particularly the glucuronide conjugates. In our study, the search for specific metabolites 
of diclofenac led to the detection of hydroxydiclofenac, hydroxydiclofenac glucuronide 
and methyl ester metabolite of diclofenac. The severe lesions observed in the intestine 
of the rainbow trout exposed to the highest concentration of diclofenac may have been 
caused by the reactive glucuronide metabolite found. The enteropathy observed was 
characterised by inflammation and lesions in the villi. These structural damages have 
been reported in humans and result in blood loss, increased permeability and bile salt 
malabsorption (Treinen-Moslen and Kanz, 2006). Our findings on the intestine contrast 
with Schwaiger et al. (2004) who found no significant damage in the intestine of 
rainbow trout exposed to 1 to 500 µg diclofenac/l. This may be because our exposure 
was conducted without any solvent. Previous work has shown that using a solvent 
carrier may modulate the toxic response in fish (Hutchinson et al., 2006). 
 
 
In conclusion, exposure to environmentally relevant concentrations of diclofenac 
was shown to impair the health of exposed rainbow trout, altering the expression of 
selected genes linked with key functional processes controlling metabolism, 
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prostaglandin synthesis and cell cycle, and inducing structural disruptions in the kidney 
and intestine. Our findings, together with other published studies, for effects of 
diclofenac on the gastrointestinal tract and kidney of fish, suggest modes of action, 
similar to those in mammals. Further work should be done to compare the plasma 
concentration of diclofenac in the exposed fish with human therapeutic plasma 
concentrations in order to predict the potential impact of diclofenac in fish (Huggett et 
al., 2003; Giltrow et al., 2009).  
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Supplementary materials 
 
S4.1 – Primers designed and optimised for real-time PCR analysis. 
Gene name Accession num Sequence 
cox1 AJ299018 F  5’-CAAACGAGAGGTAGCATCAATC-3’ 
R  5’- GTTCTTCAAATGTGTGGTAGGG-3’ 
cox2  AJ238307 F  5’-CCAGGACGATTAAACCAAACAG-3’ 
R  5’- ACCGCTTCAACAACGATAGG-3’ 
cyp1a1 U62796 F  5’-GCACAATAACCCTCACCTCAG-3’ 
R  5’- GCCACTCAGAACAACCACAG-3’ 
p53 M75145 F  5’-CCATCCTCACCATCATCACC-3’ 
R  5’- TCCTCTGTCTTCCTGTCTCG-3’ 
Gene sequences were found in NCBI GenBank database and designed using Beacon designer 
software 3.0. 
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S4.2 – Condition factor of rainbow trout. Each column represents mean + SE (n=15). There 
were no significant differences in the treatment groups between day 0 and day 21 (one-way 
ANOVA, p>0.05). 
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S4.3 – Histological sections of liver tissue from control and diclofenac-exposed rainbow 
trout. 1) water control, 2) exposed to 1 µg/l and 3) exposed to25 µg/l. There were no effects 
observed. Magnification 40x; H&E stain.  
Technical limitations did not permit the capture of images at a higher magnification. 
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CHAPTER 5: Development of analytical techniques for metabolic 
profiling of biofluids in rainbow trout (O. mykiss) 
 
5.1. Introduction 
The “omics” technologies have become powerful tools to examine the changes 
in gene expression, protein and metabolite levels caused by diseases, toxic insults or 
environmental stimuli (Fiehn et al., 2000; Aardema and MacGregor, 2002). However, 
the information obtainedfrom genomics and proteomics studies  do not indicate how 
these changes relate to the biological functions of an organ or organism. Metabolomics, 
also known as metabonomics is a developing technology that measures all the small-
molecule metabolites in a biological system (Goodacre et al., 2004; Weckwerth and 
Morgenthal, 2005). Analysing the subtle alterations of the metabolic profile can offer 
valuable insights into the physiological status of an organism. This approach has proved 
useful to elucidate gene function, pharmaceuticals impacts and has considerable 
potential for the discovery of biomarkers of chemical exposure (Fiehn, 2001).  
Several analytical techniques exist for metabolomics analysis including nuclear 
magnetic resonance spectroscopy (NMR), liquid chromatography coupled to mass 
spectrometry (LC-MS), gas chromatography coupled to MS (GC-MS) and capillary 
electrophoresis coupled to MS (CE-MS). So far, a single technique has not been capable 
of extracting all the metabolites present in a biological sample (Moco et al., 2007). 
NMR spectroscopy is a technique of choice for analysis of biofluids and intact tissues. 
NMR requires minimal sample preparation, no chromatographic separation and offers a 
non destructive approach (Viant et al., 2003; Samuelsson et al., 2006; Ekman et al., 
2007). LC-MS has been increasingly employed in metabolomics studies (Wilson et al., 
2005; Bedair and Sumner, 2008). This technique is more sensitive than NMR and 
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provides more comprehensive data of the metabolome (Weckwerth and Morgenthal, 
2005). However LC has some limitations including longer analysis times, need for 
chromatographic separation and extensive sample preparation. The recent development 
of ultraperformance liquid chromatography linked to time-of-flight mass analysers 
(UPLC-TOF-MS) has improved the chromatographic resolution and enabled the 
identification of a broad range of metabolites in complex matrices (Plumb et al., 2002). 
Biofluids, especially urine and blood plasma, have been frequently used to 
assess the effects of xenobiotics exposure as they are easily collected and can be 
analysed with little preparation (Aresta et al., 2006; Lutz et al., 2008; Pasikanti et al., 
2008). Fewer studies exist on bile profiling (Pettersson et al., 2006; Plumb et al., 2009). 
Bile is produced by liver cells and is critical for both digestion of fats and excretion of 
many endogenous compounds and xenobiotics (Farina et al., 2009). Thus the metabolic 
profiling of bile may offer crucial information on liver and intestinal malfunctions. 
However bile contains many compounds (e.g. bile salts) that may produce interferences 
in the matrix and affect the detection of low abundance molecules. 
Here we describe the development of analytical methods to profile the 
metabolite composition of biofluids. The sample preparation techniques solid phase 
extraction (SPE) and methanol extraction were developed to extract a wide range of 
metabolites from the bile and plasma respectively. Analytical methods using UPLC 
coupled to electrospray time-of-flight mass spectrometry (UPLC-TOF-MS) were 
developed for metabolite profiling. Results from profiling of the plasma and bile 
samples from diclofenac-exposed rainbow trout are presented in this chapter and 
chapter 6 respectively. 
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5.2. Materials and methods 
5.2.1. Chemicals 
Diclofenac (purity ≥98%), cholic acid (purity ≥99%), taurocholic acid (>97%), 
urea (≥98%), uric acid (≥99%), bilirubin (≥98%), eicosapentaenoic acid (EPA, ≥99%), 
docosahexaenoic acid (DHA, >98%), tripalmitate (≥99%), L-thyroxine (≥98%), L-α-
phosphatidylcholine (≥99%), creatinine (anhydrous) and prostaglandin B2 (PGB2, 
≥98%) were purchased from Sigma-Aldrich (Gillingham, UK).The eicosanoids 11R-
hydroxyeicosatetraenoic acid (11-HETE), prostaglandin E2 (PGE2) and thromboxane 
B2 (TXB2) (purity ≥98%) were purchased from Cayman Chemical (Michigan, USA). 
The deuterated internal standards [2,2,4,6,6,17α-21,21,21-d9] progesterone (P-d9) and 
[2,4,16,16-d4] 17β-estradiol sodium 3-sulphate (E2-d4-S) (isotope purity >98%) were 
obtained from C/D/N Isotopes (Quebec, Canada). Sodium acetate, sodium hydroxide 
(NaOH) and ammonium hydroxide (NH4OH) were supplied by Sigma-Aldrich. 
Solvents and water (all HPLC grade) and formic acid were purchased from Rathburn 
(Walkerburn, UK). 
Stock solutions of individual standard were prepared as described in Table 5.1 
and stored at -20ºC. Working standard solutions containing all the compounds were 
obtained by further dilution in methanol (1 ng/μl and 10 pg/μl). 
 
5.2.2. Sample collection 
Blood taken from the caudal vein and bile were sampled from juvenile female 
rainbow trout exposed to waterborne diclofenac (0.5, 1, 5 and 25 µg/l) and water control 
for 21 days. The fish maintenance and experimental set up are described section 2.10.1. 
Plasma samples were obtained by centrifugation of the blood. The biofluids were stored  
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Table 5.1: Preparation of standard stock solutions. 
Compounds Class Stock solution (concentration) 
11-HETE eicosanoid bought in ethanol (100 ng/ μl) 
Bilirubin  metabolite marker of liver 
toxicity 
in water + 15% NH4OH (10 μg/μl)  
Cholic acid bile acid in ethanol:water (1:1) (10 μg/μl) 
Creatinine metabolite marker of kidney 
toxicity 
in water (10 μg/μl) 
DHA and EPA fatty acid in ethanol (10 μg/μl) 
E2-d4-S and P-d9  internal standard in ethanol (100 ng/μl) 
PBG2 eicosanoid bought in ethanol (10 ng/ μl) 
PGE2 eicosanoid bought in ethanol (100 ng/ μl) 
Phosphatidylcholine bile phospholipid in ethanol:water (1:1) (10 μg/μl) 
Taurocholic acid bile salt in ethanol:water (1:1) (10 μg/μl) 
Thyroxine metabolite marker of tissue 
toxicity 
in acetone + 30% NH4OH (10 μg/μl) 
TXB2 eicosanoid bought in ethanol (100 ng/ μl) 
Urea metabolite marker of kidney 
toxicity 
in water (10 μg/μl) 
Uric acid  metabolite marker of kidney 
toxicity 
in water + 3% NaOH (10 μg/μl) 
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in two volumes of methanol at -80°C and aliquots used to develop appropriate 
extraction and LC-MS methods for metabolomics analyses. 
 
5.2.3. Preparation of bile samples  
One of the major problems with profiling bile on LC-MS is the presence of high 
concentrations of bile acids which on electrospray ionisation (ESI), tend to suppress the 
ions of other metabolites. Therefore the aim was to develop a SPE method to separate 
conjugated bile acids such as taurocholic acid (major bile acid in fish and other 
vertebrates) from other metabolites of interest including eicosanoids that may be 
targeted by diclofenac action. 
Samples of bile from control fish (n=4, containing 50 μl bile with 100 μl 
methanol) were diluted in 7 μl sodium acetate buffer solution (pH 7). Another group of 
4 bile samples were evaporated to dryness, reconstituted in 500 µl of 0.1 M phosphate 
buffer (pH 6) and hydrolysed using the method described section 2.13.1. Hydrolysed, 
non-hydrolysed and blank samples (containing 50 μl water instead of bile) were 
extracted using 60 mg Strata X-AW SPE cartridges (Phenomenex, Macclesfield, UK). 
The cartridges were pre-conditioned as described 2.13.2. In order to collect a wide range 
of metabolites, while reducing ion suppression, elution was carried out with four 
solvents with different polarity: 2 ml ethyl acetate (EA; free metabolites fraction), 2 ml 
methanol (M; peptides fraction), 2 ml 2% formic acid in methanol (FA; eicosanoids 
fraction) and 2 ml 2% ammonium hydroxide in methanol (N; conjugated metabolites 
fraction). After vacuum drying the extracts were brought up in 100 μl methanol:water 
(1:1, v/v). Aliquots of 100 µl of untreated bile samples from control fish (n=4) along 
with the SPE extracts for the non-hydrolysed and hydrolysed bile samples were filtered 
using 0.22 µm ultrafiltration tubes (Millipore) and transferred to HPLC vials for 
chemical analysis. 
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5.2.4. SPE fractionation and recovery of standard metabolites 
Four replicate samples of 10 ml sodium acetate buffer solution (pH 7.0) were 
spiked with 100 μl of both standards and IS working solutions at 10 pg/μl (see section 
5.2.1). The samples were fractionated by SPE using the protocol described in the above 
section (section 5.2.3). However the standards were eluted using EA, FA and N 
solvents, because previous work showed that very few compounds were eluted in the M 
fraction. The standards were analysed by UPLC-TOF-MS and quantified using a 
calibration a 5-point calibration curve constructed for each standard. 
 
5.2.5. Preparation of plasma samples 
The plasma metabolome was extracted using a methanol extraction protocol 
adapted from Bruce et al. (2008). Plasma samples (n=4) were thawed on ice and 
aliquots of 200 μl were spiked with 80 μl of both a mixture of eicosanoids solution 
(PGE2, TXB2, PGB2, 11-HETE and PGJ2) and the IS solution at 10 pg/μl. To evaluate 
the efficiency of the extraction method, plasma samples were mixed with 3 different 
methanol solutions for final solvent percentages of 70, 80 and 90%. After 
centrifugation, the supernatant was transferred to clean glass vials, vacuum dried, 
brought up in 100 µl methanol:water (1:1, v/v) and filtered using Sirocco TM Protein 
Precipitation Plates (Waters, UK). The purified samples were placed in HPLC vials and 
stored at -20°C.  
 
5.2.6. UPLC-TOF-MS analysis 
Metabolomics analysis was carried out on a Waters Acquity UPLC system 
coupled to a Micromass QTOF mass spectrometer. Details of the UPLC column and 
MS parameters are provided in section 2.7.2. 10-μl aliquots of bile and 20-μl aliquots of 
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plasma extracts were injected at a flow rate of 0.09 ml/min and run in either +ESI or –
ESI mode to detect the protonated [M+H] and deprotonated [M-H] ions respectively. 
The following mobile phase was used to profile the bile: 95:5% water-methanol (A) and 
methanol (B) both containing 0.2% formic acid. The solvent gradient was initiated at 
50% B up to 100% B in 12 min and maintained for 4 min before re-equilibration to 50% 
B for 4 min. To optimise the chromatographic detection and resolution, plasma samples 
were run using both an acidified mobile phase (5% acetonitrile and 0.2% formic acid in 
water (A) and 0.2% formic acid in acetonitrile (B)) and a neutral mobile phase (5% 
acetonitrile and 0.2% ammonium hydroxide in water (A) and 0.2% ammonium 
hydroxide in acetonitrile (B)). A linear gradient was used initiated at 10% B up to 100% 
B in 10 min. This was kept for 6 min and re-equilibrated to 10% B for 8 min.  
 
5.2.7. Data handling 
MassLynx raw data files were transformed and processed using MarkerLynx V 
4.1 (Waters, Milford, USA). This application, which provides automated peak detection 
and integration, was used to estimate the number of markers in each sample. The 
chromatograms were aligned with the IS E2-d4-S in –ESI and P-d9 in +ESI. The 
parameters used for the peak detection were set as follows: mass tolerance or mass 
accuracy of the data 0.04 Da, width of an average peak at 20% height 20 sec, baseline 
noise between peaks 100, number of masses per RT 50, minimum intensity allowed for 
a spectral peak to be considered as a marker 1% of the base peak intensity; mass 
window tolerance in which a spectral peak was considered to be the same marker 0.04 
Da and RT tolerance 0.1 min.  
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5.2.8. Multivariate data analysis of plasma samples 
Multivariate data analysis was performed using 15 plasma samples from each 
replicate tank 0, 0.5, 1, 5 and 25 µg diclofenac/l. For this, all m/z x RT datasets were 
normalised to the maximum spectral area in each sample and exported to Simca-P 
(Umetrics Ltd, Bekshire, UK) where they were log-transformed and mean-centered to 
reduce skewness. Principal component analysis (PCA) was conducted to visualise the 
data and detect any outliers. The supervised method projections to latent structures 
discriminant analysis (PLS-DA) was then performed to identify the metabolites affected 
by diclofenac exposure. 
 
5.3. Results 
5.3.1. Method development for metabolic profiling of bile 
5.3.1.1. Analysis of the chromatograms for the bile extracts 
Bile was analysed in both + and –ESI and produced total ions chromatograms 
(TIC) with many ions present at saturation (Figure 5.1). The spectral analysis of the 
large saturated peaks indicates the presence of bile acids most likely taurocholic acid 
(mass accuracy 2.3 ppm) and other taurine related compounds (Figure 5.2). The 
chromatographic analysis also showed that more peaks were produced in –ESI than in 
+ESI. This is expected as most bile acids formed deprotonated ions [M-H]. SPE 
fractionation permitted the separation of conjugated bile acids and other conjugates in 
the N fraction, whilst other metabolites were eluted in the remaining fractions. Figure 
5.3 shows the chromatograms of fractionated non-hydrolysed bile extracts. The TIC 
produced for the bile metabolites eluted in EA, M and FA fractions were similar to 
those of the blanks eluted with the same solvents. This indicates that few bile 
metabolites are present in those fractions and the peaks observed are impurities from  
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Figure 5.1 – Total ion chromatograms (as base peak intensity BPI) of untreated bile from 
water control fish in +ESI and –ESI modes. The saturated peaks observed in the 
chromatograms are caused by the high levels of bile acids. The parameters of the LC-MS were 
optimised but the sensitivity was not improved and the peaks remained saturated. 
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Figure 5.2 – Spectral ion chromatograms of the saturated peaks in untreated bile in +ESI 
and –ESI modes. The prevailing m/z ions 514 and 516 are most likely the bile salt taurocholic 
acid. 
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Figure 5.3 – Total ion chromatograms (as base peak intensity BPI) of fractionated non-
hydrolysed bile from a control fish and a blank sample in –ESI mode. The chromatograms 
indicate that most compounds were eluted in the N fraction, which resulted in over saturated 
peaks. Eluting fractions EA: ethyl acetate, M: methanol, FA: formic acid in methanol, N: 
ammonium hydroxide in methanol. 
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the cartridges. The chromatogram of the N fraction, however, had large saturated peaks 
caused by the presence of bile acids. To deconjugate these compounds and facilitate 
their detection, bile samples were hydrolysed. The chromatograms of fractionated 
hydrolysed bile are presented Figure 5.4. As observed in the non-hydrolysed 
fractionated samples, the chromatograms of the hydrolysed bile extracts in EA, M and 
N fractions were comparable to the blanks. Hydrolysis did reduce the number of 
saturated peaks but some taurine related compounds remained in the N fraction. 
 
5.3.1.2. Quantitative analysis of the bile extracts 
Chromatographic data were further analysed using MarkerLynx to estimate the 
numbers of metabolites detected in untreated bile, fractionated non-hydrolysed bile and 
fractionated bile (Table 5.2 and 5.3). MarkerLynx data indicated that some metabolites 
were lost during SPE fractionation. The untreated bile samples contained more 
metabolites than the fractionated non-hydrolysed and hydrolysed bile samples. It was 
also observed that SPE fractionation introduced impurities in the samples. The analysis 
of blank samples revealed the presence of up to 538 ions. To ensure that the metabolites 
eluted in the EA, M and FA fractions were accurately detected and identified, the 
injection volume was increased. Increasing the injection volume to 10 µl provided more 
potential bile metabolites in the EA and FA fractions but did not improve the number of 
peaks detected in the M fraction.  
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Figure 5.4 – Total ion chromatograms (as base peak intensity BPI) of fractionated 
hydrolysed bile and blank samples in –ESI mode. Eluting fractions EA: ethyl acetate, M: 
methanol, FA: formic acid in methanol, N: ammonium hydroxide in methanol. 
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Table 5.2 – Number of markers estimated by MarkerLynx for non-hydrolysed bile 
samples untreated and fractionated using SPE. 
Fractionation  Sample  Untreated 
Bile EA M FA N Total 
1 2252 - 
(134) 
- 
(-) 
77 
(1104) 
453 530 
2 1660 - 
(310) 
- 
(-) 
194 
(1081) 
788 982 
3  1526 - 
(355) 
- 
(-) 
56 
(974) 
643 699 
4 1613 - 
(178) 
- 
(-) 
68 
(1509) 
503 571 
Po
si
tiv
e 
E
SI
 
mean+ SE 1763 + 330.8 696 + 85 
1 4121 8 
(158) 
- 
(398) 
17 
(3396) 
2719 2744 
2 3952 - 
(99) 
- 
(403) 
29 
(4135) 
2839 2868 
3 3485 - 
(112) 
- 
(336) 
23 
(3331) 
2589 2623 
4 3935 11 
(173) 
- 
(217) 
20 
(3874) 
3225 3256 
N
eg
at
iv
e 
E
SI
 
mean+ SE 3873 + 673 2873 + 485 
ESI: electrospray ionisation, EA: ethyl acetate fraction, M: methanol fraction, FA formic acid in 
methanol fraction and N: ammonium hydroxide in methanol fraction. Numbers of markers 
obtained after subtracting the average number of markers detected in the blank samples for the 
same fraction. Rows highlighted indicate the average number of bile markers detected in 1 µl 
SPE extract. In brackets is the number of markers detected after injecting 10 µl SPE extracts. 
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Table 5.3 – Number of markers estimated by MarkerLynx for hydrolysed bile samples 
fractionated using SPE. 
Fractionation  Sample  
EA M FA N Total 
1 - 
(67) 
5 
(55) 
10 
(649) 
1039 1054 
2 - 
(43) 
8 
(62) 
27 
(763) 
1171 1206 
3 - 
(58) 
7 
(71) 
25 
(684) 
1091 1123 
4 - 
(93) 
12 
(63) 
20 
(741) 
1162 1194 
Po
si
tiv
e 
E
SI
 
mean + SE 1174 + 161 
1 100 
(633) 
6 
(77) 
139 
(1447) 
1558 1903 
2 176 
(633) 
11 
(78) 
197 
(1186) 
1572 1956 
3  122 
(862) 
23 
(104) 
85 
(1101) 
2128 2358 
4 128 
(787) 
18 
(167) 
205 
(1254) 
2131 2482 
N
eg
at
iv
e 
E
SI
 
mean + SE 2175 + 356 
ESI: electrospray ionisation, EA: ethyl acetate fraction, M: methanol fraction, FA formic acid in 
methanol fraction and N: ammonium hydroxide in methanol fraction. Numbers of markers 
obtained after subtracting the average number of markers detected in the blank samples for the 
same fraction. Rows highlighted indicate the average number of bile markers detected in 1 µl 
SPE extract. In brackets is the number of markers detected after injecting 10 µl SPE extracts. 
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5.3.2. SPE fractionation and recovery of standard metabolites 
The UPLC-TOF-MS analysis revealed that many of the target metabolites were 
successfully extracted and quantified using 60 mg SPE cartridges. The chromatographic 
peaks of these compounds are illustrated in Figure 5.5. The SPE recovery efficiency, 
elution solvent, retention time (RT) and m/z value of the ions formed in +ESI mode and 
–ESI mode are listed in Table 5.4. The IS steroids E2-d4-S and P-d9, were detected in –
ESI and +ESI modes respectively. Both compounds were recovered at levels greater 
than 80%.  
Recoveries of the target metabolites from aqueous matrix ranged from 45% for 
11-HETE to 91% for cholic acid. SPE method separated taurocholic acid from the other 
metabolites classes. The eicosanoids PGE2, TXB2, PGB2 and 11-HETE were eluted in 
the FA fraction and were detected in –ESI mode forming only [M-H] ions. Despite the 
addition of formic acid in the mobile phase, TXB2 did not produce a sharp peak and 
gave the most variable recovery efficiency. This compound may have been degraded 
Thyroxine and phosphatidylcholine were only detected as protonated ions [M+H] in 
positive mode. Bilirubin was detected in both ionisation modes but was not recovered 
after SPE fractionation. The smaller molecules creatinine, urea and uric acid could not 
be detected under the UPLC conditions used in our study.  
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Figure 5.5 – Chromatograms of target metabolites usually found in fish bile and the 
internal standards used for quantification. 
 
  
Table 5.4 – UPLC-TOF-MS analysis of target metabolites in aqueous samples: chemical formula, the calculated m/z of the ionic species  
formed in either +ESI or –ESI modes and SPE recovery efficiency. 
Standards Formula [M+H] [M-H] RT Recovery UPLC-TOF-MS 
analysis* 
11-HETE C20H32O3 321.2430 319.2273 8.25 45 + 2 FA/-ESI 
Cholic acid C24H40O5 409.2954 407.2797 7.39 91 + 4 EA+FA/-ESI 
DHA C22H32O2 329.2481 327.2324 10.04 90 + 6 EA+FA/-ESI 
E2-d4-S C18H20D4O5S 357.1674 355.1518 5.47 93 + 2 N/-ESI 
EPA C20H30O2 303.2324 301.2168 9.61 86 + 4 EA+FA/-ESI 
P-d9 C21H21D9O2 324.2889 322.2733 6.98- 81 + 1 EA/+ESI 
PGB2 C20H30O4 335.2222 333.2066 6.67 80 + 5 FA/-ESI 
PGE2  C20H32O5 353.2328 351.2171 5.45 78 + 2 FA/-ESI 
Phosphatidylcholine C42H82NO8P 760.5856 758.5700 13.77 69 + 5 FA/-ESI 
Taurocholic acid C26H44NO7S 516.2995 514.2838 6.55 89 + 3 N/-ESI 
Thyroxine C15H11I4NO4 777.6945 775.6789 6.21 87 + 5 FA/+ESI 
TXB2 C20H34O6 371.2434 369.2277 11.99 70 + 8 FA/-ESI 
*Eluting fraction used to quantify the analytes – EA: ethyl acetate fraction; FA: formic acid in methanol fraction; N: ammonium hydroxide 
in methanol fraction; [M+H]: protonated ion; [M-H]: deprotonated ion; RT: retention time. Recoveries expressed in % mean + SE. 
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5.3.3. Method development for metabolic profiling of plasma samples 
The number of peaks displayed increased with increased methanol 
concentrations (Table 5.5). However the comparisons between blank and plasma 
samples extracted with the overall 90% methanol solution indicated that the 90% 
methanol extracts also contained many impurities. Therefore it was concluded that 
overall 80% methanol solution (assuming that plasma is 100% aqueous) was the best 
extraction method for the metabolic profiling of plasma samples.  
Blood plasma were analysed in both +ESI and –ESI modes, TIC in both 
ionisation are shown Figure 5.6. The sensitivity and reproducibility of the UPLC-TOF-
MS was assessed based on the analysis of chromatograms for control plasma samples 
and plasma spiked with a low concentration of eicosanoids (4 ng/ml of plasma). TIC 
produced for control and spiked samples were nearly identical (data not shown). This is 
to be expected as the eicosanoids spikes were very low and plasma contains many 
metabolites creating interferences. Thus the eicosanoids normally detected as 
deprotonated ions [M-H] in negative mode (Figure 5.7), were ion suppressed. This 
resulted in a reduced intensity signal, especially for PGB2 and PGE2. 
The limit of detection (LOD) for the eicosanoids detected in water and plasma 
samples run with the acidic mobile phase are reported Table 5.6. Most eicosanoids had 
a LOD below 3 ng/ml in water samples. However the detection capabilities were 
reduced in the plasma samples and LOD varied from 4.9 ng/ml for PGE2 to 8.7 ng/ml 
for PGJ2.  
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Table 5.5 – Number of markers detected after methanol extraction of plasma samples. 
Methanol solution 70% 80% 90% 
Sample 1 2762 3348 3645 
Sample 2 2459 3426 3541 
Sample 3 2263 3247 3220 
Sample 4 2647 3681 3918 
Mean + SE 2533 + 420 3426 + 587 3581 + 615 
Mean blank  193 + 45 270 + 48 904 + 36 
Numbers of markers in this table were obtained after subtracting the average number of markers 
detected in the blank samples. 
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Figure 5.6 – Total ion current (as base peak intensity BPI) of plasma sample from a 
control fish in +ESI mode (a) and –ESI mode (b). 
 
a) 
b) 
5. Development of analytical techniques for metabolic profiling of biofluids 
138 
 
 
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
100
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
100
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
100
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
100
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
100
Time
Time
Time
Time
Time
11-HETE
PGB2
TXB2
PGE2
PGJ2
R
el
at
iv
e 
ab
un
da
nc
e
BPI 18
BPI 93
BPI 122
BPI 19
BPI 56
 
Figure 5.7 – Chromatograms of eicosanoids standards (4 pg/µl) in water samples run in    
–ESI mode with acidic mobile phase.  
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Table 5.6 – Limit of detection (LOD) of eicosanoids in water and plasma samples using 
UPLC-TOF-MS. 
 LOD in water samples 
+ SE (ng/ml) 
LOD in plasma samples 
+ SE (ng/ml) 
11-HETE 1.3 + 0.8 3.2 + 1.4 
PGB2 1.5 + 1.1 6.2 + 1.6 
PGE2 1.6 + 0.9 4.9 + 0.6 
PGJ2 2.2 + 0.4 8.7 + 0.8 
TXB2 4.7 + 0.7 5.1 + 1.3 
LOD expressed as mean + SE 
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To improve the chromatographic detection, plasma samples were run in an 
acidic (formic acid) and neutral (ammonium hydroxide) mobile phase. The pH of the 
mobile phase affects the formation of ionic species and can enhance or reduce the signal 
intensity. In this study, the acidic mobile phase was preferred as it provided a sharper 
chromatographic peak and less background noise (Figure 5.8). It was noted that the m/z 
value of 11-HETE produced two peaks on the chromatogram. However, the mass 
spectra of the peaks showed that another eicosanoid was co-eluted with 11-HETE. This 
explains the increase in signal intensity in the spiked samples (BPI of 93 in water and 
up to 247 in spiked plasma samples). 
 
5.3.4. PCA and PLS-DA analyses of plasma samples from diclofenac exposure 
Plasma samples from fish exposed to diclofenac for 21 days and control fish 
were run in +ESI and –ESI modes using the acidic mobile phase and analysed using 
multivariate data analysis to identify the metabolites affected by diclofenac exposure. 
The projection method PCA was carried out to display the interrelationship between the 
plasma samples of exposed fish (0.5, 1, 5 and 25 µg diclofenac/l) and the water controls.  
The supervised clustering method PLS-DA was then applied to identify the class 
separating variables. The resulting PCA and PLS-DA loadings gave poor models as 
shown by the low values of the explained (R2X and R2Y for PCA and PLS-DA 
respectively) and predicted variation (Q2) in Table 5.7. This indicates that the models 
did not represent accurately the data. Many potential outliers were found in the PCA 
models indicating a great variability within the data set. Normally outliers must be 
removed for subsequent analysis by removing strong outliers resulted in the appearance 
of new outliers. Therefore it was decided to remove 5-10 of the stronger outliers and 
perform PLS-DA regardless. PLS-DA slightly improved the class separation compared 
with the PCA models (Figure 5.9).  
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Figure 5.8 – Selected ion chromatograms (-ESI) of the eicosanoids recovered in the 80% 
methanol extracts of spiked plasma samples. a) acidic mobile phase, b) neutral mobile phase.  
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Table 5.7 – Performance parameters of multivariate discriminant models for the 
comparison of control and diclofenac exposed rainbow trout (0.5, 1, 5 and 25 µg/l). 
UPLC-
TOF-MS 
Groups Multivariate 
method 
Components R2X R2Y Q2 
-ESI All PCA 6 0.428  0.28 
-ESI All PLS-DA 3 0.227 0.298 0.074 
+ESI All PCA 6 0.566  0.438 
+ESI All PLS-DA 2 0.533 0.955 0.0473 
-ESI C, 0.5, 1 PCA 5 0.332  0.157 
-ESI C, 0.5, 1 PLS-DA 2 0.118 0.737 0.118 
+ESI C, 0.5, 1 PCA 5 0.561  0.345 
+ESI C, 0.5, 1 PLS-DA 2 0.352 0.162 -0.0522 
-ESI C, 5, 25 PCA 5 0.34  0.154 
-ESI C, 5, 25 PLS-DA 2 0.095 0.624 -0.017 
+ESI C, 5, 25 PCA 4 0.352  0.187 
+ESI C, 5, 25 PLS-DA 2 0.179 0.426 0.123 
ESI: electrospray ionisation; R2X: variation explained by the model; R2Y: cumulative variation 
explained by the model;Q2: cumulative variation predicted by the model. The groups C, 0.5, 1, 5 
and 25 correspond to fish exposed to diclofenac at concentrations 0, 0.5, 1, 5 and 25 µg/l 
respectively. 
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Figure 5.9 – Score plots from partial least squares discriminant analysis (PLS-DA) of fish 
plasma following diclofenac exposure (n=24 to 28). ●: control; ►: 0.5 µg/l; x: 1 µg/l; ▲: 5 
µg/l and ■: 25 µg/l. Top two models show the relationship between all the control and exposed 
fish. Data were then remodelled to show the relationship for control vs low dose (0.5 and 1 µg/l) 
and control versus high dose (5 and 25 µg/l). Column a): UPLC-TOF-MS analysis in -ESI mode 
and b): in +ESI mode. 
a) b) 
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5.3.5. Identification of class-separating variables 
No discriminative variables were found between the control and fish exposed to 
either 0.5 or 1 µg diclofenac/l. The stronger discrimination occurred between the control 
and the highest diclofenac exposure concentration (25 µg/l). Only one marker (m/z 
298.004 in –ESI) was found responsible for the small class separation. Inspection of the 
raw data revealed that this compound was present at low levels in plasma samples from 
5 µg/l exposure tanks and at higher levels in all the samples from 25 µg/l exposure tanks 
(Figure 5.10). The elemental composition tool calculated the theoretical mass formula 
of the m/z 294.008 marker and provided a theoretical formula of C14H11NO2Cl2 with a 
mass accuracy of 1 ppm. This elemental composition corresponds to the deprotonated 
ion of diclofenac. No other endogenous metabolites were found to be responsible for the 
class separation. 
 
5.4. Discussion 
Biofluids contain a great diversity of substances with varied chemical properties 
and concentration ranges (Pasikanti et al., 2008). In these complex matrices, high 
abundant molecules can interfere and mask the detection of low abundant molecules. 
Ideally, the methodologies employed for metabolomics studies must be able to detect 
free steroids, organic acids, sugar as well as other low abundant signalling molecules to 
observe many changes occurring as they can be easily collected without killing the 
organism (Dorado et al., 2003; Samuelsson et al., 2006; Wagner et al., 2007). However 
an increasing number of studies are now using analysing the metabolic profile of bile to 
find metabolite markers of xenobiotics exposure. Indeed, this biofluid has been found to 
contain high concentrations of xenobiotics and endogenous compounds that are later 
excreted from the body (Pettersson et al., 2006; Farina et al., 2009). 
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Figure 5.10 – Mass spectra of diclofenac ion (m/z 294.008) in –ESI mode in plasma samples 
of a) control fish, b) exposed to 5 µg diclofenac/l and c) exposed to 25 µg/l. 
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bile in mice and dogs (Plumb et al., 2009). Here, we demonstrated that SPE 
fractionation of bile can improve the chromatography by separating the conjugates from 
the other free molecules. Bijlsma et al. (2009) reported that SPE methods using acid in 
the conditioning step can decrease the interferences within the matrix and increased the 
recovery efficiency. The untreated bile samples contained more metabolites but many 
were co-eluted which resulted in large saturated peaks in the chromatograms. This may 
affect the detection of small abundance metabolites. Previous studies have reported that 
SPE and UPLC-TOF-MS technology are reliable tools to analyse conjugated and free 
molecules in biological samples (Flores-Valverde and Hill, 2008; Plumb et al., 2009). 
The efficiency of the extraction method was confirmed using a range of targeted 
metabolites likely to occur in bile. Satisfactory recoveries were obtained from spiked 
aqueous samples for most compounds (69-93%) except for 11-HETE recovered at less 
than 50%.  
The targeted metabolites (e.g. eicosanoids, thyroxine, fatty acids) and the 
metabolites non-conjugated present in the bile samples were eluted in the EA and FA 
fractions. As the MarkerLynx analysis showed few peaks in both fractions and virtually 
nothing in the M fraction, the FA and EA fractions can be combined in subsequent 
studies to reduce the number of samples for analysis. The N fraction was used to extract 
the conjugated metabolites. Bile contains up to 90% of bile acids in a conjugated form 
as well as conjugated metabolites of drugs (Alnouti et al., 2008) and indeed the vast 
majority of bile metabolites were eluted in the conjugated N fraction. The 
chromatographic analysis showed that taurocholic acid and other taurine related 
compounds were present at saturation which may affect the chromatographic resolution. 
LC-MS based metabolomics require good quality chromatograms to ensure accurate 
identification of metabolites and the conjugated fraction may hold important 
information that is difficult to interpret. Hydrolysed bile samples produced TIC with 
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less saturated peaks compared to the TIC of non-hydrolysed bile samples. Hydrolysis is 
used to cleave conjugates and produce free molecules that may be more easily detected 
and quantified using the technology platform reported upon here. Some limitations were 
observed in the UPLC-TOF-MS system as the smallest signalling molecules urea, uric 
acid, bilirubin and creatinine could not be detected even in the standards. The 
optimisation of the MS parameters did not overcome this problem.  
Plasma is a matrix rich in proteins that may interfere with the detection of other 
signalling molecules through ion suppression. It is important to clean the samples and 
reduce the matrix interference effects prior to MS analysis. The extraction protocol 
published by Bruce et al. (2008) was adapted to our study and the methanol extracts 
were further purified by filtration in order to remove the protein precipitates and 
minimize ion suppression. Our conclusions were supported by their findings that the 
overall 80% methanol solution gave the best extraction efficiency. The method 
development was carried out with samples spiked with eicosanoids only. Diclofenac is 
known to act by inhibiting the cyclooxygenase interfering with the productions of 
eicosanoids. Research has shown that at environmental concentrations diclofenac can 
accumulate in fish organs and interfere with the metabolic activities (Schwaiger et al., 
2004; Hoeger et al., 2005). Thus changes in the abundance of certain eicosanoids were 
expected. Eicosanoids are small signalling molecules present in various tissues (e.g. 
kidney, intestine, brain) in the low pg range and have been quantified successfully using 
GC or LC-MS technologies (Tsukamoto et al., 2002; Blewett et al., 2008). Using our 
analytical methodologies, the lower LOD were in the ng range. The mobile phase 
composition was investigated to optimise the detection of selected eicosanoids in the 
plasma. The addition of acids in the mobile phases are known to improve the resolution 
and shape of the chromatographic peaks in +ESI mode by assisting protonation of 
molecules (García, 2005). However, the metabolites in plasma samples were best 
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detected in –ESI mode and less is known about the influence of acidic mobile phases in 
this ionization mode. Here, the addition of formic acid to acetonitrile provided a sharper 
chromatographic peak for the selected eicosanoids but the signal intensity was 
decreased. The observations are in accordance with the general conception that 
deprotonated ions are not easily formed under acidic pH conditions (Wu et al., 2004). 
The chromatographic analysis of target eicosanoids in water and spiked plasma samples 
indicated clearly that the detection of eicosanoids is mitigated by matrix interferences 
and the MS technology platform used is not sensitive enough for the identification of 
very low abundance signalling molecules. Other substances such as salts, ion pairing 
agents and other ionic endogenous compounds may still be interfering with the 
ionization process (Annesley, 2003).  
The multivariate data analysis of plasma samples from diclofenac exposure 
indicated that the methodologies employed were not sensitive and accurate enough to 
allow the identification of potential metabolite markers of chemical exposure. There 
were no real differences between the metabolic profiles of control and diclofenac-
exposed rainbow trout. The low coefficients for the explained variance of the PCA and 
PLS-DA models (R2 between 0.09 and 0.5) imply that the variation observed in the data 
may not be related to diclofenac exposure. The difference between the explained (R2Y) 
and the predicted (Q2Y) coefficients indicate that the PLS-DA models are over-fitted 
and there was no true class separation between the samples. Thus the models could not 
be validated. As mentioned earlier eicosanoids are very low abundance molecules (pg 
range). However our metabolomics data were acquired from only 150 µl plasma 
samples and it is possible that the volumes of used were too low to identify these 
unstable molecules. Larger volumes of plasma may be more appropriate to extract and 
identify eicosanoids. The limit of detection for the eicosanoids in water samples were 
low and ranged between 1.3 ng/ml + 0.8 and 4.7 ng/ml + 0.7 whilst eicosanoids are 
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often found in pg/ml or less. Matrix effects observed previously further reduced the 
detection capabilities of the UPLC-TOF-MS. Therefore, it is possible that low 
abundance endogenous metabolites were affected by diclofenac but could not be 
detected or identified. Class separation observed between the control fish and trout 
exposed to 5 and µg/l was attributed to the pharmaceutical diclofenac. Surprising 
diclofenac was not detected at the lower exposure concentrations (0.5, 1 and 5 µg/l). 
Previous studies have demonstrated that chronic exposure of rainbow trout to sewage 
effluents containing 0.2 to 2 µg diclofenac/l could lead to bioaccumulation in the 
plasma with a bioconcentration factor up to 11 (Brown et al., 2007). This implies that 
the analytical techniques applied in this study to analyse the metabolic profile of plasma 
need to be further optimised. 
 
5.5. Conclusions 
Metabolomics is now recognised as a widely used technique for evaluating the 
toxicity of pharmaceuticals. Here, we demonstrated that bile is a suitable biofluid for 
metabolomics studies on fish and may provide key information on the uptake and toxic 
effects of xenobiotics in aquatic vertebrates. The SPE and UPLC-TOF-MS system 
developed were sensitive enough to detect and identify a wide range of bile metabolites 
(eicosanoids, fatty acids, bile acids). Therefore this methodology has the potential to be 
applied to investigate the effects of pharmaceuticals and other pollutants in fish. The 
hydrolysis treatment proved beneficial to reduce the amount of taurocholic acid present 
at saturation. Other deconjugating enzymes may be used to ensure that most of the 
conjugated metabolites present in the bile are cleaved. The methodologies employed to 
analyse the plasma metabolome require further optimisation in order to successfully 
detect low abundance metabolites and identify potential metabolites markers of 
diclofenac exposure.  
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CHAPTER 6: Identifying the biological effects of diclofenac in fish 
using metabolomics profiling 
 
6.1. Introduction 
Metabolomics has been dedicated to the study of metabolite composition and 
dynamics in a cell, organ and organism (Katajamaa and Oresic, 2007). This technology 
has been employed in toxicology, biomedical research, drug development and plant 
physiology (Clarke and Haselden, 2008; Tianniam et al., 2008; Wishart, 2008; Issaq et 
al., 2009). Over the past decade, metabolomics studies have shown some great potential 
as a diagnostic tool to discover biomarkers of diseases. Brindle et al. (2002) showed that 
metabolomics combined with pattern recognition techniques on human serum can be 
used to diagnose the presence and severity of coronary artery disease with high (90%) 
accuracy. Metabolic profiling of cerebrospinal fluid has also been employed to identify 
metabolites of microbial origin to distinguish bacterial meningitis from viral meningitis 
(Coen et al., 2005). In cancer research, the use of metabolomics has led to the 
identification of urinary nucleosides as markers for the early diagnosis of colorectal 
cancer (Feng et al., 2009).  
The specificity of the markers identified in biomedical research suggests that 
laboratory-based metabolomics studies could be used to determine the exposure to a 
specific chemical in the environment. Recent research has demonstrated the ability of 
metabolomics application to assess the effects of environmental exposure to xenobiotics 
in aquatic wildlife (Samuelsson et al., 2006; Viant et al., 2006; Ekman et al., 2007; 
Flores-Valverde and Hill, 2008). Viant et al. (2006) studied the metabolic profile of 
Japanese medaka (Oryzias latipes) embryos exposed to the herbicide dinoseb and they 
were able to associate the metabolic changes with reduced growth rate and increased 
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embryotoxicity. However, very few metabolomics studies have been able to identify 
biomarkers of exposure and elucidate the mode of action of xenobiotics and their 
physiological implications in fish (Poynton et al., 2008).  
Environmental surveys have shown that significant amounts of pharmaceuticals 
are continuously discharged in the aquatic environment via wastewater treatment plants 
(WWTPs) (Heberer, 2002; Larsson et al., 2007; Farré et al., 2008). These compounds 
remain biologically active and can interfere with the metabolism of non-target 
organisms (Thibaut et al., 2006; Carlsson et al., 2009). In the literature, however there 
are less than 100 publications that have reported the effects of human pharmaceuticals 
exposure (mainly synthetic estrogens) on the metabolic profile of aquatic organisms 
(Iguchi et al., 2006; Katsiadaki et al., 2009). The effects of non-steroidal 
pharmaceuticals on fish have received very little attention despite the fact that these 
compounds are frequently detected in the aquatic environment up to a few µg/l. 
 In this study, rainbow trout (Oncorhynchus mykiss) was used as a model species 
to evaluate how diclofenac might affect fish metabolism. Diclofenac is a non-steroidal 
anti-inflammatory known to affect the production of prostanoids, molecules controlling 
many physiological processes, by inhibiting the cyclooxygenase (cox) enzymes. 
Cellular metabolic pathways are highly conserved among species and side effects 
observed in mammalian systems (e.g. reduction of folate biosynthesis) may occur in 
fish resulting in deleterious physiological changes. This chapter reports the application 
of solid phase extraction (SPE) and UPLC-TOF-MS methodologies developed in 
Chapter 5 to profile the bile of rainbow trout from diclofenac exposure in Chapter 4. 
Multivariate data analysis was conducted using principal component analysis (PCA), 
partial least squares analysis discriminant analysis (PLS-DA) and orthogonal PLS 
(OPLS) in order to identify the endogenous metabolites affected by diclofenac and to 
infer possible biological pathways affected. This study also aimed to identify the 
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metabolites of diclofenac potentially responsible for the damage observed in the 
intestinal epithelium of exposed fish reported in Chapter 4. 
 
6.2. Materials and Methods 
6.2.1. Chemicals  
Diclofenac, β-glucuronidase (type VII from Escherichia coli), sulphatase (type 
VI from Aerobacter aerogenes), sodium acetate and ammonium hydroxide were 
purchased from Sigma-Aldrich (Poole, UK). The internal standard (IS) steroids 
[2,2,4,6,6,17α-21,21,21-d9] progesterone (P-d9) and [2,4,16,16-d4] 17β-estradiol 
sodium 3-sulphate (E2-d4-S) were obtained from C/D/N Isotopes (Quebec, Canada). All 
solvents and water were of HPLC grade and purchased from Rathburn (Walkerburn, 
UK). 
 
6.2.2. Diclofenac exposure and sample collection 
Exposure of juvenile female rainbow trout (Oncorhynchus mykiss) to diclofenac 
was conducted as described in Mehinto et al., (see Chapter 4, section 4.2.1). Briefly, 
fish (125-230 g body weight) were placed in groups of 15 per duplicate tank (n=30 per 
treatment) and exposed to waterborne diclofenac at nominal concentrations 0.5, 1, 5 and 
25 µg/l and a water control. After 21 days of exposure, fish were anaesthetised with 
benzocaine and killed by destroying the brain according to UK Home Office Animal 
Licence procedures. Bile samples were taken using a syringe and kept at -80ºC in glass 
vials containing two volumes of methanol. 
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6.2.3. Bile hydrolysis 
In order the cleave the bile salts and facilitate the detection of other signalling 
molecules, fish bile (from water control, 0.5 and 5 µg/l treatment groups) was 
deconjugated by enzymatic hydrolysis adapted from the method described by Gibson et 
al. (2005). Bile samples of 300 µl were evaporated to dryness in a SpeedVac 
concentrator (Savant Instruments Inc.- SpeedVac Plus) and reconstituted with 500 µl of 
0.1 M phosphate buffer (pH 6.0) and 200 µl of each β-glucuronidase (1000 units/ml) 
and sulphatase (2 units/ml) enzymes. The samples were then incubated at 37°C for up to 
16 hr. The activity of each of the hydrolysis enzymes was monitored by incubation with 
standards substrates of 4-nitrophenol-β-glucuronide and 4-nitrophenol sulphate (as 
explained in section 2.13.1).  
 
6.2.4. Metabolite extraction and UPLC-TOF-MS analysis  
Non-hydrolysed bile (300 μl, n= 16 for water control and 25 µg/l tanks) and 
hydrolysed bile (900 μl, n=12-16 for water control, 0.5 and 5 µg/l tanks) was used for 
the metabolomics study. Each bile sample was diluted in sodium acetate buffer (300 
mM, pH 7.0) to make up a volume of 8 ml and fractionated using the solid phase 
extraction (SPE) methodology optimised in Chapter 5. Briefly, SPE was performed with 
the pre-conditioned Strata X-AW cartridges (60 mg, Phenomenex, Macclesfield, UK). 
Bile metabolites were eluted with ethyl acetate and 2% formic acid in methanol, and 
both extracts were combined into 1 fraction (EA+FA fraction containing neutral and 
acidic compounds). The cartridges were then eluted with 2% ammonium hydroxide in 
methanol (N fraction containing conjugated metabolites and anionic compounds). The 
SPE extracts were dried to remove any solvent, reconstituted in 100 µl of 
methanol:water (1:1, v/v) and filtered with centrifuge tubes filters of 0.22 µm pore size 
(Millipore).  
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Bile metabolites were separated on an Acquity UPLC BEH C18 column (100 
mm x 2.1 mm, 1.7 μm particle size; Waters, Elstree, UK) and analysed using a 
Micromass (Manchester, UK) TOF-MS system operated in +ESI mode and –ESI mode 
to detect the metabolites in their protonated or deprotonated form. The injection volume 
was of 5 µl and each sample was run using the acidified UPLC mobile phase 95:5% 
water-methanol (A) and methanol (B). The flow rate was 0.09 ml/min and the solvent 
gradient started at 50% B (for non-hydrolysed bile) and 30% B for (hydrolysed bile) up 
to 100% B in 12 min and maintained for 4 min before re-equilibration to the in initial 
percentage of solvent B for 4 min. The ionisation parameters used for this study are 
described in section 2.7.2. In order to avoid any instrument bias, samples were run in a 
random order. 
 
6.2.5. Data transformation, pre-processing and pre-treatment 
Raw data obtained from the UPLC-MS were pre-processed using MarkerLynx 
V4.1 (Waters, Milford, USA). The chromatograms were aligned with the IS P-d9 in 
+ESI mode and E2-d4-S to correct the retention time between runs and all m/z x RT data 
sets were normalised to the maximum spectral area observed in each sample. The 
parameters used for the detection of the spectral peaks were optimised to reduce the 
background noise to a minimum and set as follows: mass window and mass tolerance 
0.04 Da, average peak width at 5% height 20 sec, peak to peak baseline noise 15, 
number of masses per retention time (RT) 50, minimum intensity allowed for a spectral 
peak was 1% of the base peak intensity; retention time window 0.1 min. Data were then 
exported into SIMCA-P software (Umetrics, UK) where they were log-transformed and 
mean-centered to reduce skewness. 
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6.2.6. Multivariate data analysis 
Chromatographic data from the fish bile analysis were subjected to multivariate 
analysis. The unsupervised method principal component analysis (PCA) was conducted 
to provide an overview of the dataset. Any strong and moderate outliers identified in the 
PCA score plots were removed prior further analysis (as described in section 2.13.4). 
The datasets were then processed using the supervised techniques partial least square 
(PLS) discriminant analysis. This projection method is used to produce predictive 
models by correlating the variations in the metabolic profile (matrix X) with exposure 
concentration of diclofenac (matrix Y). The number of significant principal components 
was determined by cross-validation. The models with predictive ability (Q2) above 0.4 
were subjected to orthogonal projection to latent structure discriminant analysis (OPLS-
DA) to identify the differential metabolites. To assess the accuracy of the models PLS 
models (Q2 >0.4) response permutation testing was performed. For each treatment, 5 
test observations were excluded from the dataset, and the data remodelled to assess for 
correct classification of the test observations and validate the model. This procedure 
was repeated until 60% (arbitrary measure) of the observations were tested for correct 
classification. 
 
6.2.7. Identification of metabolites  
The discriminative variables (RT x m/z signal) of diclofenac exposure were 
selected from the S-plot of the OPLS models, a plot of contribution of variables vs. 
confidence where high confidence variables with large changes between the groups are 
found at the extreme ends of the “S”. Raw data of the selected metabolites were not 
normally distributed, thus they were statistically analysed using the non parametric test 
Kruskal-Wallis analysis of variance with Mann Whitney U post hoc test for pair-wise 
comparison of the control vs. each exposure concentration. Using this approach it is 
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advised to use a correction method (e.g. Bonferroni correction) to reduce the risk of type 
I errors (i.e. metabolites falsely identified as discriminating between 2 groups). 
Metabolites of statistical significance (p<0.01) were subjected to Bonferroni correction.  
Elemental composition of the discriminative variables was calculated using 
MassLynx V4.1, giving a deviation between the predicted and the experimental m/z, in 
ppm. Theoretical formula with the best isotopic fit and a deviation <5 ppm were 
selected. This information, together with any fragmentation data from the TOF analysis 
of the metabolites in each SPE fraction was used to attempt an identification of the 
metabolites markers of diclofenac exposure. The following databases were used to 
search the structural identity of the bile metabolites: human metabolome 
(http://www.hmdb.ca/), KEGG ligand (http://www.genome.jp/ligand/), PubChem 
(http://pubchem.ncbi.nlm.nih.gov/), and BiGG (http://bigg.ucsd.edu/). 
 
6.3. Results 
6.3.1. PCA overview of the free metabolites and conjugated metabolites fractions 
from non-hydrolysed bile in control and diclofenac-exposed (25 µg/l) fish 
Multivariate data analyses were performed to determine the changes in the bile 
metabolic profile of juvenile rainbow trout exposed to diclofenac. None of the PCA 
analyses for the non-hydrolysed bile datasets analysed in both the –ESI mode and +ESI 
modes gave good models as shown by the low values obtained for the observed (R2X) 
and predicted (Q2) variation in these datasets (Table 6.1). However some clustering of 
samples was observed in the free metabolites fraction (EA+FA) analysed in +ESI mode 
(data not shown). The PCA score plots of the conjugated metabolites fraction (N) 
showed 4 outliers in –ESI mode and 2 outliers in +ESI mode. Visual examination of the 
spectra for these 6 samples revealed very high levels of bile salts such as taurocholic 
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acid (m/z 514). Therefore these samples were removed for subsequent analysis but the 
PCA analyses of the modified data did not improve the models. 
 
6.3.2. Overview of PLS-DA and OPLS models for non-hydrolysed bile  
Class separation was achieved at PLS-DA level between the control and 
diclofenac-exposed fish. The high values for the predicted variation (R2Y >0.99) and 
observed variation (Q2 >0.8) indicated that good models were produced for the free 
metabolites fraction analysed in both ionisation modes (Table 6.2). The clear class 
separation of the control vs. 25 µg/l treatment groups is illustrated in the PLS-DA score 
plots in Figure 6.1. The analysis of the conjugated metabolites fraction did not result in 
tight clusters for both treatment groups. High values were estimated for the explained 
variation with R2Y= 0.944 in +ESI mode and 0.996 in –ESI mode, but the predictive 
ability values (Q2) were lower (<0.75) than those reported in the free metabolites 
fraction. Response permutation testing was performed to assess the validity of the PLS-
DA models. The models had a classification success of >80% except for the conjugated 
metabolites fraction (55%) analysed in +ESI mode and it is possible that this PLS-DA 
model was overfitted (Table 6.2). 
In order to further investigate the class separation between control and 25 µg 
diclofenac/l fish, OPLS-DA was conducted. The resulting “S” plot for the free 
metabolites fraction indicated 21 discriminative variables (m/z) in +ESI mode and 5 
discriminative variables in –ESI mode. Only 7 discriminative variables were detected in 
the conjugated metabolites fraction analysed in –ESI mode and none in the same 
fraction analysed in +ESI mode. 
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Table 6.1 – Performance parameters of principal component analyses for the comparison 
of the metabolic profiles in non-hydrolysed bile extracts. 
Fraction ESI 
mode 
Groups Multivariate 
method 
Principal 
components
R2X Q2 
EA+FA + C, 25 PCA 2 0.252 0.087 
EA+FA - C, 25 PCA 2 0.217 0.0375 
N + C, 25 PCA 3 0.408 0.221 
N - C,25 PCA 2 0.28 0.101 
EA+FA: ethyl acetate and formic acid in methanol fraction (free metabolites include steroids 
and eicosanoids); N: ammonium hydroxide in methanol fraction (conjugated metabolites); ESI: 
electrospray ionisation; Groups C and 25 correspond to fish exposed to water control and 25 µg 
diclofenac/l; R2X: variation explained by the PCA models; Q2: cumulative variation predicted 
by the model. 
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Table 6.2 – Multivariate discriminant models for non-hydrolysed bile samples of control 
and diclofenac-exposed rainbow trout. 
Fraction ESI 
mode 
Groups Multivariate 
method 
Principal 
components 
R2X R2Y Q2 External 
validation 
EA+FA + C, 25 PLS-DA 2 0.248 0.991 0.907 89% 
EA+FA + C, 25 OPLS 1+1 0.248 0.991 0.846  
EA+FA - C, 25 PLS-DA 2 0.168 0.993 0.831 85% 
EA+FA - C, 25 OPLS 1+1 0.168 0.993 0.806  
N + C, 25 PLS-DA 2 0.28 0.944 0.73 55% 
N + C, 25 OPLS 1+2 0.325 0.99 0.41  
N - C, 25 PLS-DA 4 0.365 0.996 0.716 80% 
N - C, 25 OPLS 1+1 0.31 0.985 0.585  
EA+FA: ethyl acetate and formic acid in methanol fraction (free metabolites and eicosanoids); 
N: ammonium hydroxide in methanol fraction (conjugated metabolites); ESI: electrospray 
ionisation; Groups C and 25 correspond to fish exposed to water control and 25 µg diclofenac/l; 
R2X and R2Y: variation explained by the PCA and PLS models respectively; Q2: cumulative 
variation predicted by the model. 
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Figure 6.1 – PLS-DA score plots using the first 2 components of the non-hydrolysed bile 
fractions of control fish (■) and fish exposed to 25 µg diclofenac/l (●), n=16. Free 
metabolites fraction in +ESI mode (a) and –ESI mode (b); conjugated metabolites fraction in 
+ESI mode (c) and –ESI mode (d). Clustering indicate that many free metabolites and 
conjugates were affected by 21-day diclofenac exposure. 
a) b) 
c) d) 
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6.3.3. PCA overview of the free metabolites (EA+FA) fraction from hydrolysed bile 
extracts. 
As mentioned earlier, high levels of bile acids present in the conjugated 
metabolites fraction (N) may have interfered with the identification of many metabolites 
in this fraction, therefore hydrolysis was performed and the cleaved metabolites were 
eluted in the free metabolites fraction. Because of this UPLC-TOF-MS analysis was 
only carried out for the free metabolites fraction (EA+FA) of the hydrolysed bile 
samples. The PCA score plots obtained from the analysis of the 3 treatment groups 
(control, 0.5 and 5 µg/l) indicated a poor separation between the treatments in both 
ionization modes. This was shown by the low values for the explained (R2X) variation 
(Table 6.3). Further PCA were performed on the control vs. 0.5 µg/l and control vs. 5 
µg/l treatment groups. The models did not show any obvious clustering of the treatment 
groups. The values of the predicted variation (Q2) were below 0.2 for all the PCA 
models of hydrolysed bile analysed which indicated that the models produced were of 
poor quality. 
 
6.3.4. Overview of PLS-DA and OPLS models for hydrolysed bile extracts. 
The supervised pattern recognition analysis (PLS-DA) of the hydrolysed bile 
samples depicted distinct clustering without any overlap in model space between the 
control samples and the samples from fish exposed to either 0.5 or 5 µg diclofenac/l 
(Figures 6.2). High values were obtained for the explained variation (R2Y), however the 
predictive ability of the model was lower for the datasets analysed in –ESI mode (Q2= 
0.647) compared with the dataset analysed in +ESI mode (Q2= 0.858) (Table 6.4). The 
UPLC-TOF-MS datasets were reanalysed using PLS-DA and OPLS to identify the class 
separating variables for just 2 of the treatment groups, i.e. the control vs. 0.5 µg/l groups  
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Table 6.3 – Performance parameters of principal component analyses for the comparison 
of the metabolic profiles in hydrolysed bile extracts. 
Groups  ESI mode Multivariate 
method 
Principal 
components 
R2X Q2 
C, 0.5, 5 + PCA 3 0.307 0.144 
C, 0.5, 5 - PCA 2 0.226 0.0701 
C, 0.5 + PCA 2 0.276 0.102 
C, 0.5 - PCA 2 0.287 0.0579 
C, 5 + PCA 2 0.256 0.101 
C, 5 - PCA 2 0.242 0.0401 
Groups C, 0.5 and 5 correspond to fish exposed to water control, 0.5 and 5 µg diclofenac/l 
respectively; ESI: electrospray ionisation; R2X: variation explained by the model; Q2: 
cumulative variation predicted by the model. 
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Table 6.4 – Multivariate discriminant models for the comparison of control and diclofenac 
exposed rainbow trout in hydrolysed bile. 
Groups ESI 
mode 
Multivariate 
method 
Principal 
components 
R2X R2Y Q2 External 
validation 
C, 0.5, 5  + PLS-DA 5 0.372 0.987 0.858 80% 
C, 0.5, 5 - PLS-DA 6 0.38 0.988 0.647 83% 
C, 0.5 + PLS-DA 3 0.338 0.995 0.909 90% 
C, 0.5 + OPLS 1+1 0.248 0.983 0.771 - 
C, 0.5 - PLS-DA 4 0.369 0.996 0.663 76% 
C, 0.5 - OPLS 1+1 0.215 0.942 0.489 - 
C, 5 + PLS-DA 3 0.292 0.995 0.902 90% 
C, 5 + OPLS 1+1 0.23 0.975 0.823 - 
C, 5 - PLS-DA 2 0.228 0.968 0.79 100% 
C, 5 - OPLS 1+1 0.228 0.968 0.769 - 
Groups C, 0.5 and 5 refer to fish exposed to water control, 0.5 and 5 µg diclofenac/l 
respectively; ESI: electrospray ionisation; R2X and R2Y: variation explained by the PCA and 
PLS models; Q2: cumulative variation predicted by the model. 
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Figure 6.2 – Score plots of the multivariate discriminant analysis of the free metabolites 
(EA+FA) fraction from hydrolysed bile from 21-day diclofenac exposure. ■ control group; 
● 0.5 µg diclofenac/l and ► 5 µg diclofenac/l. PLS-DA scores 3D plots of the 3 treatment 
groups analysed in +ESI mode (a) and –ESI mode (b); OPLS score plots for control vs. 0.5 µg/l 
in +ESI mode (c) and –ESI mode (d); OPLS score plots for control vs. 25 µg/l in +ESI mode (e) 
and –ESI mode (f). Clustering indicate that many free metabolites and conjugates were affected 
by 21-day diclofenac exposure. 
a) 
c) d) 
f) 
b) 
e) 
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and control vs. 5 µg/l groups. All the analyses resulted in good models as indicated by 
the explained (R2Y) and predicted variation (Q2) (Table 6.4). The analyses performed in 
–ESI mode for the control and 0.5 µg/l groups provided the weakest models and this 
was demonstrated by the lower predictive values in the PLS-DA (Q2= 0.663) and OPLS 
(Q2= 0.489) models. The classification success determined from the external validation 
testing varied from 76-100%. In the S-plot of the free metabolites fractions analysed in 
+ESI mode, 86 discriminative variables were found and in the same fractions analysed 
in –ESI mode, a total of 28 discriminative variables were selected for further analysis. 
 
6.3.5. Identity of metabolites of diclofenac 
The loading plots (S-plot) of the OPLS models are used to describe the 
relationship between the variables of the control fish and those of the diclofenac-
exposed fish, thus highlighting the metabolites responsible for the class separation. The 
variables significantly elevated or reduced by diclofenac exposure are found on 
opposites sides of this plot (Figure 6.3) and represent the metabolites in a positively 
charged, [M+H] negatively charged [M-H] and/or sodium adduct [M+Na] form.  
Amongst the variables selected in the S-plots, the ion 294.008 [M-H] and 
296.025 [M+H] was detected in the free metabolites fraction of the fish exposed to 
diclofenac, from the lowest exposure concentration of 0.5 µg/l. This variable was 
identified as diclofenac using the elemental composition tool and comparison of 
retention time on UPLC with that of an authentic standard. Three potential metabolites 
of diclofenac were also found in the bile of exposed rainbow trout. Their putative 
chemical formula and structural identity is shown in Table 6.5. Figure 6.4 represents the 
ion chromatograms of diclofenac and hydroxydiclofenac, methyl ester metabolite and 
hydroxyldiclofenac glucuronide in fish bile. Like diclofenac, the hydroxy-metabolite 
was detected as a protonated [M+H] and a deprotonated [M-H] ion in bile 
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Figure 6.3 – a) S-plot from the OPLS analysis of hydrolysed bile of control and 5 µg 
diclofenac/l exposed fish in the free metabolites fraction analysed in –ESI mode. b) trend 
view of some of the markers of diclofenac exposure identified by OPLS analysis of control 
and 5 µg/l exposed trout. 
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Table 6.5 – Identification of diclofenac and putative metabolites. 
m/z Fraction/ESI RT Putative 
formula 
ppm Putative identity 
294.008 EA+FA/-ESI 8.03 C14H10NO2Cl2 0 Diclofenac 
250.018 EA+FA/-ESI 8.03   fragment of 294: loss of CO2 
298.004 EA+FA/-ESI 8.03   Cl isotope of 294 
310.003 EA+FA/-ESI 4.39 C14H10NO3Cl2 -0.9 Hydroxydiclofenac 
230.038 EA+FA/-ESI 4.39   fragment of 310: loss of HCl 
266.014 EA+FA/-ESI 4.39 C13H10NOCl2 0 fragment of 310: loss of CO2 
314.000 EA+FA/-ESI 4.39   Cl isotope of 310 
331.993 EA+FA/-ESI 4.38 C14H10NO3Cl2Na 3.9 sodium adduct of 310 
310.0402 EA+FA/+ESI 9.29 C15H14NO2Cl2 0.6 Methyl ester metabolite 
486.032 N/-ESI 1.89 C20H18NO9Cl2 1.3 Hydroxydiclofenac 
glucuronide 
m/z: mass to charge ratio; EA+FA: free metabolites fraction; N: conjugated metabolites fraction; 
ESI: electrospray ionization; RT: retention time; ppm: part per million. Highlighted in grey are 
the compounds and in white the fragments formed by the UPLC-TO-MS. 
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from the lowest exposure concentration (0.5 µg/l). Mass spectral analysis indicated that 
the ions 250.03, 266.01 and 331.99 detected in –ESI mode are fragments and sodium 
adduct of the hydroxy-metabolite formed as a result of the UPLC-TOF-MS analysis 
(Figure 6.5). The methyl ester metabolite found as a protonated ion and the 
hydroxylated glucuronide metabolite found as a deprotonated ion, were only detected in 
the non-hydrolysed bile samples of fish exposed to 25 µg/l. 
 
6.3.6. Identity of metabolite markers of diclofenac exposure 
The variables (RT x m/z signals) representing diclofenac and the putative 
metabolites were removed from the models in order to detect metabolites of endogenous 
origin whose concentrations were affected by diclofenac exposure. The most 
discriminative variables between control and diclofenac-exposed trout are summarised 
in Table 6.6. Non parametric statistical analysis was conducted on the original 
(normalised but skewed) UPLC-TOF-MS data to confirm that all the variables selected 
in the OPLS loading plots were indeed altered by diclofenac exposure. In the different 
fractions of non-hydrolysed and hydrolysed bile, a total of 60 metabolites passed the 
Bonferroni correction analysis. The elemental composition tool was used on the mass 
spectra of these potential metabolites markers in order to assign a theoretical chemical 
formula (deviation <5 ppm). The elucidation of the structural identification of the 
metabolites using the UPLC-TOF-MS data (m/z) was not possible due to the lack of 
positive matches in any of the available databases. Any information collected on the 
metabolites (e.g. fragments and adducts formed) were recorded to facilitate their 
identification. Data will be analysed by FT-MS to give more accurate mass 
measurements which will reduce the number of candidate formulas for the metabolites. 
Due to time limitations these data are not yet available.  
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Figure 6.4 – Total ion chromatograms showing diclofenac and its metabolites in rainbow 
trout after 21-day exposure to diclofenac. 
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Figure 6.5 – Spectral ion chromatograms of diclofenac and hydroxydiclofenac fragments 
produced by UPLC-TOF-MS analysis. 
loss of CO2 
loss of HCl 
loss of CO2 
diclofenac 
hydroxydiclofenac 
sodium adduct 
Hydroxydiclofenac 
glucuronide 
BPI 350 
  
Table 6.6a – Markers of diclofenac exposure identified in non-hydrolysed bile of rainbow trout. 
Fraction/  
ESI mode  
Marker ion 
m/z RT 
Putative 
formula of ion 
Theoretical 
mass 
pp
m 
Effect of 25 µg 
DCF/l p value 
Putative compound/ 
comments 
EA+FA/-ESI 287.193 2.79 C14H27N2O4  -2.4 ↑ 0.000*  
EA+FA/-ESI 333.206 9.31 C20H29O4 333.2066 0 ↑ 0.000* Lipooxygenase product 
N/-ESI 171.014  1.01    ↑ 0.000*  
EA+FA/+ESI 402.197 6.38    ↓ 0.0005  
EA+FA/+ESI 414.994 2.52    ↑ 0.000*  
EA+FA/+ESI 573.298 12.70    ↓ 0.0005  
EA+FA/+ESI 627.309 8.92    ↑ 0.000* Na adduct 649.279 
EA+FA/+ESI 657.341 9.10    ↑ 0.0005 Na adduct 679.314 
EA+FA/+ESI 685.326 10.09    ↑ 0.000* Na adduct 707.296 
EA+FA/+ESI 689.119 0.91    ↓ 0.000*  
EA+FA/+ESI 715.360 10.20    ↑ 0.000* Na adduct 737.330 
EA+FA/+ESI 743.342 11.13    ↑ 0.000* Na adduct 765.313 
EA+FA/+ESI 747.129 1.03    ↑ 0.000*  
EA+FA/+ESI 773.375 11.20    ↑ 0.00005 Na adduct 795.346 
EA+FA/+ESI 831.391 12.01    ↑ 0.0005 Na adduct 853.360 
EA+FA/+ESI 889.405 12.49    ↑ 0.0005 Na adduct 911.376 
EA+FA/+ESI 917.385 12.73    ↑ 0.0004  
EA+FA/+ESI 975.400 12.96    ↑ 0.0005 Na adduct 997.371 
  
 
 
Table 6.6b – Markers of diclofenac exposure identified in hydrolysed bile of rainbow trout. 
ESI mode  Marker ion m/z RT 
Putative 
formula of ion 
Theoretical 
mass ppm 
Effect of DCF /p value 
0.5 µg/l      5 µg/l 
Putative compound/ 
comments 
-ESI 379.284 10.05 C23H39O9 379.2848 -1.1  ↑ 0.000* Glycerolipid? 
-ESI 392.149 8.56     ↓ 0.000* 
loss of gluthamyl 263.116 
2x 392 ion 785.308 
-ESI 394.166 9.10     ↓ 0.000* loss of gluthamyl 265.129 
-ESI 398.192 10.20     ↓ 0.000* loss of gluthamyl 269.157 
-ESI 420.180 9.60     ↓ 0.000* 
loss of gluthamyl 291.141 
2x420 ion 841.365 
-ESI 442.223 8.11 C25H32NO6  0.2 ↓ 0.0001 ↓ 0.000* ? 
-ESI 478.226 9.73     ↑ 0.000* loss of gluthamyl 349.185 
-ESI 799.320 8.58     ↓ 0.000* gluthamate group? 
-ESI 805.379 9.59     ↓ 0.000*  
+ESI 320.235 11.68    ↓ 0.0004   
+ESI 341.245 9.00    ↑ 0.00003 ↑ 0.000*  
+ESI 355.293 8.20     ↓ 0.000*  
+ESI 457.353 10.20    ↓ 0.0005 ↑ 0.000* endogenous? 
+ESI 532.379 10.89     ↑ 0.0004  
  
 
 
Table 6.6b continued 
ESI mode  Marker ion m/z RT 
Putative 
formula of ion 
Theoretical 
mass ppm 
Effect of DCF (p value) 
0.5 µg/l      5 µg/l 
Putative compound/ 
comments 
+ESI 561.402 11.09    ↓ 0.000* ↓ 0.000*  
+ESI 590.423 11.30    ↓ 0.000* ↓ 0.000*  
+ESI 619.443 11.49    ↓ 0.000* ↓ 0.000* fragment 262.194 
+ESI 621.409 8.12    ↓ 0.000*   
+ESI 623.251 1.23    ↓ 0.000* ↑ 0.000*  
+ESI 629.291 8.80    ↓ 0.000*  fragment 317.156 
+ESI 641.443 11.50    ↓ 0.000*   
+ESI 659.388 10.10     ↑ 0.0004  
+ESI 667.976 11.63    ↓ 0.000*   
+ESI 679.449 8.68    ↓ 0.000*   
+ESI 696.991 11.80    ↓ 0.000*   
+ESI 715.509 9.09     ↓ 0.00005  
+ESI 743.498 9.47    ↓ 0.000*   
+ESI 747.300 1.48    ↓ 0.000* ↓ 0.000*  
+ESI 765.486 9.47     ↓ 0.000*  
+ESI 771.508 12.23    ↓ 0.000*   
  
 
 
Table 6.6b continued 
ESI mode  Marker ion m/z RT 
Putative 
formula of ion 
Theoretical 
mass ppm 
Effect of DCF (p value) 
0.5 µg/l      5 µg/l 
Putative compound/ 
comments 
+ESI 787.401 9.10     ↓ 0.000* fragment 737.491 
+ESI 795.533 9.49    ↓ 0.000* ↓ 0.000* phospholipid? 
+ESI 800.524 12.36    ↓ 0.000*  phospholipid? 
-ESI 823.528 9.80     ↓ 0.000* phospholipid? 
-ESI 853.573 9.81    ↓ 0.000* ↓ 0.000* phospholipid? 
-ESI 859.586 10.10    ↓ 0.000* ↓ 0.000* phospholipid? 
-ESI 881.566 10.10    ↓ 0.000*  fragment 829.538 
-ESI 911.611 10.11    ↓ 0.000* ↓ 0.000* phospholipid? 
-ESI 917.624 10.39     ↓ 0.000* phospholipid? 
-ESI 935.691 10.19    ↓ 0.000*  phospholipid? 
-ESI 939.605 10.40    ↓ 0.000* ↓ 0.000* phospholipid? 
-ESI 945.697 8.85    ↓ 0.000* ↑ 0.000* endogenous? 
EA+FA: free steroid fraction; N: conjugated steroid fraction; ESI: electrospray ionization, m/z: mass to charge ratio; RT: retention time, ppm: part per million, 
DCF: diclofenac 
*p value below 1 x10-6 
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Putative identities were obtained for only 2 markers, but FT-MS analysis is 
required for confirmation. The variable m/z 333.206 [M-H] found in non-hydrolysed 
bile was increased in fish exposed the highest concentration of diclofenac (25 µg/l). The 
putative chemical formula indicates that this ion may be an eicosanoid, possibly a 
lipooxygenase product. The variable m/z 379.284 [M-H] found in the hydrolysed bile 
was identified as a potential glycerolipid. The concentration of this metabolite was 
elevated in fish exposed to 5 µg diclofenac/l. In the hydrolysed bile analysed in –ESI 
mode, the metabolite marker m/z 442.223 was suppressed by diclofenac exposure from 
0.5 µg/l. A theoretical mass was obtained using the elemental tool composition (<0.2 
ppm) but no structural identity has been found yet. 
 
6.4. Discussion 
Metabolomics enables the study of all the metabolites present in a biological 
system (Moco et al., 2007). Hence, the characterisation of the primary and secondary 
endogenous metabolites can provide valuable insights in the cellular processes and their 
responses to pollutants. Nuclear magnetic resonance (NMR)-based and mass 
spectrometry (MS)-based systems are the most commonly analytical platforms in 
metabolomics. The development of ultra-performance liquid chromatography (UPLC)-
MS has provided a high-resolution and high-mass accuracy technique to extract and 
identify metabolites (Moco et al., 2007). The main pitfall of MS techniques is the 
existence of matrix effects such as ion suppression that affect the detection of low 
abundance molecules (Antignac et al., 2005). Bile contains high levels of bile acids that 
can mask the presence of other metabolites by ion suppression and suitable techniques 
have to be used to detect the lower abundance signalling molecules. As reported in 
Chapter 5, SPE fractionation allowed the separation of conjugated metabolites (e.g. 
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taurocholic acids) from other free metabolites (including fatty acids, eicosanoids, 
phospholipids, etc.). Pattern recognition techniques used to analyse non-hydrolysed bile 
samples resulted in poor models for the conjugated metabolites fraction and very few 
discriminative metabolites were detected due to interferences with taurocholic acid. 
Conjugation of endogenous and exogenous metabolites is a major process in 
detoxification (Bailey and Dickinson, 2003). During phase II reactions, glucuronic acid, 
sulphate and/or glutathione are conjugated onto pharmaceuticals in order to increase the 
solubility and facilitate renal excretion. Glucuronic acid also binds to fatty acids and 
bile acids by a glycosidic bond in the liver and these conjugates are transported to the 
bile before excretion from the body. In order to overcome the matrix effects in the 
conjugated fraction, fish bile was hydrolysed using glucuronidase and sulphatase 
enzymes, which aim to deconjugate the metabolites, linked to glucuronic acid and 
sulphate molecules. Previous studies have reported the benefits of hydrolysis to 
investigate the bile metabolome (Smith and Hill, 2004; Gibson et al., 2005). 
The metabolomics datasets obtained from the UPLC-TOF-MS analysis had 
more variables (i.e. metabolites) than observations (i.e. samples), thus multivariate data 
analyses (PCA, PLS-DA and OPLS) were employed as graphical and statistical tools to 
extract meaningful information from the multi-dimensional datasets (Eriksson, 2006). 
The unsupervised projection method PCA was applied to visualise the general trend of 
the datasets without losing any important information. PCA models for our datasets did 
not show clustering tendency and this was confirmed by the low values (R2X and Q2) 
obtained by cross-validation. It may be that the low abundance of metabolites relating to 
diclofenac exposure and the presence of high abundance metabolites (e.g. bile acids) 
resulted in highly variable datasets. Research has shown that such complex data can 
reduce the performance of PCA and this analysis should be followed by a supervised 
analysis such as PLS-DA (Oldiges et al., 2007). PLS-DA carried out in this study 
6. Identifying the biological effects of diclofenac in fish using metabolomics profiling 
176 
clearly improved the separation between the treatment groups. The main problem of a 
supervised projection method is the tendency to overfit the models (i.e. poorly represent 
the datasets). It has been reported that adequate cross-validation and external validation 
can overcome this problem (Broadhurst and Kell, 2006). The PLS-DA models for non-
hydrolysed and hydrolysed bile were validated with more than 80% accuracy in the 
classification of treatment groups and OPLS analysis was able to discriminate the 
metabolites responsible for the class separation. The multivariate analysis revealed that 
exposure to diclofenac at concentrations as low as 0.5 µg/l interfered with the 
metabolism of rainbow trout and many metabolites were found to be altered after the 
21-day exposure. Bonferroni correction was applied to reduce the risk of type I errors 
(false discoveries). The drawback of this correction method is that true metabolites 
markers of exposure and effect may not pass the Bonferroni corrected levels leading to 
the inflation of type II errors (Broadhurst and Kell, 2006). 
Bile is a major route for the excretion of diclofenac in mammals and the 
detection of this compound in all the exposed fish confirm the uptake of diclofenac 
from the water. Our findings are supported by previous studies that reported the 
bioaccumulation of diclofenac in fish plasma and bile following the exposure to 
environmentally relevant concentrations (see Mehinto et al. Chapter 4; Brown et al., 
2007). Research in mammals has demonstrated that up to 5% of diclofenac entering the 
body is excreted as phase I metabolites produced by hydroxylation and methylation 
(Bort et al., 1999; Jjemba, 2006). Phase I metabolites were putatively identified as 
hydroxydiclofenac detected from 0.5 µg/l exposure concentration and methyl ester 
metabolite detected at 25 µg/l exposure concentration. Phase II metabolites, glucuronide 
diclofenac and glutathione diclofenac have also been identified in mammals and the 
bioactivation of these conjugates has been implicated in diclofenac-induced toxicity 
effects (Tang et al., 1999; Boelsterli, 2003). It is thought that the conjugated metabolites 
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bind covalently to proteins and form diclofenac conjugate-protein adducts that are 
recognized by the immune system as foreign, leading to an immune response and toxic 
damage mainly in the liver (Grillo et al., 2003). The glucuronide and glutathione 
conjugates of diclofenac were not detected in the bile of diclofenac-exposed trout, but 
they may have been masked by taurocholic acid present in the conjugated metabolites 
fraction. However, the hydroxylated form of the glucuronide metabolite was detected in 
the conjugated fraction of non-hydrolysed bile in fish exposed to 25 µg/l. The presence 
of diclofenac and its reactive metabolites in bile has been recognized as an important 
factor in intestinal injuries observed in patients treated with the pharmaceutical 
(Treinen-Moslen and Kanz, 2006). The identification of diclofenac and a possible 
glucuronide metabolite could explain the morphological damages found in the small 
intestine of rainbow trout exposed to environmentally relevant concentrations (see 
section 4.3.5). The deleterious effects of diclofenac and its metabolites have been 
previously demonstrated by Hoeger et al. (2008). They observed that diclofenac and the 
metabolites accumulated in brown trout (Salmo trutta) and entered the enterohepatic 
circulation, resulting in a prolonged availability in the bile which may cause intestinal 
injuries. 
This metabolomics study has revealed that many bile metabolites were affected 
by diclofenac exposure. Due to time restrictions, the metabolites have not yet been 
identified but research is undergoing using FT-MS in an attempt to do so. Metabolomics 
approaches generate large amounts of data and elucidation of the structure and name of 
the endogenous metabolites is often the most difficult and time consuming task 
(Goodacre et al., 2004). The databases available for metabolite recognition are presently 
predominated with metabolites of humans and other mammalian systems. Thus it is 
perhaps not surprising that the resulting putative molecular weights for the metabolites 
markers discovered in fish bile did not match the molecular weights of any metabolites 
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in these databases. A preliminary examination of the data indicated that more 
metabolites were reduced by diclofenac exposure than those induced and many of them 
seem to be phospholipids. This is surprising as phospholipids are converted into fatty 
acids and the inhibition of prostanoids synthesis would suggest an increase of 
arachidonic acid and phospholipids. The effects of diclofenac on phospholipids 
biosynthesis have not been previously reported and a definite identity for the 
phospholipids-like metabolites could provide further insight on the mode of action of 
diclofenac in fish. One variable (m/z 442.223) was found to be completely suppressed 
even at an exposure concentration of only 0.5 µg diclofenac/l and this may potentially 
be an effective physiological metabolite marker of diclofenac exposure.  
Among the metabolites elevated as a result of diclofenac exposure, the variable 
m/z 333.206 was putatively identified as a lipooxygenase product in the non-hydrolysed 
bile fraction. This metabolite showed a significant increase in the 25 µg/l treatment 
group compared with the controls but it was not discriminatory in the hydrolysed bile of 
trout exposed to 0.5 and 5 µg/l. Few data exist on the metabolic pathways affected by 
diclofenac in fish to make any meaningful conclusions on these observations. Most 
studies on diclofenac have used traditional endpoints such as toxicity testing (EC50), 
histopathology or target gene expression to evaluate the effects of exposure (Hallare et 
al., 2004; Schwaiger et al., 2004; Triebskorn et al., 2004; Hoeger et al., 2005; Hong et 
al., 2007). The observations here on the metabolome of exposed rainbow trout compare 
favourably with these other studies (see Chapter 4). Indeed, we reported earlier that 
diclofenac can significantly inhibit the cox activity in the liver, gills and kidney of 
rainbow trout. Arachidonic acid serves as a substrate for the synthesis of other 
eicosanoids (Figure 6.5) and the inhibition of prostanoids synthesis pathway may lead to 
an enhanced activity of the lipooxygenase and epooxygenase enzymes. This may 
explain the increase of this putative lipooxygenase product.  
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5. Conclusions 
The present study has demonstrated that the exposure to diclofenac via the water 
lead to significant changes in the metabolic profile of bile in rainbow trout. This is of 
environmental significance as our lowest exposure concentration (0.5 µg/l) is within the 
range of concentrations detected in WWTP effluents (up to 1 µg/l) and surface waters in 
the UK (up to 0.2 µg/l) (Hilton and Thomas, 2003; Ashton et al., 2004; Kasprzyk-
Hordern et al., 2008). Future research should focus on the disruption of the fish 
metabolome at lower concentrations. It has also been shown that a metabolomics 
approach is a useful approach for identifying metabolites of the test compound. The 
putative identification of hydroxydiclofenac and hydroxydiclofenac glucuronide 
suggests that diclofenac metabolism in fish is the same, or at least similar, to that 
occurring in mammals. However, the glutathione metabolite, another key conjugate of 
diclofenac was not detected and was possibly masked by taurocholic acid. Analytical 
methods need to be developed to detect these reactive metabolites in bile, especially at 
the lowest exposure concentration in order to determine any correlations with the 
pathology observed in the small intestine. Although most of the endogenous metabolites 
affected are, as yet, unidentified, this study further demonstrates the potential of 
metabolomics for the discovery of new biomarkers of chemical exposure and potentially 
provides valuable information on the genes or tissues affected by the exposure. The 
significant increase in the putative lipooxygenase product in exposed fish suggests that 
diclofenac not only inhibits prostanoids synthesis but may also interfere with the 
synthesis of other classes of eicosanoids affecting other physiological processes.  
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CHAPTER 7: General Discussion 
 
In 2007, the global consumption of diclofenac was estimated at 877 tons per 
year (Zhang et al., 2008). The recent availability of diclofenac over the counter is likely 
to cause an increase in the amounts used and may result in higher concentrations in UK 
aquatic environments. There has been a series of studies indicating that diclofenac can 
induce harm in wildlife and this thesis sets out to determine the fate of diclofenac and 
its interactions with biological systems in the aquatic environment through the use of 
microbiology, molecular and metabolomics techniques. 
The studies undertaken on biodegradation of diclofenac demonstrated that it was 
highly resistant to degradation by microbes in the activated sludge and the receiving 
waters (section 3.3). Previous enrichments studies with pharmaceuticals as sole carbon 
source have reported similarly low biodegradation rates for diclofenac (Quintana et al., 
2005; Yu et al., 2006). Enrichment experiments, however, are based on the assumption 
that microbial populations can be sustained with only one carbon source, whereas in 
reality pharmaceuticals degradation often occurs through co-metabolism involving more 
than one microbial species and carbon source. Specific microbes degrade partially the 
parent compound and the resulting products are further degraded by other types of 
microbes. Thus other carbon sources are required to sustain the growth and diversity of 
different microbial populations that collectively allow for the degradation process of 
diclofenac to occur. In essence, therefore enrichment studies employing a single 
chemical (here diclofenac) as a sole carbon source do not necessarily reflect degradation 
activities that occur in natural environments. A further consideration in the 
biodegradation studies undertaken is that they were designed to promote the growth of 
bacteria, but other microorganisms may be involved in the degradation process (e.g. 
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fungi, rotifers). Many bacteria that play vital roles in biodegradation in natural 
environments have been found to be not culturable under laboratory conditions (Dias 
and Bhat, 1964), contributing further to the loss of microbial diversity and degradation 
potential in the cultures. The composition of the culture media can also influence the 
microbial growth. Minimal salts media (MSM) employed in this study had been 
previously optimised to culture and isolate bacteria from soil samples (Tett et al., 1994) 
and the nutrients requirements may be different for aquatic microbes, thus this medium 
may not have been optimal for the microbes of interest.  
The removal of diclofenac in WWTPs has been estimated between 17 and 80%, 
with most studies reporting degradation below 40% in the activated sludge (Ternes, 
1998; Stumpf et al., 1999; Lindqvist et al., 2005; Zorita et al., 2009). It is thought that 
biodegradation occurs predominantly in the aerobic part of the activated sludge, 
however adopting aerobic conditions for the enrichments resulted in less than 20% of 
the initial concentration of diclofenac being removed over a 30-40 days period and these 
results were supported by the putative degradation pathway of diclofenac under aerobic 
conditions (section 3.2.9). This indicates that diclofenac may not be readily degraded 
under aerobic conditions and that anaerobic biodegradation may account for the 
removal of pharmaceuticals. Previous studies on the biodegradation of pharmaceuticals 
in WWTPs have reported up to 35% of diclofenac removed by anaerobic degradation 
but only 10% by aerobic degradation (Zwiener and Frimmel, 2003). Other factors too, 
such as pH, can affect the diversity of the microbial populations and degradation rates. 
Urase and Kikuta (2005) have reported that the degradation rate of NSAIDs increased 
under acidic conditions. All of these factors illustrate the difficulties in mimicking 
accurately the conditions in the environment and in maintaining the microbial diversity 
that has often been reported to produce the highest degradation potential. Therefore 
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extrapolating between the biodegradation of environmental pollutants under laboratory 
conditions and what may occur in the natural environment must be done with care. 
More advanced biodegradation studies are now using laboratory-scale fixed-bed 
bioreactors and membrane bioreactors, which imitate the tanks in WWTPs. Contrasting 
with enrichment studies, the microbes are cultured in their original medium and the 
dynamics of the microbial populations are less affected. Using these techniques, the 
degradation of diclofenac has been observed up to 60% (Gonzalez et al., 2006; Kraigher 
et al., 2008; Kosjek et al., 2009). Although the degradation rates are improved, 
laboratory-scale bioreactors, however, are not ideal for isolating the microbes actively 
degrading the pharmaceuticals. Formation of biofilms in those bioreactors is believed to 
be important for the degradation process (Zwiener and Frimmel, 2003; Gröning et al., 
2007). Because the microbes in biofilms are protected from external stressors, co-
metabolism and gene transfer are facilitated, thus enhancing the degradation potential of 
the microbial populations. Biofilms can be reproduced in laboratory and may be a more 
efficient way to culture complex degrading microbial populations.  
The observations on microbial growth during the biodegradation study showed 
that diclofenac can be toxic effects to those microbial populations. In a standardised 
bioassay with Vibrio fischeri it was indeed confirmed that diclofenac was the most toxic 
NSAID tested (EC50 >10) (section 3.3.4), concurring with previous research (Farré et 
al., 2001; Cleuvers, 2003). Although standardised acute toxicity assays have proven 
very useful for establishing environmental risk assessments for pharmaceuticals, the test 
organisms used are not necessarily found in the ecosystems where these 
pharmaceuticals are most prevalent. Vibrio fischeri, for example, is a marine species 
and although diclofenac has been reported in seawater, the highest concentrations are 
found in freshwater environments (Kümmerer, 2009). This argues for more studies on 
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the toxic effects of diclofenac on organisms occurring in the activated sludge and 
freshwater environments. Other acute toxicity tests using freshwater invertebrates and 
algae have reported EC50 for diclofenac well below 10 mg/l (Ferrari et al., 2003). 
Nevertheless, in this thesis, studies demonstrated that both some Gram positive and 
Gram negative bacteria from the activated sludge had a high tolerance for diclofenac 
(section 3.3.5). Minimum effective concentrations for growth inhibition ranged between 
50 mg/l for Zoogloea ramigera and 90 mg/l for Pseudomonas putida, and illustrate that 
environmental concentrations of diclofenac appear harmless to some microbes. 
Molecular analysis of mixed microbial communities exposed to diclofenac provides a 
better insight into the effects of the pharmaceutical on the dynamics within the 
microbial communities in the environment. Kraigher et al. (2008) reported that exposure 
to NSAIDs from 50 µg/l can indeed affect the diversity of the microbial communities in 
the activated sludge and reduce the growth of key microorganisms for degradation 
processes. 
The apparent recalcitrance and microtoxicity of diclofenac suggest that this 
compound has the potential to accumulate in aquatic organisms with an enhanced 
likelihood to cause deleterious effects. Exposure and effect studies in rainbow trout 
confirmed this assumption, with altered expression of genes playing key roles in 
xenobiotic metabolism (cyp1a1), eicosanoids synthesis (cox1 and cox2) and cell repair 
(p53) as well as histopathological lesions in the gills, kidney, liver and small intestine 
(Chapter 4). Diclofenac residues were found in the bile of exposed rainbow trout 
showing both its metabolism and active excretion from the body. This was supported by 
the increase expression of cyp1a1 in the liver and gills of diclofenac-exposed fish, as 
reported previously (Hong et al., 2007). The bioconcentration of diclofenac measured in 
the bile (BC 509-657), however, indicates that it is not degraded completely and is 
bioavailable in fish tissues and biofluids. Research in mammals, and more recently in 
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fish, has demonstrated that diclofenac present in the bile can enter the enterohepatic 
circulation instead of being evacuated via the urine (Boelsterli, 2003; Hoeger et al., 
2008). In the kidney of exposed rainbow trout, the significant reduction in cyp1a1 
expression implies that diclofenac bioaccumulated in this tissue (although this was not 
directly measured) and this may explain the nephrotoxicity observed in this tissue (see 
Figure 4.4a). A metabolomics analysis of fish urine may provide better insights into the 
physiological functions altered by diclofenac exposure and help to establish a link 
between the pathology observed and the functions impaired in the kidney. 
Diclofenac is a non selective cyclooxygenase (cox) inhibitor and as such it can 
suppress the expression of both cox isoforms in mammals. Although cox genes are 
highly conserved in aquatic vertebrates, there is no previous work reporting the effects 
of diclofenac on cox gene expression in non mammalian organisms. Here we showed 
that sub-chronic exposure (21 days)to environmentally relevant concentrations of 
diclofenac resulted in a significant reduction of both cox1 and cox2 expression in the 
liver, gills and kidney (section 4.3.4). Histopathological examinations also indicated 
that exposure to diclofenac from 0.5 µg/l caused damages in the kidney and small 
intestine. This indicates that pharmaceuticals released in the environment remain 
bioactive and long term exposure may lead to a complete inhibition of cox expression 
resulting in severe morphological damages and functional impairment, and ultimately 
affecting the survival of the fish. Despite the significant effects on gene expression in 
the liver, there was no apparent structural damage in this tissue, as determined by light 
microscopy on the tissue. Triebskorn et al. (2004), however, have previously shown that 
electron microscopy is more suitable as a technique to determine the scope of damage in 
tissues after exposure to chemicals, and thus it is possible that there were effects in the 
exposed trout, but to detect them required a higher resolution microscopy technique. 
Very few studies have reported damage to the small intestine of fish. In mammals, 
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however, gastrointestinal injuries are common side effects of diclofenac (Seitz and 
Boelsterli, 1998; Treinen-Moslen and Kanz, 2006) and additional medicine has been 
prescribed to help protect the gut lining. This study presents clear evidence that 
diclofenac can damage the small intestine of fish (see figure 4.3a) and this may have 
subsequent effects on processes such as nutrient absorption. The findings support 
previous research suggesting that the presence of diclofenac in enterohepatic circulation 
can lead to intestinal damages (Hoeger et al., 2008). Histopathology on the gills was not 
undertaken in the fish exposure study, and this was a shortfall of this work as it may 
have provided visual evidence of the inhibitory effects of diclofenac on prostanoids 
synthesis; altered cellular structure of the gills including chloride cells and granulocytes, 
are often used as biomarkers of malfunctions in homeostasis and immune response.  
The elevated gene expression of p53 observed in the gills of diclofenac-exposed 
fish (1 and 5 µg/l) is in accordance with the histopathological lesions such as cell 
necrosis reported in previous work (Schwaiger et al., 2004; Hoeger et al., 2005). Some 
of the effects of diclofenac on p53 gene expression, however, were unexpected. Hong et 
al. (2006) had shown that acute exposure of medaka (O. latipes) to diclofenac (1 µg/l 
and 8 mg/l) resulted in a significant induction of p53 expression in the liver, gills and 
small intestine. In this study, however, p53 gene expression was not affected in the liver 
and although cellular necrosis was induced in the kidney we found no significant 
reduction of p53 expression in this tissue. P53 is involved in complex molecular 
cascades leading to the induction of apoptosis to discard damaged cells or cell cycle 
arrest to repair DNA. Analysing the expression of the genes induced by p53 and 
responsible for cell death and cell repair may provide better insights of the effects 
caused by diclofenac on cellular programming. To our knowledge, this is the first study 
report the genotoxic effects of diclofenac in fish at environmentally relevant 
concentrations.  
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Metabolomics approach was applied to the diclofenac-exposed rainbow trout 
(plasma and bile) in order to identify the potential pathways implicated in the 
metabolome disruption. Recent metabolomics studies on fish have reported that the 
exposure to xenobiotics can lead to significant changes in their metabolite composition, 
indicating that pharmaceuticals can strongly interfere with the metabolism of non target 
organisms (Gibson et al., 2005; Samuelsson et al., 2006; Viant et al., 2006; Ekman et 
al., 2007; Katsiadaki et al., 2009). Biofluids have often been employed in metabolomics 
and several techniques are available to extract and identify the various classes of 
signalling molecules. So far a single analytical technique has not been able to extract all 
the metabolites and new methodologies need to be developed to do so. Initially, 
methanol extraction and UPLC-TOF-MS techniques optimised to analyse the fish 
plasma metabolome were capable of extracting a large number of metabolites but the 
low abundance metabolites (e.g. eicosanoids) seemed poorly detected. The techniques 
optimised were unable to detect changes in the metabolome of diclofenac-exposed fish 
even though changes were observed in the bile and there were clear effects on gene 
expression. The metabolomics data indicated that diclofenac accumulated to detectable 
levels in the plasma of fish exposed to 5 and 25 µg diclofenac/l without any apparent 
interference with the endogenous metabolic profile of the fish. The reasons for this were 
perhaps that the metabolites affected by diclofenac predominantly represented low 
abundance molecules and that the methodology used was unable to detect these 
molecules due to the high levels of proteins in the plasma that caused interferences in 
the matrix. The analytical techniques therefore still require optimisation to be able to 
successfully extract and detect endogenous metabolites in the plasma. The new SPE and 
UPLC-TOF-MS methodology developed to profile the bile was highly successful for 
extracting and detecting a range of signalling molecules including eicosanoids, fatty 
acids and other metabolites (free and conjugated) in response to diclofenac exposure. 
7. General Discussion 
 188
Fractionation enabled the separation of the bile acids causing ion suppression from 
other metabolites and the recoveries of targeted bile metabolites were in most cases 
above 75% (section 5.3.2). Furthermore, additional treatment of the bile by hydrolysis 
permitted the deconjugation of bile salts (e.g. taurocholic acid) and certain conjugated 
metabolites which improved the detection of endogenous metabolites previously 
masked by taurocholic acid. Although conjugation is often done with a glycosidic bond, 
the glucuronidase and sulphatase enzymes did not cleave all the bile conjugates and 
other enzymes may be required to cleave those remaining conjugates. Using the 
optimised methodology, analysis of the bile metabolome resulted in significant 
differences in metabolic profiles of exposed rainbow trout compared with the control 
fish. The perturbation of over 60 endogenous metabolites was found in fish exposed to 
environmentally relevant concentrations of diclofenac (see Table 6.6).  
The putative identification of hydroxydiclofenac, a methyl ester metabolite and 
hydroxylated glucuronide diclofenac indicate that the metabolism of diclofenac and side 
effects observed in mammals may also occur in aquatic vertebrates. Indeed, diclofenac-
induced toxicity observed in a previous study (section 4.3.5) has been previously 
reported in mammals, birds and aquatic organisms and has often been related to the 
accumulation of diclofenac and the production of reactive metabolites (Seitz and 
Boelsterli, 1998; Tang et al., 1999; Hickey et al., 2001; Boelsterli, 2003; Grillo et al., 
2003; Meteyer et al., 2005; Ng et al., 2006). Further investigations are needed on the 
glucuronide metabolite of diclofenac to determine if glucuronic acid is on the acyl 
group. Acyl-glucuronide is a highly reactive metabolite in mammals (Bailey and 
Dickinson, 2003) and this may explain the intestinal pathology observed in diclofenac-
exposed rainbow trout. Many of the endogenous metabolites isolated in this study have 
not yet been identified yet, this is a time consuming process and the putative molecular 
weights do not match the masses for their equivalents in mammals that are in the 
7. General Discussion 
 189
databases. Preliminary investigations suggest that diclofenac had strong inhibitory 
effects on a range of functional pathways at environmentally relevant concentrations; 
many resulting in a significant reduction of phospholipids synthesis (see Table 6.6b). 
Interestingly, one metabolite marker has been completely suppressed by diclofenac, 
even at the lowest exposure concentration (0.5 µg/l). It is envisaged that subsequent 
identification of this (and other) metabolites may reveal new pathways affected by 
diclofenac exposure and help to gain a better understanding of its mode of action in fish. 
One of the metabolite markers affected and identified as a possible lipooxygenase 
product, highlights the extent to which diclofenac can affect the arachidonic cascade. It 
seems that the inhibition of cyclooxygenase enzyme can enhance the activity of the 
lipooxygenase enzyme and increase the synthesis of other eicosanoids. This study has 
helped to demonstrate the potential of metabolomics for determining the effects and 
mechanisms of action of pharmaceuticals (especially diclofenac) in fish; however 
meaningful conclusions require further work on the identification of the discriminative 
metabolites in order to provide more definitive links to physiological functions. 
 
 
Future research 
There are many avenues for future research that would enhance our knowledge 
on the biological implications of exposure to NSAID in the environment. Here are some 
key areas that seem to be the most needed. In the first instance, if we are to understand 
the fate and persistence of NSAID in the environment there is the need for optimisation 
of microbial culture techniques to enable us to identify the microbial species and genes 
involved in diclofenac and other NSAID degradation. Biodegradation studies using 
7. General Discussion 
 190
bioreactors have shown promising results and the use of stable isotope probing 
(radioactive labelled diclofenac) may be useful to help identify the microbes actively 
degrading diclofenac. To better understand the implications for exposure to NSAID on 
microbial populations, chronic exposure of mixed microbial communities are needed to 
assess the toxicity of diclofenac on metabolic processes other than growth (e.g ATP 
production, biofilm formation).  
To assess the impacts of exposure to NSAIDs on fish and other aquatic 
organisms, longer term exposures to environmentally relevant concentrations are 
needed. These will provide us with more realistic assessments on the potential for these 
drugs to induce harm in wildlife. Expanding effects measurement to include genomics 
too will likely advance our understanding significantly on the pathways and processes 
affected (and thus potential to impair health). 
There is little doubt that genomics has the potential to expand our knowledge 
significantly on the potential for harm of pharmaceuticals in the environment and 
develop a more thorough understanding on the mechanisms of action. Metabolomics 
techniques on biofluids, including blood plasma and bile hold very significant promise. 
These methods however, need to be further optimised to enable the detection of low 
abundance signalling molecules, such as eicosanoids affected by diclofenac in the 
plasma. The development of methodologies able to reduce the levels of bile salts and 
decrease the matrix effects may permit the detection of the glutathione metabolite of 
diclofenac. The analysis of fish urine should also be considered to further understand 
the mechanism of toxicity of diclofenac in the kidney. 
Considering the effects of diclofenac specifically, obtaining the structural 
identity of the hydroxylated glucuronide of diclofenac will be valuable in determining if 
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this compound is the acyl-metabolite of diclofenac responsible for hepatotoxicty, renal 
injuries and gastrointestinal injuries reported in mammals.  
Finally, the application of FT-MS to the metabolomics work would be better 
able than TOF-MS to identify the metabolites affected by diclofenac exposure. This 
technology platform provides a more accurate molecular weight, which will reduce the 
number of candidate metabolites proposed in the available databases. 
 
 
Conclusions 
Diclofenac proved to be persistent in the aquatic environment and toxic effects 
were observed in aquatic organisms. The recalcitrance of diclofenac to microbial 
degradation is of environmental concern, especially as its usage may increase in the 
coming years and that it is known to be capable of inducing harm in various wildlife 
species. Research is needed to better understand the biodegradation process of 
diclofenac in order to determine how WWTPs processes can be optimised for its 
removal. The identification of key microbial species and genes able to degrade 
pharmaceuticals could be beneficial for bioremediation. Information on the molecular 
mechanisms may be used to engineer microbial populations pre-disposed for the 
degradation of pharmaceuticals.  
The toxic effects of sub-chronic exposure to environmentally relevant 
concentrations of diclofenac, reported in these studies, illustrate that diclofenac can act 
in fish in a similar manner than in mammals. This infers that long term exposure may 
result in side effects such as kidney failure and intestinal pathology which may be 
detrimental to the health and survival of aquatic vertebrates. The results from our 
studies further highlight the need for more suitable tests in chemical and environmental 
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risk assessments based on chronic exposure to low concentrations of pharmaceuticals 
rather than acute toxicity tests with sub-lethal concentrations. The changes in the 
metabolite profiling of fish bile from the lowest exposure dose suggest that 
environmental concentrations can alter fish physiology. The discovery of metabolites 
and functional pathways affected by diclofenac at environmental concentrations are 
critical to understand the potential threat of this compound in the ecosystem.  
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